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Summary	
	 1	
Summary 	Fatty	 acids	 (FAs),	 in	 free	 form	 or	 incorporated	 into	 complex	 lipids,	 constitute	 an	inseparable	 part	 of	 the	 daily	 human	 diet.	 Different	 carbon	 atom	 chain	 length	 and	saturation	 rate	 leads	 to	 a	 huge	 variety	 of	 FAs	 of	which	 long-chain	 fatty	 acids	 (LCFAs)	being	the	dominant	type.	The	main	focus	of	this	work	is	medium-chain	FAs	(MCFAs),	a	group	of	 saturated	FAs,	mainly	 found	 in	 coconut	 oil,	 palm	kernel	 oil	 and	milk.	MCFAs	have	shorter	carbon	atom	chain	lengths	and	therefore	different	properties	compared	to	longer	 FAs.	 The	 cellular	 metabolism	 of	 MCFAs	 is	 still	 insufficiently	 investigated	particularly	when	compared	to	LCFAs.		This	 thesis	 analyzes	 the	 metabolism	 of	 MCFAs	 with	 aim	 to	 better	 comprehend	 their	effect	on	the	human	body,	to	examine	their	unique	properties,	and	to	contribute	to	the	general	understanding	of	MCFAs.	The	metabolism	of	MCFAs	was	 investigated	 in	different	 cell	 lines,	 in	mouse	organs,	 in	differentiating	3T3-L1	cells,	and	in	dedifferentiating	hepatocytes.		Alkyne-FAs	and	click	labeling	 technique	were	used	 to	analyze	 the	metabolism	of	MCFAs.	The	 triacylglycerol	(TAG)	 synthesis	 from	 MCFAs	 was	 the	 main	 object	 of	 research.	 It	 was	 shown	 that	different	cell	lines	routinely	used	in	cell	culture	experiments	could	not	synthesize	TAGs	from	MCFAs,	 however,	 primary	hepatocytes,	 3T3-L1	 adipocytes	 and	organ	 slices	 from	liver	and	gut	could.	It	was	also	found	that	differentiating	3T3-L1	cells	gain	the	function	of	 TAG	 synthesis	 from	 MCFAs,	 whereas	 primary	 hepatocytes	 lose	 this	 function	 after	longer	cultivation	in	2D	cell	culture.	mRNA	sequencing	data	obtained	for	differentiating	3T3-L1	cells	and	dedifferentiating	hepatocytes	showed	changes	in	various	genes	related	to	lipid	metabolism.	MCFA	 uptake	 into	 cells	 was	 also	 investigated.	 Cells	 that	 could	 not	 synthesize	 MCT	(medium	chain	triacylglycerols)	could	still	uptake	MCFAs.	Moreover,	a	very	interesting	effect	 of	 CPT1	 inhibitor	 etomoxir	 on	 the	 MCFA	 metabolism	 was	 observed.	 Etomoxir	reduced	TAG	synthesis	from	MCFAs	and	enhanced	the	formation	of	unknown	substances	secreted	into	the	medium	by	C11	MCFA	fed	hepatocytes.		Further,	different	enzymatic	activities	in	the	glycerol	phosphate	pathway	were	analyzed	in	Huh7	cells,	primary	hepatocytes	and	3T3-L1	cells.	It	was	shown	that	although	Huh7	cells	 and	 dedifferentiated	 hepatocytes	 cannot	 synthesize	 TAGs	 from	MCFAs,	 but	 their	lysates	possess	different	enzymatic	activities	for	this	synthesis.	This	 thesis	 is	 concluded	 by	 introducing	 hypothetical	models	 for	MCFA	metabolism	 in	hepatocytes	and	3T3-L1	cells,	which	suggest	the	involvement	of	mitochondria	in	MCFA-TAG	synthesis.	
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1. Introduction 
Fatty	 acids	 (FAs)	 are	 important	 biomolecules	 made	 of	 a	 hydrocarbon	 chain	 and	 a	terminal	carboxyl	group.	They	are	building	blocks	for	a	wide	variety	of	lipids	and	serve	as	an	energy	source	in	catabolic	processes.	Depending	on	fatty	acid	carbon	chain	length	they	are	classified	as	short	(>8	carbon	atoms),	medium	(8-12	carbon	atoms),	long	(12<	carbon	atoms)	and	very	long-chain	(22<	carbon	atoms)	fatty	acids.	Based	on	the	degree	of	 saturation	 fatty	 acids	 can	 be	 saturated	 (no	 double	 bonds),	 monounsaturated	 (one	double	 bond)	 or	 polyunsaturated	 (more	 than	 one	 double	 bond).	 The	 length	 and	 the	degree	of	saturation	determinate	specific	properties	of	different	FAs,	such	as	solubility	in	aqueous	solutions,	lipophilicity,	melting	point	and	susceptibility	to	oxidation.		The	most	widely	 investigated	FAs	are	 long-chain	 fatty	acids	(LCFAs)	such	as	oleic	acid	(C18:1)	 and	 palmitic	 acid	 (C16:0),	 which	 is	 reasonable	 as	 they	 both	 are	 the	 most	abundant	FAs	in	human	and	other	organisms.		In	the	organism	FAs	are	stored	in	the	form	of	triacylglycerols	(TAGs)	also	known	as	fats	or	oils.	 In	 the	western	world	 fats	 traditionally	used	 for	cooking,	 such	as	sunflower	oil,	rapeseed	 oil,	 olive	 oil,	 lard	 and	 butter,	 are	 basically	 composed	 of	 saturated	 and	unsaturated	LCFAs.	In	 recent	 years	 many	 people	 have	 changed	 eating	 habits	 and	 are	 searching	 for	alternative	 healthy	 fats.	 Therefore,	more	 and	more	 people	 start	 using	 coconut	 oil	 for	their	 daily	 food	 preparation.	 Coconut	 oil	 is	mainly	made	 of	medium-chain	 fatty	 acids	(MCFAs).	There	is	much	less	research	data	on	the	metabolism	of	these	FAs	compared	to	LCFAs.	In	this	thesis,	the	metabolism	MCFAs	was	analyzed	in	more	detail.		
1.1. Medium-chain fatty acids and medium-chain 
triacylglycerols 	MCFAs	are	saturated	FAs	containing	8	-	12	carbon	atoms	(Papamandjaris	et	al.,	1998).	Octanoic	acid	(8:0,	caprylic	acid),	decanoic	acid	(C10:0,	capric	acid)	and	dodecanoic	acid	(C12:0,	 lauric	 acid)	 belong	 to	 traditional	 MCFAs	 (Marten	 et	 al.,	 2006).	 Main	 natural	sources	of	these	FAs	are	coconut	oil,	palm	kernel	oil	(which	is	not	the	same	as	palm	oil)	and	mammalian	milk	(Marten	et	al.,	2006),	see	Table	1.		
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Table	1.	Main	natural	sources	of	MCFAs.	Numbers	represent	%	of	all	FAs.	Fatty	acid	 Coconut	oil	 Palm	kernel	oil	 Bovine	milk	 Human	milk	Octanoic	acid	 6-10	%	*	 2-5	%	*	 1-3	%	#	 0,2-1	%	§	Decanoic	acid	 5-10	%	*	 3-5	%	*	 2-4	%	#	 1,5-4	%	§	Dodecanoic	acid	 39-54	%	*	 44-51	%	*	 2-5	%	#	 4-14	%	§	*	marks	reference	(Lemarié	et	al.,	2016)	#	marks	reference	(Jensen,	2002)	§	marks	references	(Bahrami	and	Rahimi,	2005;	Yuhas	et	al.,	2006)		As	 MCFAs	 are	 saturated	 FAs,	 some	 people	 associate	 them	 with	 bad	 unhealthy	 fats.	However,	because	of	the	smaller	size	MCFAs	have	different	physicochemical	properties	and	presumably	a	different	metabolism	as	 saturated	LCFAs.	Differences	 start	with	 the	hydrolysis	 of	 dietary	 medium-chain	 triacylglycerols	 (MCTs;	 natural	 or	 synthetically	generated	TAGs	composed	of	MCFAs;	in	this	thesis	MCT	refers	to	TAG	having	at	least	one	MCFA).		The	 digestion	 of	 dietary	 fats	 starts	 in	 the	 stomach.	 Here	 TAGs	 are	 firstly	 partially	hydrolyzed	by	gastric	and	lingual	lipases.	Then	hydrolysis	is	completed	by	a	pancreatic	lipase	in	the	small	intestine.	The	hydrolysis	process	of	MCTs	in	the	gut	facilitated	by	the	pancreatic	 lipase	 is	 faster	 and	 more	 efficient	 than	 the	 hydrolysis	 of	 long-chain	triacylglycerols	 (LCTs)	 (Bach	 and	 Babayan,	 1982).	 Furthermore,	MCFAs	 generated	 by	hydrolysis	 are	 more	 effectively	 absorbed	 by	 intestinal	 cells	 than	 LCFAs	 (Bach	 and	Babayan,	 1982).	 After	 absorption	 most	 of	 the	 MCFAs	 are	 directly	 transferred	 to	 the	portal	 vein	 for	 the	 transport	 to	 the	 liver	 (Nancy	You	 et	 al.,	 2008).	On	 the	 other	 hand,	LCFAs	 are	 usually	 re-esterified	 into	 TAGs	 and	 then	 incorporated	 into	 chylomicrons	(particles	for	lipid	transport	in	organisms),	which	then	enter	the	lymphatic	system	and	finally	reach	the	systemic	circulation	and	liver	(Bach	and	Babayan,	1982),	see	Figure	1.	MCTs	are	used	in	diets	of	patients	that	have	specific	lipid-metabolism	related	disorders.	In	 cases	 of	 pancreatic	 insufficiency,	 where	 digestion	 and	 absorption	 of	 LCTs	 are	impaired,	MCTs	could	be	well	utilized	(1994).	In	general,	MCTs	have	been	used	in	adults	and	 children	with	 disorders	 of	 lipid	 digestion,	 lipid	 absorption	 and	 lipid	 transport	 as	well	as	in	the	deficiency	of	chylomicron	synthesis.	
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Figure	1.	Digestion	and	absorption	mechanism	of	dietary	MCTs	and	LCTs.	Digestion	of	MCTs	 starts	 in	 the	upper	 gastrointestinal	 tract	 and	 is	mediated	by	 gastric	 and	 lingual	lipases.	 Both	 LCTs	 and	 MCTs	 are	 then	 finally	 digested	 in	 the	 small	 intestine	 by	 the	 action	 of	 the	pancreatic	 lipase,	 which	 generates	 2-monoacylglycerol	 and	 free	 fatty	 acids.	 Next	 intestinal	absorption	of	FAs	follows.	A	huge	part	of	MCFAs	is	directly	transferred	to	the	liver	via	the	portal	vein	in	 an	 albumin-bound	 form.	 LCFAs	 are	 re-esterified	with	 2-monoacylglycerol	 into	 TAGs,	 which	 are	then	 incorporated	 into	 chylomicrons	 and	 are	 transferred	 via	 the	 lymph	 to	 the	 general	 circulation	from	 where	 they	 reach	 muscle	 and	 adipose	 tissue.	 Here	 TAG	 is	 hydrolyzed	 and	 chylomicron	remnants	 are	 formed,	 which	 are	 then	 finally	 taken	 up	 by	 the	 liver.	 Images	 are	 taken	 from	http://www.servier.com/Powerpoint-image-bank	and	modified	using	the	diagram	from	(Lemarié	et	al.,	2016).		
1.2. Functions of triacylglycerols 	TAG	consists	of	a	glycerol	backbone	and	three	FAs	attached	by	ester	bonds	(Yen	et	al.,	2008).		This	neutral	lipid	is	a	highly	reduced	molecule	and	stores	energy	in	the	form	of	carbon-hydrogen	bonds.	TAG	is	known	as	the	most	effective	molecule	for	energy	storage	in	human	organism	(Yen	et	al.,	2015).		The	 primary	 place	 for	 TAG	 synthesis	 and	 storage	 is	 the	 adipose	 tissue.	 TAG	 is	 also	synthesized	 in	 the	 liver	 for	 the	 production	 and	 assembly	 of	 very	 low-density	lipoproteins	 (VLDL)	 to	 transport	 neutral	 lipids	 to	 other	 tissues	 as	 well	 as	 in	 the	
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mammary	gland	for	the	production	of	milk	fat	globules	(Yen	et	al.,	2015).	In	the	intestine	TAG	synthesis	is	related	to	absorption	and	re-esterification	of	digested	dietary	fats.		The	main	well-known	TAG	function	is	the	storage	of	FAs	later	used	for	energy	utilization	and	 synthesis	 of	 membrane	 lipids	 (Yen	 et	 al.,	 2008).	 TAG	 is	 also	 important	 for	 the	formation	of	the	moisture	barrier	of	the	skin	(Yen	et	al.,	2008).	 It	acts	as	a	mechanical	cushion	 around	 internal	 organs	 and	 within	 joints	 and	 has	 a	 great	 role	 in	 insulation	(Coleman	 and	 Mashek,	 2011).	 The	 TAG	 synthesis	 in	 cells	 may	 protect	 them	 from	potentially	 toxic	 membrane-damaging	 effects	 of	 excess	 FAs	 and	 acyl-CoAs	 (Coleman,	2004;	Yen	et	al.,	2008).		However,	 there	 are	 also	 some	negative	 aspects	 related	 to	TAG	overload	 in	 organisms.	Excessive	accumulation	of	TAG	in	human	adipose	tissue	leads	to	obesity	and	is	related	to	organ	 dysfunction	 in	 non-adipose	 tissues	 (Yen	 et	 al.,	 2008).	 An	 overload	 of	 TAG	 in	insulin-sensitive	 organs	 other	 than	 adipose	 tissue,	 such	 as	 liver	 and	 skeletal	 muscle,	results	 in	 an	 inhibition	 of	 insulin	 action	 (insulin	 resistance)	 (Friedman,	 2002).	 The	accumulation	 of	 TAG	 in	 the	 liver	 causes	 the	 non-alcoholic	 fatty	 liver	 disease	 (NAFLD)	(Cohen	 et	 al.,	 2011;	 Fabbrini	 et	 al.,	 2010)	 in	 the	 heart	 it	 leads	 to	 cardiomyopathy	(Pulinilkunnil	et	al.,	2014;	Sharma	et	al.,	2004).		The	main	focus	of	the	current	work	is	the	TAG	synthesis	from	MCFAs	and	the	catabolism	of	these	FAs.	For	this	reason,	different	steps	in	TAG	synthesis	and	FA	breakdown	via	the	β-oxidation	 will	 be	 discussed	 in	 the	 upcoming	 chapters.	 But	 before	 being	 able	 to	participate	in	any	cellular	lipid	metabolism,	FAs	need	to	get	inside	the	cell,	and	therefore	FA	transport	will	be	initially	discussed.		
1.3. Fatty acid transport 	Experiments	 have	 shown	 that	 FAs	 can	 cross	 the	 plasma	 membrane	 both	 by	 passive	diffusion	 and	 by	 protein-mediated	 transport.	 Scientists	 still	 debate,	 which	 way	 of	 FA	transport	is	the	dominant	one	(Hamilton	et	al.,	2001,	2002;	Kamp	et	al.,	2003;	Schwenk	et	al.,	2010).	However,	 it	 is	now	believed	that	protein-mediated	transport	 is	 the	major	way	for	cellular	FA	uptake	especially	in	tissues	with	elevated	FA	metabolism,	such	as	the	heart,	 skeletal	muscle	 (Wu	 et	 al.,	 2006),	 liver	 (Doege	 et	 al.,	 2006)	 and	 adipose	 tissue	(Schaffer	and	Lodish,	1994).	Several	candidate	proteins	are	thought	to	be	involved	in	FA	transport	 across	 the	 plasma	membrane,	 including	 fatty	 acid	 translocase	 (FAT/CD36),	
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plasma	 membrane-associated	 fatty	 acid	 binding	 protein	 (FABPpm)	 and	 fatty	 acid	transport	proteins	(FATPs).	There	are	six	known	FATPs	that	belong	to	a	class	of	solute	carrier	family	27	(SLC27).	FATPs	also	function	as	very	long-chain	acyl-CoA	synthetases	(ACSVLs),	see	chapter	1.4.1.	Once	transported	inside	the	cells,	FAs	are	bound	to	cytosolic	fatty	acid	binding	proteins	(FABPs).	They	are	thought	to	facilitate	LCFA	movement	inside	the	cell	and	to	protect	cell	membranes	from	a	detergent-like	action	of	FAs	(Grevengoed	et	al.,	2014).	In	cells	such	as	hepatocytes,	adipocytes	and	cardiomyocytes,	where	FA	metabolism	is	very	intensive,	FABPs	 comprise	1-5%	of	 total	 cytosolic	 proteins	 (Haunerland	 and	 Spener,	 2004).	 The	FABP	 family	 consists	 of	 at	 least	 nine	 protein-coding	 genes	 (Smathers	 and	 Petersen,	2011).			
1.4. TAG synthesis  	 	In	eukaryotes	TAG	 is	 synthesized	by	 two	major	pathways,	 the	glycerol	phosphate	and	the	 monoacylglycerol	 (MAG)	 pathway	 (Takeuchi	 and	 Reue,	 2009),	 see	 Figure	 2.	 The	glycerol	 phosphate	 pathway	 is	 present	 in	most	 cells.	 In	 contrast,	 the	MAG	pathway	 is	only	 found	 in	 enterocytes,	 hepatocytes	 and	 adipocytes	 (Yen	 et	 al.,	 2008).	 These	pathways	use	glycerol-3-phosphate	(G3P)	and	MAG	respectively	as	initial	acyl	acceptors	(Yen	et	al.,	2015).	Both	pathways	use	fatty	acyl-CoA	thioesters	as	donors	of	acyl	groups	(Grevengoed	et	al.,	2014).	In	the	glycerol	phosphate	pathway,	G3P	is	stepwise	acylated	with	 two	 acyl-CoA	 molecules	 to	 form	 lysophosphatidic	 acid	 (LPA)	 and	 subsequently	phosphatidic	acid	(PA).	PA	 is	 then	dephosphorylated	to	generate	diacylglycerol	(DAG).	In	the	final	step,	DAG	is	converted	to	TAG	by	the	action	of	diacylglycerol	acyltransferases	(DGATs).	In	the	MAG	pathway,	DAG	is	directly	synthesized	from	MAG	by	acylation	and	is	then	 converted	 to	TAG.	 This	 pathway	 for	 the	TAG	 synthesis	 is	most	 prominent	 in	 the	small	 intestine,	 where	 TAG	 is	 mainly	 synthesized	 from	 components	 of	 hydrolyzed	dietary	fats	(Mansbach	and	Gorelick,	2007).		Separate	 steps	 in	 the	 TAG	 synthesis	 pathway	 will	 be	 discussed	 in	 more	 detail	 in	upcoming	chapters	starting	with	acyl-CoA	synthesis.	
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Figure	2.	Pathways	of	TAG	synthesis.	Proteins	 participating	 in	 de	 novo	 TAG	 synthesis	 can	 be	 found	 on	 mitochondria,	 endoplasmic	reticulum	(ER)	and	lipid	droplets	(LDs).	The	first	step	in	TAG	synthesis	is	the	generation	of	LPA	from	acyl-CoA	and	G3P	and	is	catalyzed	by	GPAT	enzymes.	The	next	step	is	the	formation	of	PA	facilitated	by	AGPAT	 (LPAAT)	 activity.	 PA	 is	dephosphorylated	by	 the	 action	of	 lipins	 to	 form	DAG.	The	 final	step	in	the	pathway	is	the	acylation	of	DAG	into	TAG.	PA	is	a	precursor	lipid	which	can	be	used	for	the	synthesis	of	other	lipids	such	as	PI,	PS,	PG	or	CL.	Similarly,	phospholipids	such	as	PC	and	PE	can	be	synthesized	 from	 DAG	 via	 Kennedy	 pathway.	 In	 liver,	 intestine	 and	 adipose	 tissue,	 TAG	 can	 be	synthesized	 from	 MAG	 by	 the	 action	 of	 MGAT	 followed	 by	 DGAT.	 (PA,	 phosphatidic	 acid;	 DAG,	diacylglycerol;	 TAG,	 triacylglycerol;	 MAG,	 monoacylglycerol;	 P,	 phosphate;	 LPA,	 lysophosphatidic	acid;	G3P,	 glycerol-3-phosphate;	 PI,	 phosphatidylinositol;	 PG,	 phosphatidylglycerol;	 CL,	 cardiolipin;	PC,	 phosphatidylcholine;	 PE,	 phosphatidylethanolamine;	 PS,	 phosphatidylserine.)	 Images	 of	mitochondria,	 endoplasmic	 reticulum	 and	 lipid	 droplet	 are	 from	http://www.servier.com/Powerpoint-image-bank.		
1.4.1. Acyl-CoA synthesis 	The	initial	substrates	for	TAG	synthesis	are	G3P	and	acyl-CoAs.	G3P	can	be	synthesized	from	the	glycolysis	 intermediate	dihydroxyacetone	phosphate	(DHAP),	as	well	as	 from	glycerol	 by	 the	 action	 of	 the	 glycerol	 kinase	 or	 from	 pyruvate	 via	 glyceroneogenesis	(Kalhan	 et	 al.,	 2001).	 	 Acyl-CoA	 is	 synthesized	 from	 coenzyme	 A	 (CoA)	 and	 FA	 by	proteins	 called	 acyl-CoA	 synthetases.	 In	 the	 human	 genome	 26	 acyl-CoA	 synthetase	genes	 were	 identified	 (Watkins	 et	 al.,	 2007).	 Depending	 on	 the	 FA	 length	 of	 the	
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preferred	 substrate,	 acyl-CoA	 synthetases	 are	 categorized	 into	 short-chain,	 medium-chain,	 long-chain	 and	 very-long-chain	 acyl-CoA	 synthetases	 (Grevengoed	 et	 al.,	 2014).	However,	 the	 FA	 acid	 chain	 length	 specificity	 of	 these	 enzymes	 is	 not	 strict	 and	 their	substrate	 preference	 overlap	 (Watkins	 et	 al.,	 2007).	 Multiple	 isoforms	 of	 acyl-CoA	synthetases	are	expressed	 in	different	 cell	 types	and	are	 located	 in	 the	membranes	of	different	organelles	and	some	even	on	the	plasma	membrane	(Grevengoed	et	al.,	2014).	Medium-chain	acyl-CoA	synthetases	(ACSMs)	are	localized	in	the	mitochondria.			
1.4.2. LPA synthesis 	In	 the	 glycerol	 phosphate	 pathway,	 the	 first	 committed	 step	 is	 the	 acylation	 of	 sn-glycerol-3-phosphate	 at	 sn1	 position	 with	 acyl-CoA	 to	 form	 1-acyl-sn-glycerol-3-phosphate,	 also	known	as	 lysophosphatidic	 acid	 (LPA)	 (Grevengoed	et	 al.,	 2014).	This	step	is	catalyzed	by	glycerol-3-phosphate	acyltransferases	(GPATs).	GPAT	enzymes	are	considered	to	be	rate	limiting	in	the	TAG	synthesis	(Wendel	et	al.,	2009).	Two	isoforms	of	 GPAT	 (GPAT1	 and	 GPAT2)	 are	 present	 in	 the	 outer	 mitochondrial	 membrane,	whereas	other	 two	 isoforms	 (GPAT3	and	GPAT4)	 reside	 in	 the	endoplasmic	 reticulum	(ER),	 see	Figure	2	 (Wendel	 et	 al.,	 2009).	 It	was	 shown	 that	GPAT4	 is	 also	 localized	 to	lipid	droplets	(LDs)	(Wilfling	et	al.,	2013).		
1.4.3. PA synthesis 	The	 second	 step	 in	 the	 glycerol	 phosphate	pathway	 is	 the	 acylation	of	 LPA	 at	 the	 sn2	position	of	 the	glycerol	backbone	 to	 form	PA	(Yamashita	et	al.,	2014).	This	 reaction	 is	catalyzed	 by	 lysophosphatidic	 acid	 acyltransferases	 (LPAATs).	 	 The	 nomenclature	 of	these	 proteins	 is	 rather	 confusing.	 Originally	 LPAATs	 1-5	were	 assigned	 to	 sn-1-acyl-glycerol-3-phosphate	acyltransferase	(AGPAT)	 family	and	were	known	as	AGPATs	1-5.		Other	 members	 of	 AGPAT	 family	 (AGPAT	 6-11)	 have	 activities	 like	 GPAT,	lysophosphatidylcholine	 acyltransferase	 (LPCAT)	 or	 lysophosphatidylethanolamine	acyltransferase	 (LPEAT).	 There	 was	 a	 proposal	 to	 rename	 AGPAT	 enzymes	 based	 on	their	 substrate	 specificities	 and	 by	 the	 order	 in	 which	 their	 cloning	 was	 reported	(Shindou	et	al.,	2009).	However,	this	proposal	did	not	fully	take	the	effect	and	the	AGPAT	name	rather	then	LPAAT	still	dominates	in	the	literature.		
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LPAAT	 1	 and	 2	 (AGPAT	 1	 and	 2)	 are	 the	 best-characterized	 LPAATs	 having	 a	 broad	tissue	 distribution	 and	 acyl-CoA	 preference	 (Yamashita	 et	 al.,	 2014).	 They	 are	 both	localized	 to	 the	 ER	 (Eberhardt	 et	 al.,	 1999).	 LPAAT	 3	 and	 5	 show	 relatively	 low	enzymatic	LPAAT	activity	compared	to	LPAAT2	and	their	role	in	TAG	synthesis	may	be	minimal	 at	 best	 (Prasad	 et	 al.,	 2011).	 It	 was	 shown	 that	 overexpressed	 LPAAT5	 is	localized	 to	 the	 mitochondria	 (Prasad	 et	 al.,	 2011).	 LPAAT4	 has	 a	 relatively	 high	expression	 in	 the	 brain	 and	 possesses	 LPAAT	 activity	 with	 a	 preference	 for	docosahexaenoyl-CoA	 (DHA-CoA)	 (Eto	 et	 al.,	 2014).	 It	 was	 shown	 that	 LPAAT3	 is	localized	to	LDs	(Wilfling	et	al.,	2013).	PA	 is	 an	 important	 branch	 point	 in	 TAG	 synthesis	 as	 it	 is	 a	 precursor	 of	 CDP-diacylglycerol,	 which	 in	 turn	 is	 a	 precursor	 of	 phosphatidylglycerol	 (PG),	phosphatidylinositol	(PI),	phosphatidylserine	(PS)	and	cardiolipin	(CL).		
1.4.4. DAG synthesis 	The	third	step	in	the	glycerol	phosphate	pathway	is	the	dephosphorylation	of	PA,	which	is	 performed	 by	 phosphatidic	 acid	 phosphatases	 (PAPs),	 also	 known	 as	 lipins.	 Three	existing	mammalian	lipin	isoforms	(lipin1-3)	are	localized	in	the	cytosol	and	translocate	to	 the	 ER	 to	 hydrolyze	 PA	 in	 the	 presence	 of	 FAs	 or	 acyl-CoAs	 (Gomez-Muñoz	 et	 al.,	1992;	 Takeuchi	 and	 Reue,	 2009).	 Lipin1	 was	 identified	 first	 and	 was	 shown	 to	 be	prominently	expressed	in	the	mouse	adipose	tissue,	skeletal	muscle	and	testis	(Péterfy	et	 al.,	 2001).	 Lipin2	 is	mainly	 expressed	 in	 the	mouse	 liver	 and	 brain,	while	 lipin3	 is	mostly	found	in	the	gastrointestinal	tract	(Donkor	et	al.,	2007).		DAG,	which	is	synthesized	in	this	step	of	glycerol	phosphate	pathway,	is	a	precursor	for	phosphatidylcholine	(PC)	and	phosphatidylethanolamine	(PE).		
1.4.5. DGAT activity - the final step in TAG synthesis 	The	acylation	of	DAG	at	 the	sn3	position	with	acyl-CoA	 is	 the	 final	step	 in	 the	glycerol	phosphate	pathway	and	is	catalyzed	by	the	DGAT	enzymes	DGAT1	and	DGAT2.	Although	they	catalyze	the	same	reaction,	these	enzymes	belong	to	different	protein	families	and	do	 not	 share	 significant	 sequence	 homology	 (Yen	 et	 al.,	 2015).	 DGAT1	 belongs	 to	 a	membrane	 bound	 O-acyl	 transferase	 (MBOAT)	 family	 together	 with	 Acyl-CoA	
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cholesterol	 acyltransferases	 (ACATs),	 whereas	 DGAT2	 belongs	 to	 a	 diacylglycerol	acyltransferase	 family	 together	 with	 monoacylglycerol	 acyltransferases	 (MGATs)	 and	some	wax	 synthases	 (Yen	 et	 al.,	 2008).	 In	 humans	 DGAT1	 is	 highly	 expressed	 in	 the	small	intestine,	testis,	adipose	tissues,	mammary	glands,	thymus,	skeletal	muscle,	spleen,	heart	and	skin;	in	mice	–	in	the	small	 intestine,	testis,	adipose	tissues,	mammary	gland	and	 skin	 (Yen	 et	 al.,	 2008).	 The	 highest	 expression	 of	 human	 DGAT2	 is	 in	 the	 liver,	adipose	 tissue,	mammary	 gland,	 testis,	 peripheral	 leukocytes	 and	 heart.	 In	 the	mouse	DGAT2	has	highest	expression	in	the	liver,	testis,	heart,	kidney,	stomach,	small	intestine,	skeletal	muscle,	 skin	 and	uterus	 (Yen	 et	 al.,	 2008).	 The	 functional	 importance	 of	 both	enzymes	was	shown	by	DGAT1	and	DGAT2	knockout	mouse	models.	DGAT2	seems	to	be	the	dominant	DGAT	protein	as	 the	DGAT2	knockout	mice	died	a	 few	hours	after	birth	and	 their	 carcass	 TAG	 content	 was	 reduced	 by	 90%	 compared	 to	 wild-type	 animals.	Furthermore,	their	permeability	barrier	function	in	the	skin	was	impaired	(Stone	et	al.,	2004).	DGAT2	is	localized	to	ER	and	LDs	(Cao	et	al.,	2007;	Kuerschner	et	al.,	2008;	Stone	et	 al.,	 2009).	 DGAT1	 knockout	 mice	 were	 viable,	 had	 reduced	 adiposity	 and	 were	resistant	to	diet-induced	obesity	(Smith	et	al.,	2000).		An	alternative,	acyl-CoA	independent	way	for	TAG	synthesis	has	been	 identified	 in	the	rat	 intestine	 (Lehner	and	Kuksis,	1993).	An	enzyme	having	 transacylase	activity	could	convert	two	DAG	molecules	into	TAG	and	MAG,	however,	the	gene	coding	for	a	protein	with	such	activity	has	not	been	identified	(Lehner	and	Kuksis,	1993;	Yen	et	al.,	2015).		
1.4.6. Monoacylglycerol pathway 	As	mentioned	before	in	chapter	1.4,	TAG	can	be	synthesized	via	the	MAG	pathway.	The	main	players	here	are	MGATs.	They	perform	the	initial	step	of	this	pathway,	which	is	the	acylation	 of	MAG.	MAG	 comes	mainly	 from	TAG	 hydrolysis.	 Three	MGATs	 (MGAT1-3)	were	 identified	 in	humans.	MGAT3	 is	only	 found	 in	humans	and	higher	mammals,	but	not	 in	 mice	 and	 other	 rodents	 (Shi	 and	 Cheng,	 2009).	 MGATs	 together	 with	 DGAT2	belong	 to	 the	 same	 protein	 family.	 In	 vitro	 MGAT3	 possesses	 both	 MGAT	 and	 DGAT	activities	(Brandt	et	al.,	2016).	Being	on	the	same	line	DGAT1	possesses	MGAT	activity	in	a	cell-free	assay	(Yen	et	al.,	2005).	All	three	MGAT	proteins	are	localized	to	the	ER	(Cao	et	al.,	2007;	Yen	and	Farese,	2003;	Yen	et	al.,	2002,	2015).			The	 second	 step	 in	 the	 MAG	 pathway	 is	 the	 same	 as	 in	 the	 last	 step	 of	 the	 glycerol	phosphate	pathway,	namely	the	acylation	of	DAG	via	DGAT	enzymes,	see	Figure	2.	
Introduction		
	 17	
1.5. TAG mobilization  	When	energy	demand	in	the	organism	increases,	TAG	is	broken	down	in	adipose	tissue	and	generated	free	FAs	are	delivered	within	the	bloodstream	to	peripheral	tissues	for	β-oxidation	 and	 ATP	 production	 (Lass	 et	 al.,	 2011).	 The	 complete	 TAG	 hydrolysis	 is	enabled	by	 three	 lipases:	 the	adipose	TAG	 lipase	(ATGL),	 the	hormone	sensitive	 lipase	(HSL)	 and	 the	 monoacylglycerol	 lipase	 (MGL).	 These	 proteins	 sequentially	 hydrolyze	TAG	to	generate	glycerol	and	FAs.	ATGL	is	the	major	TAG	hydrolase	in	adipose	tissue.	It	catalyzes	the	initial	rate-limiting	step	of	TAG	breakdown	(Zimmermann	et	al.,	2004).	ATGL	predominantly	generates	sn-1,3	 and	 sn-2,3	 DAG	 (Eichmann	 et	 al.,	 2012).	 This	 DAG	 is	 then	 hydrolyzed	 by	 HSL	 to	produce	MAG,	which	in	the	final	step	is	hydrolyzed	by	MGL.		In	mice	 ATGL	 is	 highly	 expressed	 in	 white	 and	 brown	 adipose	 tissue	 and	 to	 a	 lesser	extent	in	the	testis,	heart,	skeletal	muscle	and	other	tissues	(Zimmermann	et	al.,	2004).	ATGL	 knockout	 mice	 have	 increased	 body	 fat	 mass	 and	 neutral	 lipids	 accumulate	 in	most	tissues	(Haemmerle	et	al.,	2006).	
In	vitro,	HSL	can	hydrolyze	various	substrates	such	as	TAG,	DAG,	MAG,	cholesterol	ester	(CE),	however,	the	highest	relative	activity	is	towards	DAG	(Fredrikson	et	al.,	1981).	As	the	 name	 implies,	 HSL	 is	 regulated	 by	 hormones	 such	 as	 catecholamine,	adrenocorticotropic	 hormones	 and	 glucagon	 that	 stimulate	 the	 activity	 of	 this	 lipase	(Kraemer	and	Shen,	2002).	The	hormonal	activation	of	HSL	occurs	via	phosphorylation	by	cyclic	AMP-dependent	protein	kinase	(PKA)	(Kraemer	and	Shen,	2002).		Under	 energy	 demand	TAG	hydrolysis	 takes	 place	 in	 the	 adipose	 tissue.	 Free	 FAs	 are	released	 from	 adipocytes	 into	 the	 blood,	 bound	 to	 albumin	 and	 delivered	 to	 other	tissues.	 FAs	 can	 also	 be	 delivered	 to	 ectopic	 tissues	 in	 form	 of	 TAG.	 Such	 TAGs	 are	packed	 into	chylomicrons	 in	enterocytes	or	 into	VLDLs	 in	the	 liver.	These	 lipoproteins	are	then	released	into	the	blood	stream	and	TAGs	are	hydrolyzed	by	endothelium-bound	lipoprotein	 lipase	 (Goldberg,	 1996).	 By	 hydrolysis	 released	 FAs	 or	 whole	 VLDLs	 are	taken	up	by	the	cells	(Goldberg,	1996;	Pillutla	et	al.,	2005).	Once	inside	the	cell,	FAs	are	activated	by	forming	thioesters	with	CoA	(Aon	et	al.,	2014),	see	chapter	1.4.1.	Activated	FAs	can	then	be	utilized	for	β-oxidation.	
Introduction		
	 18	
1.6. Mitochondrial β-oxidation		FAs	 generated	 by	 TAG	 hydrolysis	 can	 be	 used	 for	 energy	 production	 via	 β-oxidation.	This	is	a	process	for	subsequent	FA	degradation	into	acetyl-CoA	molecules.	Although	the	β-oxidation	can	also	take	place	in	peroxisomes,	the	mitochondrion	is	the	major	organelle	for	this	type	of	fatty	acid	oxidation	(Aon	et	al.,	2014).		LCFAs	activated	 to	 long-chain	acyl-CoAs	cannot	directly	enter	 the	mitochondria	as	 the	mitochondrial	membrane	 is	 impermeable	 for	 them	(Houten	and	Wanders,	2010).	This	problem	 is	 solved	 by	 the	 carnitine	 shuttle.	 Carnitine	 palmitoyltransferase	 I	 (CPT1)	initiates	 the	 transport	 by	 converting	 an	 acyl-CoA	 into	 the	 acylcarnitine	 (Houten	 and	Wanders,	 2010),	 see	 Figure	 3.	 Acylcarnitine	 gets	 into	 mitochondrial	 intermembrane	space	and	from	here	it	is	translocated	across	the	inner	mitochondrial	membrane	by	the	enzyme	 called	 carnitine-acylcarnitine	 translocase	 (CACT),	 which	 exchanges	 carnitines	from	 the	matrix	 for	 acylcarnitines	 from	 the	 intermembrane	 space.	 Once	 translocated,	acylcarnitines	 are	 converted	 back	 to	 acyl-CoAs	 by	 the	 action	 of	 carnitine	palmitoyltransferase	 II	 (CPT2),	 which	 is	 located	 on	 the	 internal	 face	 of	 the	 inner	mitochondrial	membrane.	Generated	acyl-CoA	can	 then	enter	β-oxidation	 cycle,	which	consists	 of	 four	 reactions.	 After	 one	 full	 cycle,	 acyl-CoA	 is	 shortened	 by	 two	 carbon	atoms	and	these	two	carboxy-terminal	carbon	atoms	are	released	as	acetyl-CoA	(Houten	and	Wanders,	2010).		Figure	 4	 shows	 four	 reactions	 of	 the	 mitochondrial	 β-oxidation	 cycle.	 In	 the	 first	reaction,	 acyl-CoA	 is	 dehydrogenated	 to	 form	 trans-2-enoyl-CoA,	 which	 has	 a	 trans-double	bond	between	C2	and	C3	carbon	atoms,	see	Figure	4,	 (Thorpe	and	Kim,	1995).	This	step	is	performed	by	acyl-CoA	dehydrogenases	(ACADs).	ACADs	are	classified	into	very	 long-chain	 acyl-CoA	 dehydrogenases	 (VLCADs),	 long-chain	 acyl-CoA	dehydrogenases	(LCADs),	medium-chain	acyl-CoA	dehydrogenases	(MCADs)	and	short-chain	acyl-CoA	dehydrogenases	(SCADs)	(Houten	and	Wanders,	2010)	depending	on	the	acyl-CoA	chain	length,	see	Figure	3.		In	the	second	step	of	mitochondrial	β-oxidation,	the	double	bond	of	trans-2-enoyl-CoA	is	hydrated	 by	 the	 enoyl-CoA	 hydratase	 to	 yield	 L-3-hydroxy-acyl-CoA,	 which	 is	subsequently	 dehydrogenated	 to	 3-keto-acyl-CoA	 in	 the	 third	 step	 by	 the	 action	 of	hydroxyacyl-CoA	dehydrogenase	(Houten	and	Wanders,	2010).	In	the	final	step,	3-keto-acyl-CoA	 is	 cleaved	 by	 3-keto-acyl-thiolase	 to	 generate	 acetyl-CoA	 and	 acyl-CoA,	
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shortened	by	two	carbon	atoms,	see	Figure	4.	Acetyl-CoA	can	then	be	used	for	the	citric	acid	 cycle	 and	 acyl-CoA	 can	 then	 enter	 another	 cycle	 of	 β-oxidation.	 Each	 β-oxidation	cycle	 yields	 one	 flavin	 adenine	 dinucleotide	 (FADH2)	 and	 one	 nicotinamide	 adenine	dinucleotide	(NADH)	(Houten	and	Wanders,	2010).	These	both	electron	carriers	can	be		used	in	electron	transport	chain	for	ATP	production	via	the	oxidative	phosphorylation.
	
Figure	3.	Mitochondrial	β-oxidation.		Acyl-CoA	 is	 converted	 to	 acylcarnitine	 by	 CPT1.	 Afterward,	 acylcarnitine	 is	 transported	 into	 the	mitochondria.	 This	 process	 is	 facilitated	 by	 CACT.	 Once	 inside	 the	 mitochondria	 acylcarnitine	 is	converted	back	to	acyl-CoA	by	CPT2.	VLCAD,	LCAD,	MCAD,	SCAD	(according	to	acyl-CoA	chain	length)	convert	 acyl-CoA	 to	 enoyl-CoA.	 Enoyl-CoA	 is	 hydrated	 to	 3-hydroxyacyl-CoA	 by	 the	 hydratase	subunit	of	the	MTP	protein	(for	long-chain	acyl-CoAs)	or	by	the	crotonase	(for	medium/short-chain	acyl-CoAs).	 MTP	 is	 a	 mitochondrial	 trifunctional	 protein	 that	 has	 hydratase,	 LCHAD	 and	 thiolase	activities.	 LCHAD	 and	 M/SCHAD	 transform	 3-hydroxyacyl-CoA	 to	 3-ketoacyl-CoA,	 which	 is	subsequently	 converted	 to	 acyl-CoA	 and	 acetyl-CoA	 by	 MCKAT	 for	 medium	 and	 short-chain	 3-ketoacyl-CoAs	and	MPT	thiolase	subunit	for	long-chain	3-ketoacyl-CoAs.	Acyl-CoA	can	then	enter	the	second	cycle	of	β-oxidation.	The	oxidation	of	unsaturated	FAs	requires	the	action	of	DCI.	C4	to	C18	represent	 the	 length	 of	 acyl-CoAs.	 (CPT1,	 carnitine	 palmitoyltransferase	 I;	 CACT,	 carnitine-acylcarnitine	translocase;	CPT2,	carnitine	palmitoyltransferase	II;	VLCAD,	LCAD,	MCAD,	SCAD	-	very	long,	 long,	 medium,	 short-chain	 acyl-CoA	 dehydrogenases;	 LCHAD,	 long-chain	 hydroxyacyl-CoA	dehydrogenase;	 M/SCHAD,	 medium	 and	 short	 chain	 hydroxyacyl-CoA	 dehydrogenase,	 MCKAT,	medium-chain	 3-ketoacyl-CoA	 thiolase;	 DCI,	 dodecenoyl-CoA	 delta	 isomerase)	 	 	 Modified	 from	(Houten	 and	 Wanders,	 2010).	 Image	 of	 mitochondria	 is	 taken	 from	http://www.servier.com/Powerpoint-image-bank.	
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Figure	4.	Reactions	of	β-oxidation	showing	substrates,	products,	enzymes	and	cofactors.		Reaction	schemes	were	taken	from	https://en.wikipedia.org/wiki/Beta_oxidation.		
1.7. Click labeling in lipid research 	In	order	 to	 follow	the	metabolism	or	 the	cellular	 localization	of	 the	 lipid	of	 interest,	 it	needs	 to	be	 labeled.	 It	 is	 relatively	easy	 to	 label	proteins	using	different	 tags	 together	with	 molecular	 cloning	 approach.	 Lipids,	 however,	 cannot	 be	 labeled	 genetically.	Moreover,	 they	 are	 relatively	 small	 molecules	 that	 need	 small	 labels.	 For	 decades	scientists	 have	 been	 using	 radioactive	 labeling	with	 14C	 or	 3H	 for	 lipid	 research.	 Such	labeling	does	not	interfere	with	the	structure	of	a	lipid	and	is	sensitive.	However,	work	with	radioactive	materials	is	an	expensive,	tedious	and	relatively	dangerous	tool,	which	requires	 specific	 laboratories	 and	 regulations.	 Recently,	 a	 new	method	 for	 labeling	 of	lipids	 based	 on	 click	 chemistry/click	 reaction	 was	 established	 (Gaebler	 et	 al.,	 2013;	Thiele	 et	 al.,	 2012).	 The	 click	 reaction	 is	 based	 on	 a	 [3+2]	 cycloaddition	 of	 terminal	alkynes	with	azides	described	by	Huisgen	(Huisgen,	1963).	Originally	this	reaction	takes	place	 at	 high	 temperature	 and	 pressure	 conditions	 and	 is	 not	 suitable	 for	 biological	systems	or	routine	laboratory	work.	In	2002	two	independent	groups	found	that	upon	
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addition	of	Cu(I)	catalyst	 the	same	reaction	could	take	place	at	room	temperature	and	mild	conditions	(Rostovtsev	et	al.,	2002;	Tornøe	et	al.,	2002).	Since	then	click	reaction	found	 the	 way	 in	 biological	 applications.	 In	 this	 work	 lipids	 that	 are	 labeled	 with	terminal	 alkynes	 were	 used.	 The	 terminal	 alkyne	 group	 is	 very	 small	 and	 can	 be	incorporated	into	FAs	without	much	disturbing	the	structure	of	the	hydrocarbon	chain	(Thiele	et	al.,	2012).	When	fed	with	such	labeled	FAs,	cells	incorporate	them	in	different	cellular	lipids.	After	lipid	extraction,	the	click	reaction	is	performed	with	azide	coupled	coumarin,	which	is	used	as	the	reporter	dye,	see	Figure	5.	Lipids	can	then	be	separated	using	 thin	 layer	 chromatography	 (TLC)	 and	 the	 fluorescence	 of	 coumarin	 can	 be	detected	with	a	camera.		The	click	method	could	also	be	used	for	the	labeling	of	proteins	(Dieterich	et	al.,	2006),	carbohydrates	(Hsu	et	al.,	2007)	and	DNA	(Salic	and	Mitchison,	2008);	nevertheless,	 it	has	an	especially	high	potential	in	lipid	research.	In	 this	 thesis	 the	 click	 labeling	 method	 was	 used	 to	 investigate	 the	 metabolism	 of	MCFAs.	
	
Figure	5.	Schematic	representation	of	the	experiment,	where	lipids	with	terminal	alkyne	
tags	are	used.	In	this	particular	case,	FA	alkyne-oleate	is	fed	to	cells	for	a	specific	time	period.	Cells	take	up	FAs	and	incorporate	them	in	different	cellular	 lipids,	one	of	which	is	PC.	After	 lipid	extraction	click	reaction	with	 azido-coumarin	 follows	 and	 coumarin	 labeled	 fluorescent	 lipids	 are	 formed.	 Lipids	 are	separated	using	TLC.	After	excitation	 fluorescence	signal	 is	detected,	which	can	 then	be	quantified.	Modified	from	(Thiele	et	al.,	2012).		
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2. Aim of this study 
	MCFAs,	which	are	a	particular	type	of	FAs,	do	contribute	to	the	modern	human	diet.	We	ingest	MCFAs	with	our	nutrition,	especially	with	coconut	oil	or	milk.	With	the	increasing	occurrence	of	these	FAs	both	in	home	made	and	in	industrially	processed	food,	there	is	a	need	 to	 better	 understand	 their	 metabolism.	 The	 scientific	 literature	 on	 MCFA	metabolism	is	relatively	sparse	and	contradictive,	nevertheless	showing	different	trends	compared	 to	 LCFA	 metabolism.	 The	 aim	 of	 this	 thesis	 is	 to	 contribute	 to	 a	 better	understanding	 of	MCFA	metabolism	 in	 two	 cell	 types	 important	 for	 lipid	metabolism,	namely	adipocytes	and	hepatocytes.	To	do	this	several	key	questions	will	be	addressed:		
• Which	cells	and	organs	can	synthesize	TAG	from	MCFAs?	
• Do	cells	that	are	unable	to	synthesize	MCTs	can	uptake	MCFAs?		
• What	is	the	rate	of	MCFA	uptake	compared	to	LCFAs?	
• Which	 enzymatic	 activities	 in	 glycerol	 phosphate	 pathway	 contribute	 to	 MCT	synthesis?	
• What	 are	 the	 possible	mechanisms	 that	 enable	MCT	 synthesis	 in	 differentiated	3T3-L1	cells	and	primary	hepatocytes?			
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3. Materials and Methods 
3.1. Materials 
3.1.1. Cell lines, cell culture media and supplements 	
Table	2.	Cell	medium	and	supplements.	
Product	 Company	and	catalog	number	DEXA	(Dexamethasone)	 Sigma-Aldrich	Chemie	GmbH;		Munich,	Germany,		D4902	DMEM	(Dulbecco's	Modified	Eagle	Medium)		 Life	Technologies	GmbH;	Darmstadt,	Germany,	31966047	DMSO	(dimethyl	sulfoxide)	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany,	276855	FBS	(Fetal	Bovine	Serum)	 Life	Technologies	GmbH;	Darmstadt,	Germany,	10270106	Gln	(L-Glutamine	(200	mM))	 Life	Technologies	GmbH;	Darmstadt,	Germany,	25030123	IBMX	(3-Isobutyl-1-methylxanthine)	 Sigma-Aldrich	Chemie	GmbH;		Munich,	Germany,		I5879	Insulin	solution,	human		 Sigma-Aldrich	Chemie	GmbH;		Munich,	Germany,		I9278	NEAA	(MEM	Non-Essential	Amino	Acids	Solution	(100X)	 Life	Technologies	GmbH;	Darmstadt,	Germany,	11140068	Opti-MEM	 Life	Technologies	GmbH;	Darmstadt,	Germany,		31985047	P/S	(Penicillin-Streptomycin	Solution)	 Life	Technologies	GmbH;	Darmstadt,	Germany,	15140130	Rosi	(Rosiglitazone)	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany,		R2408	RPMI	1640	 PAN	Biotech	GmbH;	Aidenbach,	Germany,	P04-17500	Trypsin-EDTA	(0.05%)	 Life	Technologies	GmbH;	Darmstadt,	Germany,	25300062	William’s	E	Medium	 PAN	Biotech	GmbH;	Aidenbach,	Germany,	P04-29510					 	
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Table	3.	Cell	lines	and	cell	line	specific	medium	conditions.	
Name	 Description	 Medium	 Medium	supplements	3T3-L1	 Fibroblast-like	 mouse	 embryonic	cell	line	 DMEM	 20%	 FBS;	 for	 differentiation	additionally:		
• 5	μg/ml	insulin,		
• 10	μM	dexamethasone,		
• 0.5	mM	IBMX		
• 5.6	μM	rosiglitazone	A431	 Human	 epidermoid	 carcinoma	 cell	line	 DMEM	 10%	FBS	Cos7	 Fibroblast-like	monkey	kidney	 cell	line	 DMEM	 10%	FBS	HCT	 Human	 colorectal	 carcinoma	 cell	line	 DMEM	 10%	FBS	Hek293	 Human	embryonic	kidney	cell	line	 DMEM	 10%	FBS	HepG2	 Human	liver	carcinoma	cell	line	 DMEM	 10%	FBS	Huh7	 Human	liver	carcinoma	cell	line	 RPMI	 10%	FBS,	10	mM	HEPES,	0.1	mM	NEAAs,	2	mM	Gln	Primary	mouse	hepatocytes	
Isolated	from	mouse	liver	 William’s	E	Medium	 10%	 FBS,	 2	 mM	 Gln,	 100	U/ml	 Penicillin,	 100	 µg/ml	Streptomycin		
3.1.2. Chemicals, reagents and lipids 	
Table	4.	Chemicals,	reagents	and	lipids.	
Product	 								Company	
10:0	DAG	(1,2-didecanoyl-sn-glycerol)	 Avanti	Polar	Lipids	Inc.;	Alabaster,	USA	
12:0	DAG	(1,2-didodecanoyl-sn-
glycerol)	
Avanti	Polar	Lipids	Inc.;	Alabaster,	USA	
18:0	DAG	(1-2-dioleoyl-sn-glycerol)	 Avanti	Polar	Lipids	Inc.;	Alabaster,	USA	
3-Azido-7-Hydroxy-Coumarin	 Thiele	et	al.,	2012	
8:0	DAG	(1,2-dioctanoyl-sn-glycerol)	 Avanti	Polar	Lipids	Inc.;	Alabaster,	USA	
Acetic	acid	 VWR	International	GmbH;	Langenfeld,	Germany	
Acetonitrile	 VWR	International	GmbH;	Langenfeld,	Germany	
Acrylamide	(30%	solution)	 Applichem	GmbH;	Darmstadt,	Germany	
Agarose,	UltraPure	 Life	Technologies	GmbH;	Darmstadt,	Germany	
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Ammonium	persulfate	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
ATP	 Applichem	GmbH;	Darmstadt,	Germany	
Bromophenol	Blue	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
BSA	(Bovine	serum	albumin	fraction	V)	 Applichem	GmbH;	Darmstadt,	Germany	
Chloroform	(CHCl3),	stabilized	with	
EtOH	
VWR	International	GmbH;	Langenfeld,	Germany	
CoA	(Coenzyme	A	trilithium	salt)	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
Collagen	(type	I)	from	rat	tail	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
Collagenase	NB	G4	from	Clostridium	
histolyticum	
Serva	GmbH;	Duisburg,	Germany	
Cu(I)TFB	
(Tetrakis(acetonitrile)copper(I)	
tetrafluoroborate)	
Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
Decanoyl	coenzyme	A	monohydrate	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
Decanoic	acid	(C10:0)	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
Deoxycholate	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
DL-BSA	(Bovine	serum	albumin	H2,	
delipidated)	
Applichem	GmbH;	Darmstadt,	Germany	
EDTA	 Applichem	GmbH;	Darmstadt,	Germany	
EGTA	 Carl	Roth	GmbH;	Karlsruhe,	Germany	
Ethanol	(EtOH)	 VWR	International	GmbH;	Langenfeld,	Germany	
Ethyl	acetate	 Julius	Hoesch	GmbH;	Düren,	Germany	
G3P	(L-α-Glycerol	phosphate	
bis(cyclohexylammonium)	salt)	
Sigma-Aldrich	 Chemie	 GmbH;	 Munich,	 Germany,	G7886	
Glycerol	 Grüssing	GmbH;	Filsum,	Germany	
Glycine	 Applichem	GmbH;	Darmstadt,	Germany	
HBSS	(Hanks’	Balanced	Salt	Solution)	 Sigma-Aldrich	 Chemie	 GmbH;	 Munich,	 Germany,	H1387	
HCl	(Hydrochloric	Acid,	12M,	37%)	 VWR	International	GmbH;	Langenfeld,	Germany	
Heparin-Natrium-25000-ratiopharm®	 Ratiopharm	GmbH;	Ulm,	Germany	
HEPES	 Applichem	GmbH;	Darmstadt,	Germany	
Hexan	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
HSLi	(Hormone-sensitive	lipase	
inhibitor)	
Cayman	 Chemical	 Company;	 Ann	 Arbor,	 USA,	CAY10499	
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Hünig’s	base	(N,N-
Diisopropylethylamine)	 TCI	Deutschland	GmbH;	Eschborn,	Germany	
Isopropanol	 VWR	International	GmbH;	Langenfeld,	Germany	
Ketamine	 Pfizer	Inc.;	New	York,	USA	
KH2PO4	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
KOH	(Potassium	hydroxide	pellets)	 Merck	Chemicals	GmbH;	Darmstadt,	Germany	
Lipase	from	porcine	pancreas	(from	
Lipase	Basic	Kit)	
Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
Lipofectamine	2000	 Life	Technologies	GmbH;	Darmstadt,	Germany	
LPA	(1-	oleoyl	-2-hydroxy-sn-glycero-3-
phosphate)	
Avanti	Polar	Lipids	Inc.;	Alabaster,	USA	
LPC	(1-Oleoyl-sn-glycero-3-
phosphocholine)	
Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
MeOH	(methanol)	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
MgCl2	 Applichem	GmbH;	Darmstadt,	Germany	
Milk	powder	 Heirler-Cenovis	GmbH;	Radolfzell,	Germany	
Na2HPO4	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
NaCl	 Th.	Geyer	GmbH	&	Co.	KG;	Lohmar,	Germany	
NaOH	(Sodium	hydroxide,	1M)	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
Oleic	acid	(C18:1)	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
Oleoyl	coenzyme	A	lithium	salt	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
PC	(lecithin	from	soybean)	 Applichem	GmbH;	Darmstadt,	Germany	
Protease	Inhibitor	Cocktail,	cOmplete™,	
EDTA-free	
Roche	Diagnostics	Deutschland	GmbH;	Mannheim,	Germany	
Rompun	 Bayer	AG;	Leverkusen,	Germany	
SDS	 Applichem	GmbH;	Darmstadt,	Germany	
Silica	gel	60	(0.063-0.200	mm)	 Merck	Chemicals	GmbH;	Darmstadt,	Germany	
Sucrose	(D-Sucrose)	 Carl	Roth	GmbH;	Karlsruhe,	Germany	
TEMED	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
Tris	 Applichem	GmbH;	Darmstadt,	Germany	
Trypan	blue	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
Tween-20	 Applichem	GmbH;	Darmstadt,	Germany	
β-Mercaptoethanol	 Applichem	GmbH;	Darmstadt,	Germany	
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3.1.3. Buffers, solutions and kits 	
Table	5.	Buffers,	solutions	and	kits.	
Buffer	 Composition	
10x	PBS	 27	mM	KCl	17.6	mM	KH2PO4	1.38	M	NaCl	101	mM	Na2HPO4	
1x	Running	buffer	 25	mM	Tris	192	mM	glycine	0.1%	(w/v)	SDS	
4x	Separating	gel	buffer		 1.5	M	Tris-HCl	pH	8.8	0.4%	(w/v)	SDS	
4x	Stacking	gel	buffer	 0.5	M	Tris-HCl	pH	6.8	0.4%	(w/v)	SDS	
5x	Laemmli	buffer	 250	mM	Tris-HCl	pH	6.8	40%	Glycerol	12%	(w/v)	SDS	5%	β-mercaptoethanol		0.01%	bromophenol	blue	
Blocking	buffer	 PBST	5%	milk		
Blotting	buffer	 40%	1x	Running	buffer	40%	water	20%	methanol	
BSA	solution	 50	mg/ml	in	75	mM	Tris-HCl,	pH	7.4	
Coupled	assay	buffer	 75	mM	Tris-HCl,	pH	7.4	10	mM	MgCl2	
DGAT	assay	buffer	 100	mM	Tris-HCl,	pH	7.4	2	mM	MgCl2	200	mM	sucrose	1	mg/ml	DL-BSA	
EDTA	 0.5	M,	pH	7.4	
EGTA	 100	mM,	pH	7.4	
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GPAT	assay	buffer	 75	mM	Tris-HCl,	pH	7.4	2	mM	MgCl2	1	mg/ml	DL-BSA	
HBSS	buffer	
pH	7.4	
1	package	of	HBSS	powder	for	1L	of	buffer	0.35	g/L	NaHCO3	
LPAAT	assay	buffer	 60	mM	Tris-HCl,	pH	7.4	3	mM	MgCl2	1	mg/ml	DL-BSA	
Lysis	buffer	 10	mM	Tris-HCl,	pH	7.4	250	mM	sucrose	1x	protease	inhibitor		
MACS	buffer	 50	ml	HBSS	buffer	2	mM	EDTA	0.005	g/ml	BSA	
PBST	 1x	PBS	0.1%	Tween-20	
Perfusion	buffer	 50	ml	William’s	E	medium	0.5	mg/ml	Collagenase		
Pre-perfusion	buffer	 50	ml	HBSS	buffer	500	µM	EGTA		50	µl	Heparin	(250	international	units)	
Wash	buffer	 1x	PBS	2%	DL-BSA		
3.1.4. Nomenclature of alkyne lipids used or mentioned in this work 	In	this	work	FAs	having	alkyne	group	at	the	end	of	carbon	atom	chain	were	used.		Figure	6	(chapter	4.1.1)	illustrates	the	structure	of	two	FAs	most	relevant	to	this	work,	namely	C11-alkyne-FA	and	C19-alkyne-FA.	Alkyne	lipids	used	in	this	thesis	are	listed	in	Table	6.	C11-alkyne-FA	belongs	 to	MCFAs	 and	 represents	 C10:0	 FA;	 C19	 alkyne-FA	 represents	C18:1	 FA.	 For	 simplicity	 C11-alkyne-FA	will	 be	 called	 C11-FA.	 TAG,	 PC,	 acyl-CoA	 and	other	 lipids	 that	 have	 C11-FA	 incorporated	 in	 their	 structure	will	 be	 called	 C11-TAG,	C11-PC,	 C11-CoA	 respectively.	 The	 same	 naming	 scheme	 is	 used	 for	 C19	 and	 other	alkyne-FAs.		
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Table	6.	Alkyne	lipids.	
Lipid	name	in	the	thesis	 Source	C9-alkyne-FA	(C9-FA)	 Synthesized	in	AG	Thiele	C11-alkyne-FA	(C11-FA)	 TCI	Deutschland	GmbH;	Eschborn,	Germany	C13-alkyne-FA	(C13-FA)	 Synthesized	in	AG	Thiele	C17-alkyne-FA	(C17-FA)	 Synthesized	in	AG	Thiele	C19-alkyne-FA	(C19-FA)	 Synthesized	in	AG	Thiele	C11-alkyne-CoA	 Synthesized	in	AG	Thiele	C19-alkyne-CoA	 Synthesized	in	AG	Thiele	
sn2-C11-FA-TAG;	sn3-C11-FA-TAG	 Synthesized	in	AG	Thiele	
sn1-C19-FA-2-hydroxy-sn-glycero-3-phosphate	(C19-LPA)	 Synthesized	in	AG	Thiele	
3.1.5. Reagent systems and kits 	
Table	7.	Reagent	systems	and	kits.	
Product	 Company	
BCA	 reagent	 (Pierce™	 BCA	 Protein	
Assay	Kit)	
Thermo	Fisher	Scientific	GmbH;	Dreieich,	Germany	
CD11	 MicroBeads,	 human	 and	
mouse	
Miltenyi	Biotec	GmbH;	Bergisch	Gladbach,	Germany	
ECL	reagent	 Produced	in	AG	Thiele			
3.1.6. Consumables 	
Table	8.	Consumables.	
Product	 Company	
1.5	ml,	2	ml,	1.5	ml	micro	tubes	 Sarstedt	AG	&	Co;	Nümbrecht,	Germany	
24-well	 plate,	 12-well	 plate,	 6-well	
plate,	type	red	
Sarstedt	AG	&	Co;	Nümbrecht,	Germany	
Biosphere®	 Fil.	 Tip	 10	 µl,	 200	 µl,	
1000	µl	
Sarstedt	AG	&	Co;	Nümbrecht,	Germany	
Cannula	BD	Neoflon™	26	GA		
0.6	x	19	mm	13	ml/min	
BD	GmbH;	Kerpen,	Germany	
Capillaries,	glass	open	end	 Hilgenberg	GmbH;	Malsfeld,	Germany,	1413017	
Cell	culture	dish	∅10	cm		 Sarstedt	AG	&	Co;	Nümbrecht,	Germany	
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Cell	 culture	dish	with	gripping	ring	
∅ 	6	cm	
VWR	International	GmbH;	Langenfeld,	Germany	
Cell	strainer	40	µm,	EASYstrainer™			 Greiner	Bio-One	GmbH;	Frickenhausen	Germany	
Cell	strainer	70	µm,	100	µm	 Corning	Inc.;	NY,	USA	
CryoPure	Tube	2.0	ml	 Sarstedt	AG	&	Co;	Nümbrecht,	Germany	
Disposable	scalpels,	Cutfix®	 VWR	International	GmbH;	Langenfeld,	Germany	
Falcon	centrifuge	tubes	15	ml,		
50	ml	
Corning	Inc.;	NY,	USA	
Fast-Read	 102	 disposable	 counting	
chambers	
BioSigma	S.r.l.;	Venice,	Italy	
Filtropur	V50	500ml	0.2	µm	 Sarstedt	AG	&	Co;	Nümbrecht,	Germany	
Glass	Beads	∅ 	0.25-0.5	mm	 Carl	Roth	GmbH;	Karlsruhe,	Germany	
LS	Columns		 Miltenyi	Biotec	GmbH;	Bergisch	Gladbach,	Germany	
Needles	21	G,	0.8	x	120	mm	 Braun	Melsungen	AG;	Melsungen,	Germany	
Needles	 BD	 Microlance™	 3,	 30	 G	
1/2",	0.3	x	13	mm	
BD	GmbH;	Kerpen,	Germany	
Nitrocellulose	 membrane	 Protran	
BA85	
GE	Healthcare;	Chicago,	USA	
PARAFILM®	M	 Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	
Pasteur	Pipets,	glass,	long	tip	 VWR	International	GmbH;	Langenfeld,	Germany	
Pipette	tips	10	µl,	200	µl,	1000	µl	 Sarstedt	AG	&	Co;	Nümbrecht,	Germany	
Safe-Lock	tubes	1.5	ml,	2	ml	 Eppendorf	 Vertrieb	 Deutschland	 GmbH;	 Wesseling,	Germany	
Screw	cap	micro	tubes,	1.5	ml	 Sarstedt	AG	&	Co;	Nümbrecht,	Germany	
Serological	pipettes	5	ml,	10	ml,		
25	ml	
Sarstedt	AG	&	Co;	Nümbrecht,	Germany	
Silica	gel	60	(0.063-0.200	mm)	 Merck	Chemicals	GmbH;	Darmstadt,	Germany	
Syringe	1	ml,	3ml	Luer-Lok™	 BD	GmbH;	Kerpen,	Germany	
Syringe	1ml	Sub-Q,	0.45	mm	(26G)	x	
12.7mm	
BD	GmbH;	Kerpen,	Germany	
Syringe	filter,	pore	size	0.2	µm	 GE	Healthcare;	Chicago,	USA	
T-75	flask,	type	red	 Sarstedt	AG	&	Co;	Nümbrecht,	Germany	
Whatman	 paper	 (VWR®Grade	 703	
Blotting	Paper)	
VWR	International	GmbH;	Langenfeld,	Germany	
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3.1.7. Plasmids and antibodies 	
Table	9.	Plasmids.	
	
Table	10.	Antibodies.	
Antibody	 Host,	Clonality	 Dilution	in	WB	 Source	Anti-ACSL1	 Rabbit,	polyclonal	 1:500	 Sigma-Aldrich*		Anti-Agpat9	 Rabbit,	polyclonal	 1:500	 Sigma-Aldrich*	Anti-Flag	 Rabbit,	polyclonal	 1:1000	 Sigma-Aldrich*	Anti-GAPDH	 Mouse,	monoclonal	 1:3000	 Novus	Biologicals$	Anti-HA	 Mouse,	monoclonal	 1:1000	 Santa	Cruz#	Anti-mouse	 Goat,	polyclonal	 1:2500	 Jackson	&	Anti-rabbit	 Goat,	polyclonal	 1:2500	 Jackson	&	*	Sigma-Aldrich	Chemie	GmbH;	Munich,	Germany	$	Novus	Biologicals	LLC;	Littleton,	USA	#	Santa	Cruz	Biotechnology	Inc.;	Santa	Cruz,	USA	&	Jackson	ImmunoResearch	Laboratories	Inc.;	Baltimore	Pike,	USA	
3.1.8. Equipment 	
Table	11.	Equipment	used	for	experimental	work.	
Device	 Company	
Bio-Rad	Mini	protean	 Bio-Rad	Laboratories	Inc.;	Hercules,	USA	
Cell	cracker		 EMBL	workshop;	Heidelberg,	Germany	
Centrifuges	 5417R;	 5424;	 5430R;	
5810	
Eppendorf	 Vertrieb	 Deutschland	 GmbH;	 Wesseling,	Germany	
CO2	incubator	CB210	 Binder	GmbH;	Tuttlingen,	Germany	
CO2	incubator	Midi	40		 Thermo	Fisher	Scientific	GmbH;	Dreieich,	Germany	
Concentrator	plus		 Eppendorf	 Vertrieb	 Deutschland	 GmbH;	 Wesseling,	Germany	
Eppendorf	Research	plus	pipettes	 Eppendorf	 Vertrieb	 Deutschland	 GmbH;	 Wesseling,	Germany	
Plasmid	name	 Resistance	 Tag	 Gene		 Source	Flag-hAGPAT9	 Kanamycin	 Myc-DDK	 Human	AGPAT9	 Origene	 technologies	Inc.;	Rockville,	USA	Flag-hDGAT2	 Ampicillin	 Flag	 Human	DGAT2	 Scot	Stone	pEGFP-C1	 Kanamycin	 EGFP	 -	 Monika	Suchanek	plk91/pMoHA_hDGAT2wt	 Ampicillin	 -	 Human	DGAT2	 Lars	Kuerschner	pMoHA_ACSL1	 Ampicillin	 3HA	 Human	ACSL1	 Christine	Moessinger	plk24/pMoHA-hDGAT2	 Ampicillin	 3HA	 Human	DGAT2	 Lars	Kuerschner	
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LEDs,	10	x	1	W420	nm	 Roithner	Lasertechnik;	Viena,	Austria	
Mini-Beadbeater-8	 BioSpec	Products	Inc.;	Bartlesville,	USA	
Mouse	dissection	instruments	 Fine	Science	Tools	GmbH;	Heidelberg,	Germany	
NanoDrop	2000	 Thermo	Fisher	Scientific	GmbH;	Dreieich,	Germany	
Nikon	 eclipse	 TS100	 inverted	
microscope	
Nikon	GmbH;	Düsseldorf,	Germany	
Peristaltic	Pump	Drive	PD	5001	 Heidolph	 Instruments	 GmbH	 &	 Co.	 KG,	 Schwabach,	Germany	
QuadroMACS	separator	 Miltenyi	Biotec	GmbH;	Bergisch	Gladbach,	Germany	
Rolera	MGI	plus	EMCCD	camera	 Decon	Science	Tec	GmbH;	Hohengandern,	Germany	
Rotary	evaporator	 Heidolph	 Instruments	 GmbH	 &	 Co.	 KG;	 Schwabach,	Germany	
Sterile	bench	 Weiss	 Pharmatechnik	 GmbH;	 Sonnenbühl-Genkingen,	Germany	
Thermomixer	comfort	 Eppendorf	 Vertrieb	 Deutschland	 GmbH;	 Wesseling,	Germany	
TLC	 developing	 chamber	 for	 20	 x	
20	cm	plate	
VWR	International	GmbH;	Langenfeld,	Germany	
Vacuum	controller	CVC	3000	 Vacuubrand	GmbH	&	Co.	KG;	Wertheim,	Germany	
Vacuum	pump,	Vacusafe	comfort	 INTEGRA	Biosciences	AG;	Fernwald,	Germany	
Vibratom	VT	1200	 Leica	Camera	AG;	Wetzlar,	Germany	
Vortex	Genie	2	 Scientific	Industries	Inc.;	Bohemia,	USA	
Water	bath		 Memmert	GmbH	&	Co.	KG;	Schwabach,	Germany		
3.1.9. Computer programs 	
Table	12.	Computer	programs	and	their	usage.	
Program	 Company/Developer	 Usage	Fiji	(ImageJ	2.0.0-rc-48)	 Johannes	Schindelin,	Albert	Cardona	 Image	processing	Microsoft	Office	2011	 Microsoft	Corporation;	Washington,	USA	 Text,	image	processing,	calculations	Adobe	Illustrator	CS5	 Adobe	Systems	Inc.;	California,	USA	 Image	processing	Gel-Pro	Analyzer	6.0	 Media	Cybernetics;	Washington,	USA	 Analysis	of	TLC	plates,	WBs	GraphPad	Prism	6	 GraphPad	Software	Inc.;	La	Jolla;	USA	 Statistics,	data	processing		
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3.2. Methods 
3.2.1. Methods of cell biology 
3.2.1.1. Cell	culture		Cell	lines	used	for	experiments	were	maintained	in	specific	medium	indicated	in	Table	3,	in	a	humidified	incubator	at	37°	C	and	5	%	CO2.	To	avoid	overgrowth,	dividing	cells	were	passaged	on	regular	basis	using	trypsin-EDTA.		
3.2.1.2. Cell	freezing	and	thawing		One	confluent	T-75	flask	of	cells	was	used	to	prepare	5	cryo	tubes	(note:	30%	confluent	flasks	were	used	when	 freezing	undifferentiated	3T3-L1	 cells).	 Cells	were	 trypsinized,	pelleted	 at	500	g	 for	5	min	 and	mixed	with	 the	 freezing	medium,	 containing	 cell	 type	specific	medium	(see	Table	3),	20%	FBS	and	10%	DMSO.	Then	the	cells	were	transferred	to	 cryo	 tubes.	The	 tubes	were	placed	 into	a	 freezing	 container	 filled	with	 isopropanol	and	 stored	 at	 -80°	 C	 overnight.	 The	 following	 day	 the	 tubes	 were	 transferred	 into	 a	liquid	nitrogen	container.	Vials	containing	frozen	cells	were	thawed	at	room	temperature	(RT).	The	thawed	cells	were	transferred	to	T-75	flasks	and	fresh	medium	was	added.			
3.2.1.3. Differentiation	of	3T3-L1	cells		3T3-L1	cells	were	grown	to	100%	confluence.	Two	days	later	differentiation	induction	medium	consisting	of	DMEM	medium,	20%	FBS,	5	μg/ml	insulin,	10	μM	DEXA,	0.5	mM	IBMX	and	5.6	μM	rosiglitazone	was	added.	When	differentiation	induction	medium	was	introduced	the	so-called	day	0	of	differentiation	was	started.	On	day	3	of	differentiation,	induction	medium	was	changed	to	insulin	medium	(DMEM	medium	containing	20%	FBS	and	 5	 μg/ml	 insulin).	 On	 day	 5	 insulin	 medium	 was	 exchanged	 (i.e.,	 fresh	 insulin	medium	was	added).	On	day	7	a	normal	growth	medium	with	20%	FBS	was	added	to	the	cells.	Cells	differentiated	for	4-11	days	were	used	for	experiments.			
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3.2.1.4. DNA	transfection	with	Lipofectamine	2000		Normally	 cells	 were	 transfected	 in	 24-well	 plate	 format.	 Transfections	 in	 other	plate/dish	 types	 were	 adjusted	 to	 this	 format.	 The	 day	 before	 transfection	 80.000–100.000	of	cells	were	seeded	into	each	well	of	a	24-well	plate.	On	the	day	of	transfection	cell	 confluence	was	60–70%.	For	 transfection	250	ng	of	plasmid	DNA	was	mixed	with	12.5	µl	of	Opti-MEM	medium.	Then	0.75	µl	of	Lipofectamine	2000	was	mixed	with	12.5	µl	of	Opti-MEM	medium.	 	Both	mixtures	were	 incubated	for	5	min	at	RT.	Then	both	of	them	were	 combined	 and	 incubated	 for	 further	 20	min.	 The	 final	 DNA:Lipofectamine	2000	 ratio	was	1:3.	 In	 the	meantime,	 cells	were	washed	once	with	PBS	 and	250	µl	 of	Opti-MEM	 medium	 was	 added	 to	 each	 well.	 After	 incubation	 the	 DNA:Lipofectamine	2000	mixture	was	 added	 to	 cells.	 24	 hours	 after	 transfection	 the	 cells	 were	 used	 for	experiments.		
3.2.1.5. Feeding	cells	with	click	lipids			Cells	were	usually	fed	with	50	µM	of	FAs	for	1.5	hours.	For	pulse	experiments	longer	or	shorter	feeding	times	were	used.	For	pulse-chase	experiments	cells	were	first	fed	with	50	µM	of	FAs	for	1	hour,	when	click	lipids	were	removed	and	chase	medium	was	added	for	 in	 experiment	 indicated	 incubation	 time.	 In	 competition	 experiments	 varying	concentrations	of	FAs	were	used.		
3.2.2. Organ slices and primary cell culture 
3.2.2.1. Preparation	and	culture	of	organ	slices		A	mouse	was	anesthetized	using	a	mixture	of	Ketamine	and	Rompun	(90	mg/kg	body	weight	 and	 9.4	 mg/kg	 body	 weight	 respectively).	 Organs	 were	 dissected	 out	 of	 the	animal	 and	 transferred	 to	 cold	 HBSS	 buffer.	 The	 following	 organs	 were	 used:	 liver,	kidney,	brain,	heart,	muscle,	 spleen,	 lung,	 small	 intestine,	 eye,	pancreas	and	 testis.	4%	agarose	solution	in	HBSS	was	prepared	and	boiled	in	the	microwave.	Afterward,	it	was	transferred	into	a	50˚C	water	bath	and	kept	there	for	approx.	10	min	until	the	agarose	reached	50˚C	 temperature.	A	12-well	plate	was	placed	on	 ice	and	2/3	of	one	well	was	filled	with	agarose.	The	organ	was	taken	out	of	the	HBSS	buffer,	dried	with	tissue,	 laid	
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down	 on	 an	 agarose	 layer	 and	 additional	 agarose	 was	 added	 to	 cover	 the	 organ	completely.	Then	the	next	organ	was	handled.	Gut,	pancreas	and	testis	were	left	 in	the	buffer.	Organs	were	cut	with	a	vibratome	in	either	200	µm	(liver,	kidney,	brain,	heart)	or	300	µm	 (muscle,	 lung,	 spleen)	 slices.	 For	 200	µm	 slices,	 the	 sectioning	 speed	was	 0.4	mm/s	and	for	300	µm	slices	–	0.7	mm/s.	Gut,	eye,	pancreas	and	testis	were	cut	with	a	scalpel	because	 it	was	not	possible	 to	cut	 them	with	 the	vibratome.	Organ	slices	were	transferred	to	wells	of	a	24-well	plate.	0.5	ml	of	DMEM	medium	with	10%	horse	serum	and	click	fatty	acids	was	added	to	each	well	and	the	plate	with	slices	was	incubated	for	1.5	hours	at	37°C	and	5%	CO2.		
3.2.2.2. Isolation	of	primary	hepatocytes		Falcons	with	buffers	used	for	hepatocyte	isolation	were	placed	in	the	water	bath	at	42˚C.	A	mouse	was	first	 injected	with	150	µl	of	heparin.	10	min	 later	a	mixture	of	Ketamine	and	 Rompun	 (90	 mg/kg	 body	 weight	 and	 9.4	 mg/kg	 body	 weight	 respectively)	 was	injected.	 The	 anesthetic	 depth	 of	 the	mouse	was	monitored	 by	 pinching	 its	 feet	 with	anatomic	forceps.	The	anesthetized	mouse	was	fixed	to	an	operation	desk.	The	abdomen	was	opened	and	the	intestine	was	moved	to	the	right	to	make	the	portal	vein	visible.	A	cannula	was	pricked	into	the	portal	vein,	the	needle	was	discarded	and	the	cannula	was	connected	to	a	tube	of	the	peristaltic	pump,	which	was	already	turned	on	and	pumped	the	pre-perfusion	buffer	at	4	ml/min	flow	rate	corresponding	to	52	rpm.	When	the	liver	turned	 yellow,	 the	 vena	 cava	 was	 cut	 and	 the	 mouse	 was	 pre-perfused	 with	 pre-perfusion	 buffer	 for	 further	 5	 min.	 After	 that	 pre-perfusion	 buffer	 was	 changed	 to	perfusion	 buffer	 containing	 collagenase.	 The	 liver	was	 perfused	with	 perfusion	 buffer	for	 further	10	min.	Then	 the	perfused	 liver	was	carefully	dissected	by	cutting	 into	 the	diaphragm	 and	 placed	 into	 a	 beaker	 glass.	 45	ml	 of	 pre-warmed	 primary	 hepatocyte	medium	was	 added	 and	 liver	was	 shaken	 and	 rubbed	 against	 the	 glass.	 The	 achieved	suspension	of	liver	cells	was	then	transferred	to	a	50	ml	falcon	and	centrifuged	for	2	min	at	 8	 g.	 The	 supernatant	 was	 removed,	 30	ml	 of	 fresh	medium	was	 added,	 cells	 were	resuspended	 and	 passed	 through	 a	 100	 µm	 cell	 strainer.	 The	 living	 cell	 number	 was	counted	using	cell	counting	chambers	and	trypan	blue.	150.000	hepatocytes	were	plated	in	every	well	of	a	12-well	plate	and	200.000	or	400.000	cells	were	plated	in	every	well	of	
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a	 6-well	 plate	 or	 3.5	 cm	 dish.	 All	 plates	 and	 dishes	 used	 for	 hepatocyte	 plating	were	coated	with	collagen.	For	hepatocyte	isolation	18-20	week	old	male	mice	were	used.		
3.2.2.3. Coating	of	dishes	with	collagen		The	plates	and	dishes	 for	 the	primary	hepatocytes	have	 to	be	coated	with	collagen,	 to	ensure	attachment	of	 the	cells.	The	coating	was	performed	under	a	sterile	bench.	0.26	mg/ml	sterile	solution	of	collagen	was	added	to	the	plates	and	dishes	(1	ml	for	one	well	of	a	12-well	plate	and	2	ml	for	one	well	of	a	6-well	plate	or	6	cm	dish).	After	30	min	the	collagen	solution	was	withdrawn	and	collected.	It	was	reused	up	to	5	times.	Dishes	were	opened	and	left	 for	20	min	to	dry	in	the	 laminar	flow	hood	with	a	UV	lamp	turned	on.	Plates	can	be	stored	up	to	2	weeks	at	RT.		
3.2.2.4. Depletion	of	macrophages	from	isolated	hepatocytes	using	MACS		For	mRNA	sequencing	 it	was	 important	to	achieve	a	very	pure	hepatocyte	suspension,	which	 would	 be	 free	 from	 macrophages.	 For	 this	 MACS	 cell	 separation	 system	 with	CD11b	 MicroBeads	 was	 used.	 These	 beads	 consist	 of	 specific	 antibodies,	 which	recognize	 macrophages	 (liver	 macrophages	 are	 known	 as	 Kupffer	 cells).	 These	antibodies	 are	 conjugated	 to	 super	 paramagnetic	 particles.	 Anti-CD11b	 antibodies	specifically	bind	macrophages	which	during	separation	then	stay	in	the	column	where	a	magnetic	field	is	applied.	Other	cell	types	are	collected	in	the	flow-through.	The	isolation	of	 hepatocytes	was	done	 as	 in	 chapter	3.2.2.2.	However,	 after	 removal	 of	 supernatant	and	addition	of	new	medium	cells	were	centrifuged	one	more	time	for	2	min	at	8	g.	The	supernatant	was	 removed	and	20	ml	of	 fresh	medium	was	added.	The	cells	were	 first	passed	through	a	70	µm	cell	strainer	and	then	through	a	40	µm	cell	strainer.	Afterward,	the	cells	were	centrifuged	for	2	min	at	8	g,	the	supernatant	was	removed	and	20	ml	of	fresh	medium	was	added.	The	cells	were	counted	and	centrifuged	for	3	min	at	15	g.	The	supernatant	was	removed	completely	and	90	µl	of	MACS	buffer	per	10	million	of	cells	was	added.	Additionally,	10	µl	of	CD11b	MicroBeads	per	10	million	of	cells	was	added.	The	cell	suspension	was	mixed	well	and	incubated	in	the	refrigerator	(4˚C)	for	12	min.	After	incubation	the	cells	were	washed	with	1	ml	of	MACS	buffer	per	10	million	of	cells,	centrifuged	for	3	min	at	400	rpm	and	resuspended	in	500	µl	of	MACS	buffer.	While	cell	
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incubation	 proceeded,	 an	 LS	 column	 was	 placed	 in	 the	 magnetic	 field	 of	 the	QuadroMACS	separator.	The	column	was	prepared	for	separation	by	rinsing	it	with	3	ml	of	 MACS	 buffer.	 The	 resuspended	 cell	 suspension	 was	 applied	 onto	 the	 column.	 The	flow-through	 containing	 unlabeled	 cells	 was	 collected.	 This	 flow-through	 is	 the	macrophage-free	cell	suspension	as	macrophages	stayed	 in	the	column,	because	of	 the	magnetic	label	and	all	other	cell	types	passed	through.	The	column	was	washed	3	times	with	3	ml	of	MACS	buffer.	All	flow-through	fractions	were	combined	together.	Cells	were	centrifuged	 for	3	min	 at	 15,	 resuspended	 in	10	ml	 of	medium,	 counted	 and	plated	on	coated	 dishes.	 It	 is	 worth	 mentioning	 that	 70-80%	 of	 hepatocytes	 still	 stays	 in	 the	column	after	3	times	of	washing.	Further	washing	increases	cell	number	only	by	approx.	2%	per	3	ml	of	MACS	buffer.			
3.2.3. Methods of protein biochemistry 
3.2.3.1. SDS-polyacrylamide	gel	electrophoresis	(SDS-PAGE)	and	western	blot		SDS-PAGE	is	a	technique,	which	enables	protein	separation	according	to	their	molecular	weight	and	is	not	affected	by	protein	charge	or	structure.	The	protein	samples	for	SDS-PAGE	were	prepared	in	either	1x	or	2x	Laemmli	Buffer	followed	by	heating	at	95˚C	for	5	min.	2x	Laemmli	Buffer	was	used	 for	protein	extraction	directly	 from	the	plate,	where	cells	were	grown.	The	Bio-Rad	Mini	protean	system	was	used	to	cast	a	discontinuous	gel	consisting	of	an	upper	stacking	gel	part	and	a	lower	separating	gel	part.	The	separating	gel	part	was	made	of	4x	Separating	gel	buffer,	 10-12%	acrylamide,	water,	 ammonium	persulfate	 (from	10%	stock	 solution)	 and	TEMED,	 see	Table	 13.	 The	 stacking	 gel	was	made	 of	 4x	 Stacking	 gel	 buffer,	 acrylamide,	 water,	 ammonium	 persulfate	 (from	 10%	stock	solution)	and	TEMED,	see	Table	13.	Protein	samples	were	 loaded	on	the	gel	and	separated	 in	 1x	 running	 buffer	 at	 40	mA	 for	 1-1.5	 hours.	 Next,	 proteins	 from	 the	 gel	were	 blotted	 onto	 a	 nitrocellulose	membrane	 using	 the	 Bio-Rad	Mini	 protean	 system	and	blotting	buffer	at	350	mA	for	1	hour.	After	blotting	the	membrane	was	blocked	for	1h	at	RT	in	blocking	buffer.	Then	the	membrane	was	incubated	with	a	primary	antibody,	which	was	diluted	 in	 blocking	buffer.	Dilutions	 of	 primary	 antibodies	 can	be	 found	 in	Table	 10.	 Incubation	 lasted	 either	 1h	 at	 RT	 or	 overnight	 at	 4˚C.	 After	 incubation	 the	membrane	was	washed	with	PBST	buffer	3x	for	5	min	followed	by	incubation	with	HRP-conjugated	 secondary	 antibodies	 for	 1	 hour	 at	 RT.	 The	 secondary	 antibodies	 were	
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diluted	1:2500	in	blocking	buffer.	Finally,	the	membrane	was	washed	with	PBST	buffer	2x	 for	 10	 min	 followed	 by	 washing	 with	 PBS	 1x	 for	 10	 min.	 Protein	 detection	 was	performed	using	ECL	reagents	and	an	EMCCD	camera	controlled	by	a	Gel-Pro	Analyzer	Software.		
Table	13.	Amounts	of	components	for	10	%	separating	gels	and	stacking	gels.		According	to	this	recipe	two	gels	can	be	prepared.	
	 Separating	gel	 Stacking	gel	Buffer	(separating	or	stacking)	 2.5	ml	 0.75	ml	Acrylamide	 3.3	ml	 0.5	ml	Water	 4.2	ml	 1.75	ml	Ammonium	persulfate	 100	μl	 12.5	μl	TEMED	 20	μl	 5	μl		
3.2.3.2. 	Cell	lysates	for	enzymatic	assays	and	western	blot		Cells	were	homogenized	using	a	cooled	EMBL	cell	 cracker	with	a	cylinder	diameter	of	8.02	mm.	For	all	cell	types,	a	clearance	of	12	µm	(8.008	mm	ball)	was	used.	Up	to	two	confluent	10	cm	dishes	of	Huh7	or	3T3-L1	cells	or	10-30	million	of	primary	hepatocytes	were	used	for	homogenization.	The	cells	were	washed	once	with	PBS	and	scraped	in	1	ml	of	ice-cold	lysis	buffer.	A	long	21-gauge	needle	was	used	to	suck	the	cell	suspension	into	the	3	ml	syringe,	which	was	then	fixed	to	the	cell	cracker.	13	syringe	strokes	were	applied	 to	 each	 side	of	 the	 cracker.	 	A	 cell	 homogenate	was	 centrifuged	 for	10	min	at	1000	g	and	4˚C	to	pellet	the	nuclei.	Post-nuclear	supernatant	was	transferred	to	a	new	tube	and	its	protein	concentration	was	measured	with	a	NanoDrop	or/and	BCA	Protein	Assay	Kit	according	to	the	manufacturer’s	instructions	using	BSA	as	a	standard.	
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3.2.4. Enzymatic assays  
3.2.4.1. DGAT	assay			Information	 concerning	 the	 amount	 and	 concentration	 of	 substrates	 can	 be	 found	 in	Table	 14.	 First,	 DAG	 dissolved	 in	 CHCl3	was	 added	 to	 a	 1.5	 ml	 tube	 and	 CHCl3	was	evaporated.	Then	2.4	µl	of	the	PC	solution	in	CHCl3	was	added	to	DAG	and	this	mixture	was	vortexed	for	2	min.	Next,	100	µl	of	DGAT	assay	buffer	containing	acyl-CoA	and	HSLi	was	pipetted	 into	 the	 tube.	Afterward,	30	µg	of	protein	 (cell	 lysate)	was	added,	which	before	was	adjusted	to	50	µl	by	adding	lysis	buffer.	The	reaction	mixture	(total	volume	150	µl)	was	first	vortexed	and	then	incubated	for	30	min	at	30˚C	while	shaking	at	800	rpm.	Finally,	the	reaction	was	stopped	by	adding	800	µl	of	CHCl3/MeOH	1/3.	After	this	final	step	lipid	extraction	followed,	see	chapter	3.2.5.1.		
			
Table	14.	Substrates	for	enzymatic	assays.	
Substrate	 Concentration	of	
stock	solution	in	mM	
Concentration	in	
assay	buffer	in		µM	
Amount	taken	for	
the	assay	in		µl	18:0	DAG	 4		 200		 7.5		12:0	DAG	 4.38		 200		 6.8		10:0	DAG	 5		 200		 6		8:0	DAG	 5.8		 200		 5.2		PC		 13		 208		 2.4		C19-CoA	 0.5		 25		 7.5		C11-CoA	 0.57		 25		 6.6		HSLi	 10		 10		 0.15		LPA		 2		 10		 0.75		LPC	 4		 10		 0.38	LPA*		 2		 40		 3		LPC*	 4		 40		 1.5		G3P	 10		 500		 7.5		ATP	 0.5		 10		 4.5		CoA	 29.3		 390		 2		C11-FA	 20		 200		 1.5		C10	CoA	 5		 25		 0.75			C18	CoA	 5		 25		 0.75			alkyne-LPA	 10		 10		 0.15		C19-FA	 20		 200		 1.5		*	used	in	coupled	acyl-CoA	LPAAT	or	LPCAT	assay		
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3.2.4.1. LPAAT	and	LPCAT	assay		Information	 concerning	 the	 amount	 and	 concentration	 of	 substrates	 can	 be	 found	 in	Table	14.	100	µl	of	LPAAT/LPCAT	assay	buffer	containing	LPA	or	LPC,	acyl-CoA	and	HSLi	was	mixed	with	 30	 µg	 of	 protein,	which	 before	was	 adjusted	 to	 50	 µl	 by	 adding	 lysis	buffer.	The	reaction	mixture	(total	volume	150	µl)	was	first	vortexed	and	then	incubated	for	30	min	at	30˚C	while	shaking	at	800	rpm.	Finally,	the	reaction	was	stopped	by	adding	800	 µl	 of	 CHCl3/MeOH	1/3.	 After	 this	 final	 step	 lipid	 extraction	 followed,	 see	 chapter	3.2.5.1.		
3.2.4.2. GPAT	assay		Information	 concerning	 the	 amount	 and	 concentration	 of	 substrates	 can	 be	 found	 in	Table	14.	First	2.4	µl	of	the	PC	solution	in	CHCl3	was	added	to	a	1.5	ml	tube	and	CHCl3	was	 evaporated.	 Then	 100	 µl	 of	 the	 GPAT	 assay	 buffer	 containing	 G3P,	 acyl-CoA	 and	HSLi	was	pipetted	 into	 the	 tube.	Next,	30	µg	of	protein	 (cell	 lysate)	was	added,	which	before	was	adjusted	to	50	µl	by	adding	lysis	buffer.	This	mixture	was	first	vortexed	and	then	 incubated	 for	30	min	at	30˚C	while	shaking	at	800	rpm.	Finally,	 the	reaction	was	stopped	 by	 adding	 800	 µl	 of	 CHCl3/MeOH	 1/3.	 After	 this	 final	 step	 lipid	 extraction	followed,	see	3.2.5.1.		
3.2.4.3. Coupled	acyl-CoA	–	LPAAT/LPCAT	assay		As	a	direct	acyl-CoA	assay	was	not	compatible	with	the	click	reaction	(data	not	shown),	acyl-CoA	 assay	 was	 coupled	 with	 either	 an	 LPAAT	 or	 LPCAT	 assay.	 Information	concerning	the	amount	and	concentration	of	substrates	can	be	found	in	Table	14.	Firstly,	FAs	and	LPA	were	mixed	in	a	1.5	ml	reaction	tube	and	the	liquid	phase	was	evaporated.	Then	13	µl	of	the	BSA	solution	was	added	and	the	tube	was	vortexed	for	2	min.	Next,	100	µl	of	the	coupled	assay	buffer	containing	CoA	and	ATP	was	pipetted	into.	Afterward,	200	µg	of	protein	(cell	lysate)	was	added,	which	before	was	adjusted	to	50	µl	by	adding	lysis	buffer.	Then	this	mixture	was	first	vortexed	and	then	incubated	for	30	min	at	30˚C	while	shaking	at	800	rpm.	Finally,	the	reaction	was	stopped	by	adding	800	µl	of	CHCl3/MeOH	1/3.	After	this	final	step	lipid	extraction	followed,	see	3.2.5.1.		
Materials	and	Methods	
	 41	
	
3.2.5. Lipid extraction and click reaction 
3.2.5.1. Lipid	extraction	after	enzymatic	assays		After	stopping	the	enzymatic	reaction	with	CHCl3/MeOH	1/3,	400	µl	of	water	was	added.	The	 tube	was	 vortexed	 and	 centrifuged	 at	 20.238	 g	 for	 30	 s.	 The	 lower	 CHCl3	 phase,	which	 contained	 lipids,	 was	 then	 transferred	 to	 a	 new	 reaction	 tube.	 Lipids	 from	 the	reaction	 tube	were	extracted	a	second	time.	For	 this	200	µl	of	CHCl3	was	added	to	 the	reaction	tube.	The	tube	was	first	vortexed	and	then	centrifuged	at	20.238	g	for	30	s.	The	lower	CHCl3	phase	was	combined	with	the	CHCl3	phase	from	the	first	extraction.	Lipids	were	used	for	the	click	reaction.		
3.2.5.2. Lipid	extraction	from	organ	slices		When	the	incubation	time	was	over	(see	3.2.2.1)	the	medium	was	discarded	and	organ	slices	were	washed	once	with	2%	delipidated	BSA	(DL-BSA)	in	PBS	and	once	only	with	PBS.	1.5	ml	screw	cap	micro	tubes	were	filled	with	glass	beads	to	approx.	200	µl	mark	and	 1	 ml	 of	 CHCl3/MeOH	 1/1	 was	 added	 to	 each	 tube.	 Each	 slice	 was	 added	 to	 a	prepared	tube.	The	tubes	were	tightly	screwed	and	bead-beated	for	4	min	at	max	speed.	Afterward,	 the	 tubes	 were	 centrifuged	 at	 20.238	 g	 for	 30	 s.	 The	 liquid	 phase	 was	transferred	to	a	new	2	ml	tube	and	800	µl	of	water	was	added.	Samples	were	vortexed	and	centrifuged	again	at	20.238	g	for	30	s.	The	lower	CHCl3	phase	was	transferred	to	a	new	1.5	ml	tube.	Then	the	usual	click	procedure	followed,	see	chapter	3.2.5.5.		
3.2.5.3. Lipid	extraction	from	cells	grown	in	plates		Cells	were	grown	in	6-well,	12-well	or	24-well	plates	and	in	3.5	cm	or	6	cm	dishes.	After	feeding	the	cells	with	click	lipids	the	medium	was	removed	and	the	cells	were	washed	once	with	wash	buffer	and	once	with	PBS.	After	washing	800	µl	of	the	MeOH/	CHCl3	3/1	mixture	was	 added	 to	 each	well	 of	 either	 plate	 type	 and	was	 incubated	 for	 1	min	 by	swinging	the	plate.	The	mixture	from	each	well	was	transferred	to	a	separate	tube.	400	µl	 of	 water	 and	 150	 µl	 of	 CHCl3	 were	 added.	 The	 tube	 was	 first	 vortexed	 and	 then	centrifuged	 at	 20.238	 g	 for	 30	 s.	 The	 lower	 CHCl3	 phase	 containing	 lipids	 was	transferred	 to	 the	 new	 reaction	 tube.	 Lipids	 were	 either	 stored	 or	 used	 for	 the	 click	reaction,	see	chapter	3.2.5.5.	
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3.2.5.4. Lipid	extraction	from	the	medium		In	FA	uptake	experiments	a	lipid	extraction	was	performed	from	the	medium	in	which	cells	were	incubated	for	in	experiment	indicated	time	and	with	indicated	amount	of	FAs.	After	 incubation	 time	 was	 over,	 the	 medium	 with	 FAs	 was	 collected	 and	 cells	 were	subjected	to	lipid	extraction,	see	3.2.5.3.	50	µl	of	this	collected	medium	was	transferred	to	the	reaction	tube	used	for	lipid	extraction.	800	µl	MeOH/	CHCl3	3/1	mixture,	400	µl	of	1%	 acetic	 acid	 and	 150	 µl	 of	 CHCl3	 were	 added	 to	 the	 medium.	 The	 tube	 was	 first	vortexed	and	 then	centrifuged	at	20.238	g	 for	30	s.	The	 lower	CHCl3	phase	containing	lipids	was	 transferred	 to	 a	 new	 reaction	 tube.	 Lipids	were	 directly	 used	 for	 the	 click	reaction,	see	3.2.5.5.		
3.2.5.5. Click	reaction		The	CHCl3	phase,	which	was	transferred	to	a	new	tube	after	lipid	extraction	(see	3.2.5.1	-3.2.5.4),	was	first	dried	in	a	vacuum	concentrator,	then	7	µl	of	CHCl3	was	added	and	the	tube	was	vortexed	for	5	min.	In	the	meantime,	the	click	reaction	mixture	was	prepared	by	mixing	10	µl	of	the	3-azido-7-hydroxycoumarin	solution	(2mg/ml)	with	250	µl	of	the	Cu(I)TFB	 solution	 (10	mM)	 in	 acetonitrile	 and	 850	 µl	 of	 ethanol.	 30	 µl	 of	 the	 click	mixture	was	 added	 to	 the	 previously	 prepared	 tube	 containing	 lipids	 and	 CHCl3.	 The	mixture	 was	 briefly	 vortexed,	 centrifuged	 and	 incubated	 at	 43˚C	 for	 2.5	 hours	 or	overnight.	A	higher	concentration	click	reaction	mixture	was	used	while	working	with	coupled	CoA	synthesis	assays	as	 the	molar	amount	of	alkyne-FAs	used	 in	 these	assays	was	very	high,	see	chapter	3.2.4.3	and	Table	14.		
3.2.5.6. Lipid	separation	by	thin	layer	chromatography	(TLC)		After	 the	 click	 reaction,	 the	 tube	 was	 centrifuged	 to	 collect	 the	 liquid,	 which	 was	condensed	under	the	cap.	Then	the	tube	was	vortexed	for	10	min.	In	the	meantime,	the	TLC	plate	was	prepared.	A	line	was	drawn	at	1.5	cm	distance	from	the	bottom	of	the	TLC	plate	and	spaces	 for	 lipid	 loading	were	marked.	The	clicked	 lipids	were	 loaded	on	 the	TLC	 plate	 using	 glass	 capillaries.	 The	 plate	was	 placed	 in	 a	 TLC	 developing	 chamber,	which	was	 filled	with	 solution	 I	 (chloroform/methanol/water/acetic	 acid	65/25/4/1),	and	kept	there	until	the	front	line	of	the	solvent	reached	6.5-9.5	cm	height	measured		
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	from	 the	 bottom.	 The	 plate	 was	 taken	 out,	 dried	 and	 placed	 in	 the	 second	 TLC	developing	chamber	with	solution	II	(hexane/ethyl	acetate	1/1).	It	was	kept	there	until	the	front	line	reached	1	cm	mark	when	measured	from	the	top	of	the	plate.	Eventually,	the	plate	was	taken	out,	dried,	soaked	in	4%	Hünig’s base	solution	in	hexane	and	dried	again.	After	this	procedure	TLC	plate	was	ready	for	the	lipid	detection.			
3.2.5.7. Detection	and	quantification	of	click	labeled	lipids			Lipids	were	detected	and	quantified	using	a	system	described	in	Thiele	et	al.,	2012.	The	LED	 light	 filtered	 through	 a	 colored	 glass	 was	 used	 for	 excitation	 of	 clicked	 lipids.	Images	were	acquired	with	an	EMCCD	camera	in	two	channels	equipped	with	different	filters.	Filter	494/20	was	used	in	a	channel	 for	detection	of	the	coumarin	fluorescence	and	 filter	 572/28	 was	 used	 in	 a	 channel	 for	 detection	 of	 background	 fluorescence.	Images	were	acquired	and	quantified	using	a	Gel-Pro	Analyzer	software.	
3.2.6. Methods of lipid biochemistry 
3.2.6.1. Alkaline	hydrolysis		Alkaline	 hydrolysis	was	 used	 to	 break	 down	 ester	 bonds	 of	 lipids	 to	 identify	 if	 lipids	having	ester	bonds	were	present	 in	samples	of	 interest.	This	 technique	was	applied	to	unknown	lipids	found	in	the	medium	(4.5.2.6).	After	lipid	extraction	(3.2.5.4)	The	CHCl3	phase	was	divided	into	two	parts.	One	part	was	used	for	hydrolysis	and	the	other	one	for	control.	CHCl3	was	evaporated	from	both	parts.	Further	steps	were	performed	only	with	the	part	used	for	hydrolysis.	300	µl	of	MeOH/EtOH	1/1	and	30	µl	of	2	M	KOH	was	added.	The	tube	was	flushed	with	argon,	sealed	with	parafilm	and	incubated	for	2	hours	at	60˚C	under	gentle	agitation.	After	that,	solvents	were	evaporated	and	100	µl	of	1	M	HCl	along	with	300	µl	of	CHCl3	were	added.	The	mixture	was	vortexed,	centrifuged	at	20.238	g	for	2	min.	The	CHCl3	phase	was	transferred	to	a	new	tube	and	CHCl3	was	evaporated.	After	this	click	reaction	was	performed	with	both	hydrolyzed	lipids	and	control	lipids.						
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3.2.6.2. Separation	of	neutral	lipids	from	phospholipids		Before	performing	TAG	hydrolysis	with	 a	 pancreatic	 lipase	 (see	3.2.6.3)	 neutral	 lipids	were	separated	from	other	lipid	classes.	First,	a	cellular	lipid	extract,	which	was	devoted	for	hydrolysis,	was	mixed	with	200	µl	of	CHCl3	in	a	tube.	This	mixture	was	sonicated	for	5	min.	Then	500	µl	of	hexane/ethyl	acetate	5/1	was	added.	A	small	column	made	of	a	Pasteur	 pipette	 and	 a	 silica	 gel	 was	 washed	 with	 hexane/ethyl	 acetate	 5/1.	 Cellular	lipids	were	 added	 to	 the	 column.	 The	 column	was	washed	with	 5	ml	 of	 hexane/ethyl	acetate	5/1	and	all	the	flow-through	containing	neutral	lipids	was	collected.	Polar	lipids	that	remained	in	the	column	were	washed	out	with	5	ml	of	MeOH/CHCl3/H2O	65/35/8	and	 then	 the	 usual	 lipid	 extraction	 followed.	 The	 hexane/ethyl	 acetate	 solution	 was	evaporated	 from	the	neutral	 lipid	 fraction	with	a	 rotary	evaporator.	The	dried	neutral	lipids	were	ready	for	hydrolysis	with	a	pancreatic	lipase.		
3.2.6.3. TAG	hydrolysis	with	a	pancreatic	lipase		For	TAG	hydrolysis	600	µl	of	1	mM	pH	8	Tris-HCl	was	added	 to	 the	dried	 lipids.	This	mixture	was	sonicated	 for	3	min	 followed	by	 the	addition	of	100	µl	of	22	%	CaCl3	and	125	µl	of	0.1	%	deoxycholate.	The	tube	was	incubated	at	40˚C	for	one	minute.	2	mg	of	the	pancreatic	 lipase	dissolved	 in	200	µl	of	water	was	added	and	the	reaction	mixture	was	 vortexed	 for	 3	min.	 The	 reaction	was	 terminated	with	 400	 µl	 of	 1	M	 acetic	 acid.	After	that	500	µl	of	MeOH/	CHCl3	3/1	was	added	and	the	reaction	tube	was	vortexed	and	centrifuged	 at	 20.238	 g	 for	 30	 s.	 The	CHCl3	phase	was	 transferred	 to	 a	 new	 tube.	The	second	 extraction	with	 200	 µl	 CHCl3	 followed.	 Both	 CHCl3	phases	were	 combined	 and	then	 washed	 with	 500	 µl	 of	 water.	 CHCl3	was	 evaporated	 and	 the	 click	 reaction	 was	performed.	
3.2.7. Statistical analysis 	The	data	are	presented	as	a	mean	±/+	standard	deviation	(SD).	The	statistical	analysis	was	 performed	 with	 GraphPad	 Prism6	 program.	 For	 comparison	 of	 two	 groups,	unpaired	 t-test	 was	 used.	 For	 more	 groups,	 one-way	 ANOVA	 analysis	 was	 applied.	 *	stands	for	p≤0.05;	**	p≤0.01;	***	p≤0.001		
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4. Results 
4.1. Metabolism of MCFAs and LCFAs in different cell 
lines and mouse organs  	
4.1.1. Metabolism of different chain length FAs in 3T3-L1 adipocytes and 
Huh7 cells 	In	Thiele	et	al.,	2012	it	was	shown	that	two	distinct	cell	lines	metabolize	FAs	of	different	carbon	 chain	 length	 in	 a	 different	 manner.	 This	 interesting	 finding	 triggered	 the	research	 described	 in	 this	 thesis.	 In	 experiments	 of	 this	work	 alkyne-FAs	 that	 can	 be	labeled	with	a	fluorescent	dye	by	applying	click	reaction	(1.7)	were	used.	The	structures	of	 two	main	 FAs	 used	 in	 this	 thesis	 can	 be	 found	 in	 Figure	 6.	 It	 is	 assumed	 that	 C9	alkyne-FA	 represents	 C8:0	 natural	 fatty	 acid	 octanoate;	 C11	 represents	 C10:0	 FA	decanoate	 (C10);	 C13	 –	 C12:0	 FA	 dodecanoate;	 C17	 –	 C16:0	 FA	 palmitate	 and	 C19	 –	C18:1	 FA	 oleate	 (C18).	 The	 detailed	 comparisons	 between	 all	 natural	 and	 alkyne-FAs	was	not	done	but	in	Thiele	et	al.,	2012	it	was	shown	that	C19-alkyne-FA	in	many	aspects	resembled	oleate.		
	
Figure	6.	Structures	of	C11-FA	and	C19-FA.		As	illustrated	in	Figure	7A,	lanes	3-8,	differentiated	3T3-L1	adipocytes	incorporated	FAs	having	 seven	 or	 more	 carbon	 atoms	 into	 cellular	 lipids,	 while	 Huh7	 cells,	 which	represent	 a	 liver	 carcinoma	 cell	 line,	 only	 incorporated	 FAs	 having	 not	 less	 than	 13	carbon	 atoms	 (Figure	 7B,	 lanes	 6-8).	 At	 first	 it	 was	 considered	 that	 this	 is	 an	 organ-specific	behavior.	For	later	experiments	C11	MCFA	was	chosen,	which	was	incorporated	into	 cellular	 lipids	by	differentiated	3T3-L1	 cells	 (Figure	7A,	 lane	5),	 but	not	by	Huh7	
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cells	 (Figure	 7B,	 lane	 5).	 To	 compare	 C11-FA	metabolism	with	 LCFA	metabolism,	 the	C19-FA	 representing	 oleate	 was	 taken.	 Next	 step	 was	 to	 find	 out	 which	 organs	 can	metabolize	C11	and	C19-FAs.		
 
Figure	 7.	 Metabolism	 of	 different	 chain	 length	 FAs	 in	 3T3-L1	 adipocytes	 and	 Huh7	
hepatoma	cells.	3T3-L1	cells	(A)	were	grown	in	3.5	cm	dishes	and	Huh7	cells	(B)	were	grown	in	6	cm	dishes.	Both	cell	types	 were	 supplemented	 for	 1	 hour	 with	 50	 μM	 of	 different	 chain	 length	 FAs.	 The	 cells	 were	incubated	and	washed.	Lipids	were	extracted	 from	 the	 cells	 and	 the	 click	 reaction	was	performed.	Finally,	 lipids	were	separated	on	TLC	plate	and	fluorescence	was	detected	by	fluorescence	imaging.	Numbers	on	the	top	of	the	image	at	the	line	“alkyne	FA”	indicate	the	total	carbon	atom	chain	length	of	FA.	 5−17	 are	 saturated	 FAs	 (except	 for	 the	 ω-alkyne	 group),	 19	 is	 alkyne	 oleate.	 S1-S4	 are	synthetically	synthesized	standards	as	indicated	on	the	right	side	of	the	image.	The	image	was	taken	from	Thiele	et	al.,	2012,	figure	6	panels	A	and	B.		
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4.1.2. C11-FA and C19-FA metabolism in different mouse organs 	Different	organs	were	dissected	 from	a	mouse	 and	organ	 slices	were	prepared.	These	slices	were	incubated	with	a	mixture	of	C11-FA	and	C19-FA	to	compare	their	ability	to	incorporate	these	FAs	into	TAG.	From	Figure	8A	(lane	1	and	4)	it	can	be	seen	that	liver	and	gut	most	effectively	incorporated	C11-FA	in	TAG.		In	these	organs	more	than	50%	of	the	detected	lipid	signal	was	assigned	to	C11-TAG	(Figure	8B).	The	C11-TAG	signal	here	was	 stronger	 than	 the	 C19-TAG	 signal	 (Figure	 8A,	 lanes	 1	 and	 4).	 A	 lower	 amount	 of	C11-TAG	was	also	detected	in	the	kidney,	testis	and	muscle	(Figure	8A	lanes	2,	3	and	7,	B).	Although	the	muscle,	in	general,	had	a	very	low	signal	in	all	lipid	classes	(Figure	8A,	lane	7),	most	of	 it	could	be	assigned	to	C11-TAG.	The	brain,	 lung,	spleen	and	eye	were	most	ineffective	in	incorporating	C11-FA	into	TAG	(under	5%,	Figure	8B).	The	fact	that	liver	 could	very	efficiently	 synthesize	C11-TAG	was	unexpected	as	previous	data	 from	Huh7	 cells	 showed	 that	 liver	 cells	do	not	 incorporate	C11-FA	 into	TAG	 (Figure	7B).	A	plausible	explanation	would	be	that	the	hepatoma	cell	line	lost	the	ability	to	metabolize	C11-FA.	 It	 is	 well	 described	 in	 the	 literature	 that	 the	 hepatoma	 cell	 lines	 differ	 from	primary	 cells	 and	 that	 they	 have	 lost	 some	metabolic	 functions	 (Castell	 et	 al.,	 2006).	Next,	it	was	analyzed	if	other	cancer	and	non-cancer	cell	lines	that	are	often	used	in	cell	culture	were	able	to	metabolize	C11-FA.	
4.1.3. C11 and C19-FA metabolism in different cell lines 
	
Figure	8.	Metabolism	of	C11	and	C19-FAs	in	slices	of	different	mouse	organs.	(A)	Different	organs	were	dissected	from	a	mouse	and	organ	slices	were	prepared.	A	mix	of	50	μM	C11	and	50	μM	C19-FAs	was	 added	 to	 the	 slices	 for	1.5	hours.	The	organ	 slices	were	washed	and	lipids	were	extracted	from	the	slices.	The	click	reaction	was	performed,	 lipids	were	separated	on	a	TLC	 plate	 and	 fluorescence	 was	 detected	 by	 fluorescence	 imaging.	 Abbreviations:	 Li	 –	 liver,	 Ki	 –	kidney,	Te	–	testis,	Gu	–	gut,	Pa	–	pancreas,	He	–	heart,	Mu	–	muscle,	Br	–	brain,	Lu	–	lung,	Sp	–	spleen,	Ey	–	eye.	 (B)	Quantification	of	data	 in	panel	A.	Values	 represent	 the	 fluorescence	 intensity	of	C11-TAG	divided	by	sum	 fluorescence	 intensity	of	C11-TAG,	C19-TAG,	PE	and	PC.	Data	 represent	mean	+SD,	n=3.	
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	The	ability	to	incorporate	C11-FA	into	TAG	was	examined	in	several	cell	lines	often	used	in	cell	culture	as	well	as	in	primary	hepatocytes.	As	shown	in	figure	9,	all	cell	lines	could	incorporate	C19-FA	into	TAG.	However,	only	primary	hepatocytes	could	synthesize	C11-TAG	(figure	9,	lane	16).	It	should	be	mentioned	that	undifferentiated	3T3-L1	cells	could	not	incorporate	C11-FA	in	TAG	(Figure	9,	lane	10),	whereas,	differentiated	3T3-L1	cells	could	 (Figure	 7A).	 Therefore	 it	was	 examined	 in	which	 step	 of	 differentiation	 3T3-L1	cells	gained	the	function	to	synthesize	C11-TAG.			
	
Figure	9.	C11	and	C19-FA	metabolism	in	different	cell	lines.	Different	 cell	 lines	were	grown	 in	24-well	 plates	until	 confluence.	 300.000	of	primary	hepatocytes	were	plated	on	6	cm	dishes	coated	with	collagen.	50	μM	of	either	C11	or	C19-FA	was	added	to	cells	for	1.5	hours.	The	cells	were	washed	and	lipids	were	extracted	from	the	cells.	The	click	reaction	was	performed,	 lipids	 were	 separated	 on	 a	 TLC	 plate	 and	 fluorescence	 was	 detected	 by	 fluorescence	imaging.	 The	 description	 of	 different	 cell	 lines	 can	 be	 found	 in	 Table	 3.	 Hepat.	 stands	 for	 mouse	primary	hepatocytes.	The	different	lipid	classes	in	which	FAs	were	incorporated	are	indicated	at	both	sides	of	the	image.			
4.2. C11 and C19-FA metabolism in differentiating 
3T3-L1 cells 	On	 day	 0	 differentiation	medium	was	 added	 to	 3T3-L1	 cells.	 At	 day	 1,	 2,	 3,	 4	 and	 11	differentiating	cells	were	incubated	with	C11	and	C19-FAs.	As	evident	from	Figure	10A	lane	 3	 and	 Figure	 10B,	 cells	 start	 to	 incorporate	 C11-FA	 into	 TAG	 at	 day	 2	 of	
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differentiation.	To	determine	this	point	in	time	more	precisely,	a	second	experiment	was	conducted	where	cells	were	differentiated	for	up	to	72	hours.	As	indicated	in	Figure	10C	and	D,	3T3-L1	cells	gain	the	function	to	metabolize	C11-FA	between	the	36th	and	42nd	hour	after	the	start	of	differentiation.	C19-TAG	was	present	in	all	conditions,	where	C19-FA	 was	 fed	 to	 cells	 (Figure	 10A	 and	 C).	 Following	 the	 subject,	 the	 process	 of	dedifferentiation	of	primary	hepatocytes	was	later	analyzed.		
		
4.3. C11 and C19-FA metabolism in dedifferentiating 
hepatocytes 
	
Figure	10.	Differentiation	of	3T3-L1	cells	in	days	and	hours.	(A,	C)	3T3-L1	cells,	grown	on	gelatin-coated	6-well	plates,	were	differentiated	for	different	periods	of	time.	At	indicated	time	point	of	differentiation,	a	mix	of	50	μM	of	C11	and	50	μM	C19-FAs	was	added	to	the	cells	for	1	hour.	On	day	11	the	cells	were	also	fed	with	single	C11	or	C19-FAs	(panel	A	lanes	7-8).	The	cells	were	washed	and	lipids	were	extracted	from	the	cells.	The	click	reaction	was	performed,	lipids	were	separated	on	a	TLC	plate	and	fluorescence	was	detected	by	a	fluorescence	imaging.	Day	0	represents	 control	 cells	 without	 differentiation	 medium.	 The	 different	 lipid	 classes,	 in	 which	 FAs	were	incorporated,	are	indicated	on	the	right	side	of	the	images.	(B,	D)	Quantifications	of	ratio	C11-TAG	 to	C19-TAG	 for	 panels	A	 and	C	 correspondingly.	 The	data	 are	 taken	 from	 laboratory	 rotation	report	of	Marlene	Buller,	2015.		
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	It	 is	well	 described	 in	 the	 literature	 that	 freshly	 isolated	primary	hepatocytes	 start	 to	dedifferentiate	 rapidly	 and	 lose	 hepatocyte-specific	 functions	 when	maintained	 in	 2D	cell	 culture	 (Bell	 et	 al.,	 2016;	 Elaut	 et	 al.,	 2006;	 Rowe	 et	 al.,	 2013).	 This	 raises	 the	question	if	hepatocytes	are	able	to	metabolize	C11-FA	during	dedifferentiation.	To	test	this,	 freshly	 isolated	 hepatocytes	 were	 kept	 in	 2D	 cell	 culture	 for	 an	 indicated	 time	period.	Then	fresh	and	older	cells	were	fed	with	either	C11	or	C19-FAs.	As	can	be	seen	in	Figure	11A	lanes	1-5,	the	cells	lost	a	great	deal	of	their	potential	to	synthesize	C11-TAG	already	 on	 day	 1	 after	 isolation	 (lane	 2).	 However,	 C19	 metabolism	 was	 nearly	unchanged	 (Figure	 11A	 lanes	 6-10).	 An	 hourly	 dedifferentiation	 experiment	 was	performed	 to	 determine,	 when	 dedifferentiating	 hepatocytes	 lose	 the	 potential	 to	incorporate	C11-FA	into	TAG.	Figure	11B	shows	that	the	ability	to	 incorporate	C11-FA	into	TAG	was	greatly	diminished	 in	 the	 time	period	between	8	and	18	hours,	whereas	the	amount	of	C19-TAG	remained	relatively	constant.	
Both	 in	 differentiating	 3T3-L1	 cells	 and	 dedifferentiating	 hepatocytes	 complex	processes	 presumably	 take	 place	 enabling	 or	 disabling	 C11-TAG	 synthesis.	 To	 better	predict	 and	 understand	mechanisms	 responsible	 for	 these	 changes	 it	 was	 decided	 to	perform	 deep	 mRNA	 sequencing	 both	 with	 3T3-L1	 cells	 and	 primary	 mouse	
	
Figure	11.	C11	and	C19-FA	metabolism	in	dedifferentiating	primary	mouse	hepatocytes.	Panels	A	and	B	represent	cells	dedifferentiated	from	0	to	5	days	and	from	0	to	30	hours,	respectively.	Primary	mouse	hepatocytes	were	isolated	from	liver	and	plated	on	collagen	coated	6-well	dishes	(A)	or	6	cm	dishes	(B).	400.000	cells	were	used	per	well	(A)	or	80.000	cells	were	used	per	dish	(B).	At	indicated	time	points,	the	medium	with	50	µM	of	either	C11	or	C19-FA	was	added	to	the	cells	for	1.5	hours.	 The	 cells	 were	 washed	 and	 lipids	 were	 extracted	 from	 the	 cells.	 A	 click	 reaction	 was	performed,	 lipids	were	 separated	 on	 a	TLC	plate	 and	 fluorescence	was	detected	by	 a	 fluorescence	imaging.	 (A)	 Day	 0	 represents	 the	 cells	 where	 FAs	 were	 added	 on	 the	 same	 day	 of	 hepatocyte	isolation.	 (B)	Hour	 0	 represents	 cells	where	 FAs	were	 added	 after	 cell	 attachment	 to	 dishes,	 i.e.	 2	hours	after	plating.	The	same	rule	is	applied	for	other	time	points.	The	different	lipid	classes	in	which	FAs	were	incorporated	are	indicated	at	both	sides	of	the	images.		
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hepatocytes.		
4.4. mRNA sequencing data 	3T3-L1	cells	were	differentiated	for	0,	12,	18,	24,	36,	48	and	60	hours.	RNA	was	isolated	from	 these	 cells	 at	 indicated	 time	 points	 and	 sequencing	 was	 performed.	 Similarly,	primary	mouse	hepatocytes	were	kept	in	cell	culture,	after	isolation	and	adherence,	for	0,	2,	8	and	18	hours.	RNA	from	hepatocytes	was	 likewise	 isolated	and	sequencing	was	done.	 In	 both	 cell	 lines	 it	 was	 looked	 at	 mRNA	 data	 for	 genes	 coding	 proteins	participating	 in	 FA	 and	 TAG	 metabolism.	 Table	 15	 summarizes	 the	 results	 of	 mRNA	sequencing.	 The	 expression	data	 of	 genes	 coding	proteins	 that	 participate	 in	 different	processes	 related	 to	FA	and	TAG	metabolism	are	grouped	and	presented	 for	 each	 cell	line	 and	 specific	 time	 point.	 Table	 15	 also	 includes	 some	 house	 keeping	 genes	 and	quality	control	genes	specific	for	each	cell	line.		The	sequencing	data	are	rather	complex	and	expression	of	none	of	the	genes	important	for	FA	and	TAG	metabolism	goes	drastically	down	to	a	negligible	amount.	So	this	data	do	not	 directly	 allow	 us	 to	 identify	 the	 candidate	 gene/protein	 responsible	 for	 the	differences	in	C11	metabolism,	which	was	observed	in	4.2	and	4.3,	but	they	can	help	to	support	or	deny	certain	hypothesis.		
4.5. Deeper analysis of the pathway from FA uptake to 
TAG synthesis 	The	pathway	 from	free	FAs	outside	 the	cell	 to	TAG	synthesis	 inside	 the	cell	 involves	a	few	 following	steps	 (Figure	26C).	First,	FAs	need	 to	enter	 the	cell.	As	discussed	 in	 the	introduction	chapter	1.3	there	are	a	few	possible	mechanisms	for	FA	entry	into	the	cell.	Then,	the	transport	inside	the	cell	and	the	acyl-CoA	synthesis	follows.	Finally,	acyl-CoA	enters	the	TAG	synthesis	pathway.	Additionally,	some	regulatory	mechanisms	could	be	involved,	 such	 as	 channeling	 specific	 FAs	 towards	 distinct	 cellular	 processes	 like	mitochondrial	β-oxidation.	A	closer	look	at	different	points	of	this	pathway	was	taken	in	order	to	identify	the	section,	where	this	pathway	fails	and	in	such	a	way	TAG	synthesis	from	MCFAs	is	disturbed.	First,	FA	entry	into	the	cell	was	analyzed.	
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Table	 15.	 mRNA	 sequencing	 data	 for	 genes	 participating	 in	 FA	 and	 TAG	 metabolism	 in	 primary	
hepatocytes	and	3T3-L1	cells.	Data	is	presented	as	gene	read	counts.	mRNA	sequencing	and	data	analysis	was	performed	by	Kristian	Händler,	Thomas	Ulas,	Susanne	Schmidt,	Stefanie	Herresthal	and	Kathrin	Klee	(AG	Schultze).	
Hepatocyte	dedifferentiation	 3T3-L1	differentiation	
Gene	
no.	
Gene	
Symbol	 0h	 2h	 8h	 18h	
Gene	
Symbol	 0h	 12h	 18h	 24h	 36h	 48h	 60h	
	 FA	uptake	at	plasma	membrane	
1	 CD36	 690.5	 597.7	 259.1	 187.5	 Cd36	 167.4	 112.6	 90.5	 133.3	 789.2	 1416.5	 3787.7	
2	 SR-B1	 1624.6	 1156.5	 507.0	 464.7	 SR-B1	 435.4	 87.1	 109.7	 162.4	 296.4	 305.4	 1006.1	
3	 Got2	(FABPpm)	 4203.48	 3134.9	 2160.36	 1719.04	 Got2	 1206.37	 1339.16	 1175.1	 1066.57	 986.63	 784.902	 732.775	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 FA	uptake/CoA	synthesis	
4	 FATP1	 16.3	 8.7	 6.7	 16.3	 FATP1	 193.1	 40.3	 28.8	 44.8	 126.4	 238.0	 547.4	
5	 FATP2	 14149.7	 9608.3	 3707.0	 874.2	 FATP2	 1.0	 1.0	 1.0	 1.0	 1.0	 1.0	 1.0	
6	 FATP4	 213.4	 145.1	 222.4	 349.5	 FATP4	 225.3	 265.4	 285.2	 287.0	 328.3	 315.5	 433.7	
7	 FATP5	 7201.7	 5371.0	 2656.3	 1148.9	 FATP5	 1.0	 1.0	 1.0	 1.0	 1.1	 1.0	 1.0	
	 	 	 	 	 	 FATP3	 7.24307	 19.7177	 34.2795	 26.1984	 31.3216	 39.3644	 38.936	
	 Cytoplasmic	FA	binding	proteins	
8	 Fabp1	 29919.0	 27803.7	 13052.2	 2468.9	 	 	 	 	 	 	 	 	
9	 Fabp2	 1573.2	 1314.6	 781.6	 360.6	 	 	 	 	 	 	 	 	
10	 Fabp4	 146.9	 191.7	 174.6	 149.1	 Fabp4	 368.6	 330.3	 327.7	 504.2	 8740.4	 23621.0	 54505.7	
11	 Fabp5	 285.0	 296.7	 686.0	 1567.4	 Fabp5	 471.6	 327.8	 479.9	 613.0	 5221.8	 9462.4	 12823.9	
12	 Fabp7	 7.5	 11.9	 2.2	 1.0	 Fabp7	 1.0	 1.0	 1.0	 1.0	 1.0	 1.0	 1.0	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 LCFA	CoA	synthesis	(ACSLs)	
13	 Acsl1	 6153.3	 2981.1	 460.3	 261.7	 Acsl1	 87.7	 635.1	 564.9	 642.2	 4061.7	 13419.7	 26600.3	
14	 Acsl3	 136.9	 92.0	 119.0	 202.4	 Acsl3	 263.2	 121.6	 116.6	 164.2	 150.5	 174.2	 274.9	
15	 Acsl4	 1127.5	 1343.8	 589.3	 841.6	 Acsl4	 553.7	 2067.1	 1284.8	 1163.2	 943.6	 1263.8	 881.5	
16	 Acsl5	 4160.8	 3619.0	 3516.8	 4087.7	 Acsl5	 927.1	 1125.6	 976.3	 864.0	 763.5	 495.6	 332.5	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 Glycerol	phosphate	synthesis	
17	 Gpd1	 4113.1	 2740.7	 1847.9	 1369.5	 Gpd1	 24.1	 31.2	 49.4	 87.9	 1105.2	 2453.1	 4626.4	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 GPAT	(sn-1	acylation)	
18	 GPAT3/	Agpat9	 195.9	 125.6	 72.3	 97.0	 GPAT3	 8.9	 64.9	 35.7	 34.9	 294.8	 813.5	 1064.5	
19	 GPAT4	 1442.6	 975.7	 518.1	 374.9	 GPAT4	 752.474	 1243.04	 1080.49	 986.807	 1120.87	 973.375	 1347.96	
20	 GPAT1	 1058.4	 666.0	 1266.4	 620.3	 GPAT1	 268.0	 553.7	 596.5	 525.1	 745.0	 691.3	 1045.8	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 LPAAT	(sn-2	acylation)	
21	 Agpat1	 20.1	 34.7	 57.8	 70.3	 Agpat1	 321.1	 401.7	 462.1	 451.2	 514.6	 449.7	 552.9	
22	 Agpat2	 789.7	 376.8	 201.2	 279.2	 Agpat2	 199.6	 253.9	 192.0	 196.8	 1584.5	 3505.2	 8808.9	
23	 Agpat3	 1907.1	 1324.4	 778.3	 659.4	 Agpat3	 576.2	 198.0	 229.0	 266.6	 429.0	 408.0	 570.8	
24	 Agpat4	 12.6	 7.6	 3.3	 1.3	 Agpat4	 216.5	 350.8	 222.1	 223.6	 264.0	 214.7	 211.8	
25	 Agpat5	 60.3	 60.6	 112.3	 143.9	 Agpat5	 481.3	 839.6	 673.2	 517.6	 594.6	 587.5	 611.3	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 PA	Phosphatase	(lipins)	
26	 Lpin1	 634.0	 220.9	 270.2	 120.4	 Lpin1	 329.2	 713.1	 643.1	 603.1	 1440.8	 1894.3	 3399.1	
27	 Lpin2	 8202.3	 6773.3	 3281.1	 1411.8	 Lpin2	 214.1	 160.2	 152.2	 210.8	 183.5	 198.0	 282.7	
28	 Lpin3	 38.9	 73.6	 220.2	 267.5	 Lpin3	 3.2	 4.9	 8.2	 7.6	 10.1	 3.0	 28.0	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 DGAT	(triglyceride	synthesis	by	sn-3	acylation)	
29	 Dgat1	 118.0	 93.1	 85.6	 95.0	 Dgat1	 160.2	 253.9	 231.7	 195.0	 591.2	 1103.4	 1734.2	
30	 Dgat2	 2723.2	 1459.7	 1295.3	 870.9	 Dgat2	 71.6	 136.4	 96.0	 93.7	 431.8	 1102.2	 3665.4	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 MGAT	(sn-2	acylation)	
31	 Mgat1	 438.2	 322.7	 334.7	 538.9	 Mgat1	 730.7	 558.7	 541.6	 560.6	 656.6	 510.5	 447.8	
32	 Mgat2	 253.6	 269.6	 394.7	 258.4	 Mgat2	 420.1	 388.6	 346.9	 281.2	 285.8	 207.0	 179.9	
33	 Mgat4b	 212.2	 315.1	 435.9	 482.3	 Mgat4b	 591.5	 248.9	 241.3	 308.0	 576.7	 621.5	 905.7	
34	 Mgat5	 22.6	 18.4	 58.9	 55.3	 Mgat5	 132.8	 184.0	 196.1	 179.9	 263.4	 264.2	 454.8	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 Cytoplasmic	de	novo	FA	synthesis	
35	 Fasn	 4064.1	 1843.0	 4648.7	 772.6	 Fasn	 2284.8	 2444.2	 2651.9	 2993.6	 4227.9	 5675.0	 24959.5	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 LCFA	desaturation	delta	9	
36	 Scd1	 136506	 93343.2	 50973.6	 23379.2	 Sdc1	 1348.8	 3616.6	 2657.3	 1829.2	 1372.0	 1027.7	 851.9	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 LCFA	elongation	
37	 Elovl1	 139.4	 133.2	 206.8	 350.8	 Elovl1	 317.1	 370.5	 346.9	 333.0	 399.4	 375.2	 470.3	
38	 Elovl2	 10086.8	 7926.6	 3352.3	 815.6	 	 	 	 	 	 	 	 	
39	 Elovl3	 1248.0	 586.9	 70.0	 9.8	 Elovl3	 1.0	 1.0	 1.0	 1.0	 1.0	 1.2	 35.0	
40	 Elovl5	 7136.4	 3833.4	 1245.3	 585.8	 Elovl5	 590.7	 622.8	 606.1	 646.2	 476.5	 522.5	 1970.9	
41	 Elovl6	 1915.9	 2026.1	 2297.1	 498.6	 Elovl6	 646.2	 725.4	 763.7	 730.6	 444.1	 300.0	 158.1	
42	 Elovl7	 8.8	 58.5	 345.8	 283.1	 	 	 	 	 	 	 	 	
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Hepatocyte	dedifferentiation	 3T3-L1	differentiation	
Gene	
no.	
Gene	
Symbol	 0h	 2h	 8h	 18h	
Gene	
Symbol	 0h	 12h	 18h	 24h	 36h	 48h	 60h	
	 Mitochondrial	carnitine	transferases	
43	 Crot	 6822.5	 4666.1	 1249.7	 900.9	 Crot	 549.7	 259.6	 272.9	 358.6	 337.3	 325.7	 435.3	
44	 Crat	 339.0	 204.7	 76.7	 117.8	 Crat	 591.5	 258.8	 205.7	 238.7	 569.9	 1531.6	 6255.5	
45	 Cpt1a	 3673.6	 2162.4	 702.7	 368.4	 Cpt1a	 1030.9	 994.9	 1110.6	 1187.6	 910.0	 615.5	 413.5	
46	 Cpt1b	 13.8	 15.1	 1	 1	 Cpt1b	 25.7	 23.0	 27.0	 26.1	 28.5	 23.0	 19.4	
47	 Cpt2	 1027.0	 623.7	 383.5	 251.9	 Cpt2	 236.6	 298.2	 300.2	 257.3	 446.8	 532.6	 769.3	
48	 Slc25a20	 721.9	 463.4	 163.4	 140.5	 Slc25a20	 206.8	 232.5	 222.1	 200.8	 204.1	 215.3	 378.4	
	 	 	 	 	 	 	 	 	 	 	
	 Mitochondrial	MCFA-CoA	synthesis	(ACSMs)	
49	 Acsm1	 2415.6	 1957.8	 1136.3	 402.3	 	 	 	 	 	 	 	 	
50	 Acsm2	 11.3	 5.4	 3.3	 2.0	 	 	 	 	 	 	 	 	
51	 Acsm3	 807.3	 649.7	 146.8	 21.5	 Acsm3	 1.0	 1.0	 1.0	 2.9	 7.3	 18.5	 271.8	
52	 	 	 	 	 	 Acsm4	 31.4	 21.4	 19.2	 23.3	 44.7	 67.4	 110.6	
53	 Acsm5	 675.5	 627.0	 371.4	 52.7	 Acsm5	 1.0	 1.0	 1.0	 1.0	 1.0	 1.2	 3.9	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 Mitochondrial	FA	β-oxidation	
54	 Acadl	 1998.8	 1609.1	 1058.5	 984.8	 Acadl	 590.7	 276.9	 283.8	 354.0	 492.8	 640.6	 1300.5	
55	 Acadm	 3348.5	 2577.2	 1407.6	 882.6	 Acadm	 684.1	 656.4	 569.0	 604.3	 1637.1	 2907.6	 4142.0	
56	 Acads	 1270.6	 906.4	 598.2	 580.0	 Acads	 648.7	 384.5	 392.2	 388.9	 586.7	 632.8	 868.3	
57	 Acadsb	 1181.4	 1086.1	 411.4	 267.5	 Acadsb	 608.4	 626.0	 554.0	 590.9	 648.8	 804.6	 1294.2	
58	 Acadvl	 3555.6	 2910.8	 1787.9	 1060.3	 Acadvl	 1191.9	 1245.5	 1203.9	 1018.2	 1261.3	 1722.5	 2555.8	
59	 Hadh	 2374.19	 1768.32	 779.42	 448.473	 Hadh	 857.901	 694.229	 711.642	 671.262	 1207.56	 1722.49	 2670.23	
60	 Hadha	 3553.12	 2307.59	 1193.03	 865.702	 Hadha	 1891.25	 1837.86	 1724.94	 1589.95	 2047.65	 2113.75	 3267.5	
61	 Hadhb	 1987.49	 1678.45	 897.278	 585.813	 Hadhb	 396.759	 392.712	 418.209	 388.319	 490.519	 601.202	 912.659	
62	 Ehhadh	 3618.41	 2647.61	 967.326	 238.231	 Ehhadh	 1	 1	 1	 1	 1	 1.19286	 1.55744	
63	 Echs1	 1825.53	 1509.52	 799.433	 535.694	 Echs1	 515.867	 863.473	 739.065	 685.816	 743.888	 971.585	 1510.71	
64	 Acaa2	 6567.63	 5329.88	 2884.19	 1273.82	 Acaa2	 469.995	 382.853	 372.961	 334.175	 432.909	 351.894	 596.499	
65	 Eci1	 1058.4	 793.742	 430.293	 266.22	 Eci1	 212.463	 187.319	 145.345	 164.759	 181.218	 219.486	 262.428	
66	 Eci2	 1694.95	 1413.14	 654.891	 255.805	 Eci2	 582.664	 475.691	 467.572	 455.852	 536.942	 577.941	 844.91	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 Transcription	regulators;	protein	regulation	
67	 Pparγ	 106.72	 114.784	 81.1664	 125.624	 Pparγ	 270.408	 224.289	 257.782	 275.957	 767.938	 1056.87	 1568.34	
68	 Pparα	 672.96	 486.208	 295.757	 82.0139	 Pparα	 45.068	 24.6472	 17.8253	 27.945	 41.3893	 57.2573	 146.399	
69	 Pparδ	 105.46	 168.927	 142.319	 103.494	 Pparδ	 203.611	 417.359	 381.188	 480.886	 507.857	 561.241	 612.852	
70	 Prkaa1	 70.309	 103.955	 135.648	 192.017	 Prkaa1	 719.478	 966.17	 898.122	 943.725	 1090.1	 973.971	 922.782	
71	 Prkaa2	 631.53	 845.72	 832.789	 266.871	 Prkaa2	 32.9962	 28.7551	 31.5371	 27.945	 35.7961	 57.8538	 90.3314	
72	 Srebf1	 3868.3	 2697.42	 681.575	 352.79	 Srebf1	 526.33	 483.085	 571.781	 712.597	 1773.03	 1885.91	 2600.14	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 TAG	hydrolysis	
73	 Pnpla2	(ATGL)	 618.97	 605.323	 416.951	 225.213	 Pnpla2	 166.591	 332.737	 263.266	 341.744	 1665.08	 3122.31	 8006.79	
74	 Lipe	(HSL)	 139.36	 83.3809	 34.4679	 48.8178	 Lipe	 255.922	 661.366	 734.952	 702.117	 2612.56	 3888.73	 7119.05	
75	 Mgll	 1887.1	 1214.98	 420.286	 123.672	 Mgll	 1.60957	 1	 2.74236	 2.32875	 14.5422	 49.5037	 137.055	
76	 Abhd5	 396.74	 316.198	 366.917	 443.916	 Abhd5	 291.332	 972.742	 988.62	 873.863	 1653.89	 2712.57	 2906.18	
77	 Lpl	 91.653	 54.1434	 24.4611	 31.8943	 Lpl	 3867.8	 9112.06	 5993.42	 4351.27	 7932.19	 17442	 36194.9	
78	 Lipc	 1642.2	 1377.41	 816.111	 573.446	 Lipc	 1	 1	 1.37118	 1	 1	 1	 1	
79	 Pnpla3	 25.11	 15.1602	 46.6985	 21.4798	 Pnpla3	 1	 1	 1	 1	 1.67794	 11.9286	 34.2636	
80	 Pnpla6	 61.52	 43.3147	 94.5088	 90.4756	 Pnpla6	 257.531	 106.804	 146.716	 135.067	 118.575	 141.95	 147.957	
81	 Pnpla7	 974.28	 741.765	 500.341	 560.428	 Pnpla7	 148.885	 35.3276	 72.6725	 56.4721	 45.3045	 42.943	 38.1572	
82	 Pnpla8	 1288.2	 960.504	 585.955	 492.083	 Pnpla8	 371.811	 441.185	 500.48	 593.249	 969.292	 1470.2	 2314.35	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 Quality	control	1:	liver	specific	genes	
83	 Abcb11	 4907.8	 3104.6	 769.4	 91.1	 Abcb11	 5.6	 1.0	 1.0	 1.0	 1.0	 1.0	 3.1	
84	 Abcg5	 1676.1	 991.9	 283.5	 24.1	 Abcg5	 1.0	 1.0	 1.0	 1.2	 1.1	 1.0	 1.6	
85	 Abcg8	 1387.4	 632.4	 112.3	 14.3	 Abcg8	 1.0	 1.0	 1.4	 1.0	 1.0	 1.0	 1.0	
86	 Adh1	 10778.6	 7345.1	 3459.0	 810.4	 Adh1	 7.2	 1.0	 1.4	 14.0	 45.3	 30.4	 31.1	
87	 Alb	 532017	 454114.0	 250540	 143461.0	 Alb	 1.0	 1.0	 1.0	 1.0	 1.0	 1.0	 1.0	
88	 F10	 2680.5	 1826.8	 1074.1	 491.4	 	 	 	 	 	 	 	 	
89	 F2	 12579.1	 9190.3	 5571.6	 3404.2	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 Quality	control	2:	adipocyte	marker	genes	
	 	 	 	 	 	 Adipoq	 8.0	 4.1	 2.7	 1.7	 54.8	 326.2	 951.6	
90	 G0s2	 100.4	 41.1	 72.3	 190.1	 G0s2	 1.6	 1.0	 5.5	 1.2	 119.7	 427.0	 948.5	
	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 Quality	control	3:	housekeeping	genes	
91	 β-actin	 7695.1	 8565.5	 12159.4	 23180.0	 β-actin	 13548.6	 9146.6	 8855.1	 8717.1	 5258.7	 4574.0	 4552.4	
92	 γ-actin	 15666.4	 17611.8	 14661.1	 14418.2	 γ-actin	 11052.9	 5566.2	 6901.1	 6710.9	 3611.5	 3114.6	 2560.4	
93	 Akt1	 281.2	 311.9	 610.4	 753.1	 Akt1	 1392.3	 1319.5	 1283.4	 1146.9	 1181.8	 875.0	 626.1	
94	 Akt2	 978.1	 776.4	 503.7	 552.6	 Akt2	 786.3	 649.9	 555.3	 486.7	 690.8	 810.5	 1445.3	
95	 Ubb	 2213.5	 1651.4	 1194.2	 938.0	 Ubb	 6869.7	 6490.4	 6931.3	 6518.8	 7085.4	 6340.1	 5723.6	
96	 Rab5a	 726.9	 759.1	 589.3	 360.6	 Rab5a	 512.6	 561.1	 485.4	 492.5	 561.6	 707.4	 827.0		
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4.5.1. FA uptake from the medium 	
4.5.1.1. C11	and	C19-FA	uptake	in	hepatocytes		In	 the	previous	section	 it	was	shown	that	dedifferentiated	hepatocytes	are	not	able	 to	incorporate	C11-FA	into	TAG.	Freshly	isolated	hepatocytes	(day	0)	and	hepatocytes,	that	were	kept	in	the	cell	culture	for	one	or	three	days	(day	1	and	day	3	respectively)	after	isolation,	 were	 used	 to	 examine	 the	 FA	 uptake.	 The	 FA	 uptake	 was	 evaluated	 by	measuring	 the	 reduction	 of	 alkyne-FAs	 in	 the	 medium	 compared	 to	 control	 sample	without	cells.	As	can	be	seen	from	Figure	12A	lanes	1-7,	after	overnight	feeding	C11-FA	signal	 was	 missing	 in	 all	 samples	 where	 cells	 were	 present	 (lanes	 1-6),	 however	 in	control	sample	without	cells	signal	was	present	(lane	7).	This	means	that	all	 three	cell	groups	took	up	C11-FA.	However,	TAG	synthesis	was	strongly	reduced	in	the	day	1	cells	(Figure	12A	lane	10)	and	basically	not	present	in	the	day	3	cells	(lane	12).	This	was	not	the	case	when	feeding	them	with	C19-FA	(Figure	12B)	because	the	TAG	amount	did	not	decrease	 in	 the	 day	 3	 cells	 compared	 to	 the	 freshly	 isolated	 hepatocytes	 (Figure	 12B	lanes	 8-13).	 After	 overnight	 feeding	 some	 of	 C19-FA	was	 still	 present	 in	 the	medium	(Figure	 12B	 lanes	 1-6).	 During	 these	 experiments	 very	 exciting	 results	 related	 to	etomoxir	treatment	was	noticed.	Etomoxir	is	an	inhibitor	of	CPT1	(1.6).	When	day	0	and	day	1	cells	were	fed	overnight	with	C11-FA	in	the	presence	of	etomoxir,	X	and	Y	bands	of	unknown	compounds	were	identified	in	the	medium	(Figure	12A	lanes	2	and	4).	These	bands	 were	 not	 present	 in	 the	 medium	 of	 day	 0	 and	 day	 1	 cells	 without	 etomoxir	treatment	(Figure	12A	lanes	1	and	3).	These	bands	were	also	present	in	day	3	cells	with	or	without	 etomoxir	 treatment	 (Figure	 12A	 lanes	 5-6).	 Furthermore,	 the	 cells	 treated	with	 etomoxir	 contained	much	 less	 C11-TAG	 compared	 to	 the	 untreated	 cells	 (Figure	12A	lanes	8-13).	 In	the	freshly	 isolated	hepatocytes	fed	with	C11-FA	without	etomoxir	or	fed	with	C19-FA	with	or	without	etomoxir	TAG	was	detected	in	the	medium	(Figure	12A	lane	1,	Figure	12B	lanes	1-2).	This	indicated	a	lipoprotein	secretion.	In	day	1	cells	no	C11-TAG	could	be	identified	in	the	medium	(Figure	12A	lanes	3-4),	though	C19-TAG	was	still	secreted	(Figure	12B	lanes	3-4).	Day	3	cells	secreted	neither	C11-TAG	nor	C19-TAG	 (Figure	 12A	 lanes	 5-6,	 Figure	 12B	 lanes	 5-6)	 indicating	 a	 failing	 lipoprotein	secretion	 in	 the	 dedifferentiating	 cells.	 Apparently,	 etomoxir	 had	 no	 effect	 on	 TAG	synthesis	 when	 feeding	 cells	 with	 C19	 (Figure	 12B	 lanes	 8-13),	 nor	 stimulated	 it	 the	secretion	of	unknown	compounds	into	the	medium	(Figure	12B	lanes	1-7).		
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Because	these	were	very	exciting	findings,	later	on,	they	were	analyzed	in	greater	detail	with	the	help	of	pulse	experiments	(4.5.2).		But	before	that	it	was	decided	to	analyze	if	other	medium	or	long-chain	fatty	acids	were	taken	up	by	freshly	isolated	hepatocytes	and	if	etomoxir	had	an	effect	there	as	well.		
	
Figure	12.	Hepatocyte	uptake	of	C11	or	C19-FA	from	the	medium.	Hepatocytes	isolated	from	mouse	liver	were	plated	on	collagen	coated	12-well	plates.	150.000	cells	were	plated	per	well.	The	medium	with	50	μM	of	C11-FA	(A)	or	C19-FA	(B)	was	added	to	cells	 for	overnight	 feeding	 (approx.	 18	 hours).	 After	 feeding	 the	medium	was	 collected	 and	50	 μl	 of	 it	was	used	 for	 lipid	extraction.	The	cells	were	washed	and	 lipids	were	extracted	 from	the	cells.	Then	the	click	 reaction	was	 performed	 both	with	 lipids	 from	 the	medium	 and	 from	 the	 cells.	 Finally,	 lipids	were	 separated	 on	 a	 TLC	 plate	 and	 fluorescence	 was	 detected	 by	 fluorescence	 imaging.	 Day	 0	represents	 cells	 to	 which	 C11-FA	 was	 added	 on	 the	 same	 day	 of	 hepatocyte	 isolation.	 Day	 1	represents	cells	 to	which	C11-FA	was	added	 the	next	day	after	 isolation	and	day	3	–	 the	 third	day	after	 isolation.	The	different	 lipid	 classes	 in	which	FAs	were	 incorporated	 and	FAs	 themselves	 are	indicated	 on	 the	 right	 side	 of	 images.	 Bands	 X,	 Y,	 Z	 indicate	 unidentified	 substances	 that	 were	secreted	into	the	medium	by	hepatocytes.	Lane	7	represents	the	control,	where	the	medium	with	FAs	was	 added	 to	 the	 well	 without	 cells.	 In	 indicated	 samples	 50	 μM	 of	 etomoxir	 was	 added	 to	 the	medium	with	the	FA.	
4.5.1.2. C9,	C13	and	C17-FA	uptake	in	hepatocytes		Freshly	isolated	hepatocytes	were	fed	with	C9,	C13	and	C17-FAs	overnight.	Then	lipids	from	the	medium	and	from	the	cells	were	extracted.	When	feeding	the	cells	with	both	C9	and	 C13-FAs	 in	 the	 presence	 of	 etomoxir	 unknown	 bands	 appeared	 in	 the	 medium	(Figure	13	lanes	1-2,	4-5)	and	etomoxir	diminished	TAG	synthesis	rate	(Figure	13	lanes	10-13).	 This	 corresponds	 with	 the	 C11-FA	 data	 from	 Figure	 12A.	When	 feeding	 with	C17-FA	no	 intensive	unknown	bands	were	detected	 in	 the	medium	(Figure	13	 lanes	7	and	 8)	 and	 the	 TAG	 amount	 did	 not	 decrease	 in	 the	 presence	 of	 etomoxir	 (Figure	 13	lanes	14-15).	This	is	similar	to	the	results	when	feeding	with	C19-FA	(Figure	12B).	
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Figure	13.	Hepatocyte	uptake	of	C9,	C13	and	C17-FAs	from	the	medium.	Hepatocytes	were	 isolated	 from	mouse	 liver	and	plated	on	collagen	coated	12-well	plates.	150.000	cells	were	plated	per	well.	The	medium	with	50	μM	of	either	C9	or	C13	or	C17-FAs	was	added	to	the	cells	for	overnight	feeding	(approx.	18	hours).	After	feeding	the	medium	was	collected	and	50	μl	of	it	was	used	for	lipid	extraction.	The	cells	were	washed	and	lipids	were	extracted	from	the	cells.	Then	click	 reaction	was	 performed	 both	with	 lipids	 from	 the	medium	 and	 from	 the	 cells.	 Finally,	 lipids	were	separated	on	a	TLC	plate	and	fluorescence	was	detected	by	fluorescence	imaging.	The	different	lipid	classes	in	which	FAs	were	incorporated	and	FAs	themselves	are	indicated	on	both	sides	of	the	image.	 Region	 “Unknown”	 indicates	 unidentified	 substances	 that	 are	 secreted	 into	 the	medium	by	hepatocytes.	 Lanes	 3,	 6	 and	 9	 represent	 controls,	where	 the	medium	with	 FA	was	 added	 to	wells	without	cells.	In	indicated	samples	50	μM	of	etomoxir	was	added	to	the	medium	with	FA.		
4.5.1.3. C11	and	C19-FA	uptake	in	3T3-L1	cells		As	 shown	before	both	 freshly	 isolated	 and	dedifferentiated	hepatocytes	 could	 take	up	C11-FA.	Following	the	previous	experiments	it	was	decided	to	verify	if	undifferentiated	(day	 0)	 and	 differentiated	 (day	 4)	 3T3-L1	 cells	 can	 also	 take	 up	 C11-FA,	 and	 if	 the	presence	of	etomoxir	has	any	effect	on	the	uptake.		Undifferentiated	 and	 differentiated	 3T3-L1	 cells	 were	 fed	 with	 either	 C11	 or	 C19-FA	overnight.	 Both	 cell	 types	 did	 take	 up	 C11-FA	 as	 it	 disappeared	 from	 the	 medium	compared	to	control	sample	(Figure	14,	lanes	1-4)	and	unknown	bands	were	identified	in	the	medium.	Since	the	results	with	and	without	etomoxir	were	the	same,	no	etomoxir	effect	could	be	observed	(Figure	14,	 lanes	1-4).	In	undifferentiated	cells	one	additional	band	 could	 be	 seen	 compared	 to	 differentiated	 cells	 (Figure	 14,	 lanes	 1-4).	 In	differentiated	cells	treated	with	etomoxir,	the	amount	of	C11-TAG	was	lower	compared	
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to	untreated	cells	(Figure	14,	lanes	13-14).	Undifferentiated	cells	had	no	C11-TAG	at	all	(Figure	14,	lanes	11-12).	Apparently,	etomoxir	had	no	effect	on	the	C19-TAG	amount	in	both	 undifferentiated	 and	 differentiated	 cells	 (Figure	 14,	 lanes	 15-18).	When	 feeding	differentiated	 cells	with	C11-FA	 the	additional	TAG	band	appeared.	 It	 ran	higher	 than	C11-TAG	 and	 at	 a	 similar	 height	 as	 C19-TAG	 (Figure	 14,	 lanes	 13-14).	 A	 plausible	explanation	would	be	that	C11-FA	was	elongated	while	overnight	feeding	and	that	both	C11-FA	and	elongated	FA	were	used	for	TAG	synthesis.	
	
Figure	14.	C11	and	C19-FA	uptake	from	the	medium	in	3T3-L1	cells.	3T3-L1	cells	were	grown	in	6-well	plates	until	confluence.	The	differentiation	medium	was	added	to	half	of	the	cells	for	4	days.	After	4	days,	the	medium	with	50	μM	of	either	C11	or	C19	fatty	acids	was	added	 to	 both	 differentiated	 and	 undifferentiated	 cells	 for	 overnight	 feeding	 (approx.	 18	 hours).	After	feeding	the	medium	was	collected	and	50	μl	of	it	was	used	for	lipid	extraction.	The	cells	were	washed	and	 lipids	were	extracted	 from	 the	cells.	Then	 the	click	 reaction	was	performed	both	with	lipids	from	the	medium	and	cells.	Finally,	lipids	were	separated	on	a	TLC	plate	and	fluorescence	was	detected	by	fluorescence	imaging.	The	different	lipid	classes	in	which	FAs	were	incorporated	and	FAs	themselves	 are	 indicated	 on	 the	 right	 side	 of	 the	 image.	 Region	 “Unknown”	 indicates	 unidentified	substances	 that	 are	 secreted	 into	 the	medium	by	3T3-L1	 cells.	 Lanes	5	 and	10	 represent	 controls,	where	the	medium	with	FA	was	added	to	wells	without	cells.	In	indicated	samples	50	μM	of	etomoxir	was	 added	 to	 the	 medium	 with	 FA.	 D0	 represents	 undifferentiated	 cells.	 D4	 represents	 cells	differentiated	for	4	days.			
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4.5.1.4. C11	and	C19-FA	uptake	in	Huh7	cells			As	 evident	 from	 the	 previous	 section,	 undifferentiated	 3T3-L1	 cells	 cannot	 synthesize	C11-TAG	but	take	up	C11-FA	from	the	medium.	To	further	explore	this	topic	the	same	experiment	as	in	chapter	4.5.1.3	was	made,	but	with	Huh7	cells.	Huh7	cells	also	cannot	synthesize	C11-TAG	(Figure	9	lane	12).	From	Figure	15A	lanes	1-5	and	B	it	can	be	seen	that	Huh7	cells	did	not	take	up	C11-FA	as	C11-FA	amount	in	the	medium	was	the	same	both	in	samples	with	and	without	cells.	However,	Huh7	cells	did	take	up	C19-FA	as	C19-FA	amount	in	the	medium	after	incubation	with	cells	decreased	significantly	(Figure	15A	lanes	6-10	and	B).	These	cells	did	not	incorporate	C11-FA	in	TAG	and	they	did	not	use	it	for	other	metabolic	processes	as	C11-FA	did	not	disappear	from	the	medium.	
	
Figure	15.	Huh7	uptake	of	C19	and	C11-FAs	from	the	medium.	(A)	150.000	cells	were	seeded	per	well	in	a	24-well	plate.	Next	day	the	medium	with	either	50	μM	of	C11-FA	or	C19-FA	was	added	to	the	cells	for	overnight	feeding	(approx.	18	hours).	After	feeding	the	medium	 was	 collected	 and	 50	 μl	 of	 it	 was	 used	 for	 lipid	 extraction.	 Then	 click	 reaction	 was	performed,	 lipids	 were	 separated	 on	 a	 TLC	 plate	 and	 fluorescence	 was	 detected	 by	 fluorescence	imaging.	FAs	and	lipids	secreted	by	cells	to	the	medium	are	indicated	on	both	sides	of	the	image.	The	lanes	4,	5,	9	and	10	represent	the	controls,	where	the	medium	with	FA	was	added	to	wells	without	cells.	(B)	Quantification	of	data	from	panel	A.	The	values	represent	fluorescence	intensity	of	C11	and	C19-FA	bands.	The	data	represent	mean	+SD,	n=5.	***	stands	for	p≤0.001.				
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4.5.1.5. Protease	treatment	of	hepatocytes		To	see	if	C11	and	C19-FAs	need	a	transport	protein	to	get	inside	the	cell	freshly	isolated	hepatocytes	were	treated	with	different	proteases.	By	doing	this	putative	FA	transport	proteins	 located	 at	 the	 outer	 side	 of	 the	 plasma	 membrane	 theoretically	 could	 be	removed.	However,	 there	was	no	significant	difference	between	control	 cells	and	cells	treated	 with	 different	 proteases	 while	 feeding	 with	 C11	 and	 C19-FAs	 (Figure	 16).	 It	should	be	mentioned	 that	no	positive	 control	 for	protease	 treatment	was	used	 in	 this	experiment,	 therefore	 the	 data	 should	 be	 interpreted	 carefully.	However,	with	 proper	controls,	 e.g.,	 performing	Western	Blot	 for	well	 known	outer	membrane	proteins,	 this	could	be	a	nice	method	for	FA	transport	experiments.			
		
	
Figure	16.	Treatment	of	hepatocytes	with	different	proteases.	Hepatocytes	were	 isolated	 from	mouse	 liver	 and	plated	 on	 collagen	 coated	6-well	 dishes.	 400.000	cells	were	used	per	well.	Different	proteases	were	added	to	cells	for	15	min	at	37˚C	in	the	absence	of	FBS.	Digestion	was	inhibited	by	adding	William’s	E	medium	supplemented	with	FBS.	Cells	from	each	digestion	were	divided	into	two	equal	parts.	One	part	was	used	for	feeding	with	50	µM	of	C11-FA	and	the	second	part	for	feeding	with	50	µM	of	C19-FA.	The	cells	were	incubated	with	FAs	for	15	min	and	washed.	 Then	 lipids	 were	 extracted	 from	 the	 cells	 and	 the	 click	 reaction	 was	 performed.	 Finally,	lipids	were	separated	on	a	TLC	plate	and	fluorescence	was	detected	by	fluorescence	imaging.		C19-FA	and	 the	 different	 lipid	 classes	 in	which	 FAs	were	 incorporated	 are	 indicated	 on	 both	 sides	 of	 the	image.		“T”	stands	for	trypsin,	“P”	for	papain,	“Ch”	–	chymotrypsin,	“Pk”	–	proteinase	K.	
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4.5.1.6. Huh7	in	differentiation	medium		Cells,	used	in	previous	experiments,	got	in	contact	with	different	substances	as	C11-TAG	synthesis	was	 investigated.	There	was	a	reasonable	need	 to	determine	 if	 the	ability	 to	synthesize	C11-TAG	was	not	influenced	by	having	a	contact	with	these	substances.	Upon	differentiation	 3T3-L1	 cells	were	 treated	with	 insulin,	 IBMX	 and	 dexamethasone.	 The	analyzed	 slices	 came	 from	mouse	 organs	 that	 also	 had	 contact	 with	 insulin	 from	 the	blood.	 It	 was	 reasoned	 that	 these	 substances	might	 affect	 the	 C11-TAG	 synthesis.	 To	verify	this	Huh7	cells	were	treated	with	insulin,	IBMX	and	dexamethasone	either	by	each	of	 them	 separately	 or	 in	 different	 combinations	 for	 3	 days.	 Afterward,	 cells	 were	 fed	with	 a	 mixture	 of	 C11	 and	 C19-FAs.	 Different	 serum	 conditions	 were	 also	 tested.	However,	none	of	 these	conditions	 facilitated	C11-FA	 incorporation	 into	TAG	and	only	C19-TAG	bands	could	be	detected	(Figure	17).	
	
Figure	 17.	 C11	 and	 C19-FA	metabolism	 in	Huh7	 cells	 grown	 in	 different	 differentiation	
medium	conditions.	60.000	 of	 Huh7	 cells	were	 seeded	 per	 one	well	 of	 a	 24-well	 plate.	When	 cells	were	 attached,	 the	medium	and	different	additional	components,	used	for	differentiation	of	3T3-L1	cells,	was	added	for	3	 days.	 The	 components	were	 added	 either	 on	 their	 own	 or	 in	 different	 combinations.	 Additional	components	 were:	 0.5	 mM	 IBMX,	 10	 μM	 dexamethasone	 (DEXA),	 and	 5	 μg/ml	 insulin.	 In	 these	conditions	the	medium	contained	10%	FBS.	The	effect	of	serum	was	also	tested	as	 indicated	 in	the	figure.	C	stands	for	FBS	and	H	for	horse	serum.	*	indicates	insulin	concentration	of	15	μg/ml.	After	3	days	of	incubation	a	mixture	of	50	μM	C11	and	50	μM	C19-FAs	was	added	to	cells	for	1.5	hours.	The	cells	were	washed	and	lipids	were	extracted	from	the	cells.	The	click	reaction	was	performed,	lipids	were	separated	on	a	TLC	plate	and	fluorescence	was	detected	by	fluorescence	imaging.	
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4.5.2. Pulse experiments and the etomoxir effect 	In	 order	 to	 better	 understand	 the	 etomoxir	 effect	 observed	 in	 hepatocytes	 and	differentiated	3T3-L1	 cells	pulse	experiments	were	 carried	out	with	C11	and	C19-FAs	and	lipids	from	the	medium	and	the	cells	were	analyzed.		
4.5.2.1. Initial	C11-FA	pulse	experiments	in	hepatocytes		Freshly	isolated	hepatocytes	were	fed	with	C11-FA	for	indicated	time	periods	in	medium	with	or	without	etomoxir.	Lipids	from	both	the	medium	and	the	cells	were	analyzed.	As	evident	from	Figure	18A,	during	short	pulse	times	(up	to	90	min)	unknown	bands	were	detected	when	analyzing	the	medium	from	both	etomoxir-treated	and	untreated	cells.	In	the	medium	from	etomoxir-treated	cells,	these	bands	were	more	intense.	Etomoxir	also	had	 an	 effect	 on	 the	 C11-TAG	 amount	 in	 cells.	 Already	 after	 20	 min	 of	 incubation,	 a	decrease	 in	 C11-TAG	 amount	 was	 observed	 in	 etomoxir-treated	 cells	 compared	 to	untreated	 cells	 (Figure	 18B,	 lanes	 3	 and	 9).	 In	 experiments	 with	 longer	 pulse	 times	(Figure	 18C,	 D)	 it	 can	 be	 seen	 that	 in	 the	 time	 period	 between	 2	 and	 4	 hours	 the	unknown	bands	disappeared	from	the	medium	of	the	untreated	cells	(Figure	18C,	lanes	1	 and	 2),	 whereas	 in	 the	 medium	 from	 etomoxir-treated	 cells	 the	 bands	 were	 quite	intense	(Figure	18C,	 lanes	8	and	9),	but	diminished	with	 time.	One	could	wonder	why	after	overnight	feeding	these	“unknown”	bands	(Figure	18,	lane	14)	were	less	intense	as	in	Figure	12A	lane	2.	In	experiment	described	in	this	chapter	(Figure	18,	lane	14)	cells	were	 fed	 with	 C11-FA	 directly	 after	 isolation	 and	 adherence	 to	 plates,	 so	 the	 total	overnight	 feeding	 time	 was	 approx.	 24	 hours.	 However,	 in	 the	 previous	 experiment	(Figure	12A	lane	2)	overnight	feeding	lasted	approximately	18	hours.	Moreover,	at	the	start	of	the	feeding	the	cells	from	the	previous	experiment	(Figure	12A)	were	6-7	hours	older	 than	 the	 cells	 in	 this	 experiment	 (Figure	 18).	 In	 chapter	 4.3	 it	 was	 already	demonstrated	 the	 influence	 of	 the	 time,	which	 cells	 spend	 in	 the	 2D	 cell	 culture	 after	isolation,	on	hepatocyte	metabolism.	Hepatocytes	incorporated	C11-FA	not	only	in	TAG	but	also	in	PC	(Figure	18B,	D).	The	 most	 interesting	 time	 points	 from	 experiments	 described	 in	 this	 chapter	 were	selected	for	further	pulse	experiments.		
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Figure	18.	Initial	C11-FA	pulse	experiments	in	hepatocytes.	After	isolation	from	mouse	liver	hepatocytes	were	plated	on	collagen	coated	3.5	cm	dishes.	200.000	cells	were	 plated	 per	 one	 dish.	 50	 μM	 of	 C11-FA	was	 added	 for	 shorter	 intervals	 (A,	 B)	 or	 longer	intervals	 (C,	D).	 The	medium	was	 collected	 and	50	 μl	 of	 it	was	 used	 for	 lipid	 extraction.	 The	 cells	were	washed	and	lipids	were	extracted	from	the	cells.	Then	click	reaction	was	performed	both	with	lipids	from	the	medium	(A,	C)	and	the	cells	(B,	D).	Finally,	lipids	were	separated	on	a	TLC	plate	and	fluorescence	was	detected	by	fluorescence	imaging.	In	the	indicated	samples	(+	etomoxir)	50	μM	of	etomoxir	was	added	 to	 the	medium	with	FA.	Lane	13	 in	panel	A	and	 lane	15	 in	panel	C	 represent	controls,	where	 the	medium	with	FA	was	added	 to	 the	well	without	 cells.	ON	stands	 for	overnight	(approx.	24	hours).		
4.5.2.2. Detailed	C11-FA	pulse	experiments	in	hepatocytes		Freshly	isolated	hepatocytes	were	fed	with	C11-FA	for	5	and	20	minutes	and	for	1,	2,	6	and	 10	 hours.	 Cells	 were	 fed	with	 FA	 either	 in	 the	 presence	 or	 absence	 of	 etomoxir.	Lipids	from	both	the	medium	and	the	cells	were	analyzed.		Already	after	20	min	of	the	incubation	time	a	significant	decrease	in	the	TAG	amount	in	etomoxir-treated	hepatocytes	could	be	detected	(Figure	19A	lanes	2,	8	and	Figure	19C).	This		decrease		stayed			constant			over			the			time.			The			PC			amount		also		decreased		in		
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Figure	19.	C11-FA	pulse	experiments	in	hepatocytes.	After	 isolation	from	mouse	 liver	hepatocytes	were	plated	on	collagen	coated	3.5	cm	dishes.	200.000	cells	were	plated	per	one	dish.	50	μM	of	C11-FA	was	added	for	a	pulse	time	indicated	in	panels	A	and	E.	After	this	time	period	the	medium	was	collected	and	50	μl	of	it	was	used	for	lipid	extraction.	Cells	were	washed	and	lipids	were	extracted.	Then	the	click	reaction	was	performed	both	with	lipids	from	the	medium	(E)	and	cells	(A).	Finally,	the	lipids	were	separated	on	a	TLC	plate	and	fluorescence	was	detected	by	fluorescence	imaging.	In	the	indicated	samples	(+	etomoxir)	50	μM	of	etomoxir	was	added	to	the	medium	with	FA.	Lane	13	in	panel	E	represents	a	control,	where	the	medium	with	FA	was	added	to	the	well	without	cells.	Graphs	B,	C	and	D	illustrate	quantifications	of	bands	indicated	at	the	right	side	of	the	panel	A	(TAG	with	elongated	FA,	 C11-TAG	 and	 C11-PC).	 Graphs	 F,	 G,	 H	 and	 I	 illustrate	 the	 quantifications	 of	 C11-FA	 bands	 and	 the	unknown	bands	 X,	 Y,	 Z	 indicated	 in	 panel	 E.	 The	 data	 represent	mean	 ±SD,	 n=3.	 *	 stands	 for	 p≤0.05;	 **	p≤0.01;	***	p≤0.001.		
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etomoxir-treated	cells	(Figure	19D).	Another	exciting	result	 is	 that	during	the	pulse	time	an	additional	upper	TAG	band	appeared	 in	cells	not	treated	with	etomoxir	(Figure	19A	and	B).	This	upper	TAG	band	likely	represents	TAG	synthesized	from	elongated	C11-FA.	After	6	hours	of	 incubation,	 this	band	reached	 its	peak	(Figure	19B).	 In	cells	 treated	with	etomoxir	upper	TAG	band	was	barely	present	 (Figure	19A	 lanes	7-12,	B).	Experiments	with	 lipid	extraction	from	 the	 medium	 showed	 that	 etomoxir	 had	 no	 significant	 effect	 on	 the	 residual	 C11-FA	amount	 (Figure	 19E,	 F).	 After	 2	 hours	 of	 feeding,	 less	 than	20	%	of	 C11-FA	was	 left	 in	 the	medium.	In	the	time	window	between	2	and	6	hours,	C11-FA	was	completely	used	up	(Figure	19F).	Once	the	C11-FA	was	nearly	depleted	from	the	medium,	the	amount	of	C11-TAG	in	the	cells	started	decreasing	as	well	(Figure	19C).		As	in	the	previous	experiment	(Figure	12A)	the	unknown	bands	X,	Y	and	Z	appeared	in	both	etomoxir-treated	 and	 untreated	 cells	 (Figure	 19E).	 The	 Z-band	 was	 more	 intensive	 in	etomoxir-treated	cells	(Figure	19E,	I).	Furthermore,	it	was	also	the	most	intensive	band	out	of	the	three.	In	the	cells	not	treated	with	etomoxir	the	intensity	of	the	X-band	increased	slightly	in	the	first	hour	but	then	disappeared	with	time	(Figure	19G).	In	etomoxir-treated	cells	the	X-band	was	more	intense	after	a	short	pulse,	but	its	intensity	declined	when	incubating	longer	than	2	hours.	The	Y-band	behaved	similarly	over	time	but	was,	 in	general,	 less	 intense	than	the	X-band	(Figure	19H).		
4.5.2.3. C19-FA	pulse	experiments	in	hepatocytes		Freshly	isolated	hepatocytes	were	fed	with	C19-FA	for	5	and	20	minutes	and	for	1,	2,	6	and	10	hours.	The	cells	were	 fed	with	 the	FA	either	 in	 the	presence	or	absence	of	etomoxir.	Lipids	from	both	the	medium	and	the	cells	were	analyzed.		As	illustrated	by	Figure	20A	and	Figure	20B	the	TAG	amount	was	barely	affected	by	etomoxir	in	 hepatocytes	 fed	 with	 C19-FA.	 The	 PC	 and	 PE	 amounts	 increased	 slightly	 in	 etomoxir-treated	 cells	 (Figure	 20C,	 D).	 The	 C19-FA	 amount	 was	 not	 affected	 by	 etomoxir	 and	 there	were	no	additional	bands	appearing	in	the	medium	(Figure	20E,	F).	During	the	pulse	time	of	10	hours,	the	TAG	amount	in	the	presence	and	in	the	absence	of	etomoxir	increased	steadily	or	 remained	unchanged	 (Figure	20A,	B).	 The	C19-FA	 could	 still	 be	detected	 in	 the	medium	after	six	hours	of	feeding	(Figure	20E	lanes	5	and	11,	F).		Further	pulse	experiments	were	conducted	with	differentiated	3T3-L1	cells.		
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Figure	20.	C19-FA	pulse	experiments	in	hepatocytes	After	isolation	from	mouse	liver,	hepatocytes	were	plated	on	collagen	coated	3.5	cm	dishes.	200.000	cells	were	plated	per	one	dish.	50	μM	of	C19-FA	was	added	for	a	pulse	time	indicated	in	panels	A	and	E.	After	this	 time	 period	 the	medium	was	 collected	 and	 50	 μl	 of	 it	was	 used	 for	 lipid	 extraction.	 The	 cells	were	washed	and	lipids	were	extracted.	Then	the	click	reaction	was	performed	both	with	lipids	from	the	medium	(E)	 and	 cells	 (A).	 Finally,	 lipids	 were	 separated	 on	 a	 TLC	 plate	 and	 fluorescence	 was	 detected	 by	fluorescence	imaging.	In	the	indicated	samples	(+	etomoxir)	50	μM	of	etomoxir	was	added	to	the	medium	with	 FA.	 Lane	 13	 in	 panel	 E	 represents	 the	 control,	 where	 the	medium	with	 FA	was	 added	 to	 the	well	without	cells.	Graphs	B,	C	and	D	illustrate	the	quantifications	of	the	bands	indicated	at	the	right	side	of	the	panel	A.	Graph	F	 illustrates	the	quantification	of	FA	bands	 indicated	 in	panel	E.	The	data	represent	mean	±SD,	n=4.	*	stands	for	p≤0.05;	**	p≤0.01.				
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4.5.2.4. C11	and	C19-FA	pulse	experiments	in	3T3-L1	cells		Similarly	as	hepatocytes,	3T3-L1	cells	were	fed	with	C11	or	C19-FAs	for	10	minutes	and	for	1	and	4	hours.	The	effect	of	etomoxir	was	analyzed.	Experiments	showed	that	cells	treated	with	etomoxir	incorporated	less	C11-FA	into	C11-TAG	and	into	C11-PC	(Figure	21A	 lanes	 1-6,	 B,	 C).	 In	 a	 time	window	between	 1	 and	 4	 hours,	 the	 C11-TAG	 amount	started	 to	 decrease	 in	 both	 conditions	 (Figure	 21B).	 This	 correlated	with	 the	 C11-FA	decrease	in	the	medium	(Figure	21D).	After	4	hours	of	feeding,	approximately	only	5%	of	C11-FA	was	left	in	the	medium.	Etomoxir	did	not	have	a	significant	effect	on	C11-FA	amount	in	the	medium	(Figure	21A	lanes	7-12,	D).	Unknown	bands	marked	with	X,	Y,	Z	appeared	 in	 the	 medium	 from	 3T3-L1	 cells.	 When	 incubated	 for	 up	 to	 1	 hour	 the	intensity	of	Y	and	Z	bands	was	not	affected	by	the	presence	of	etomoxir	(Figure	21F,	G).	After	 4	 hours	 with	 etomoxir	 treatment,	 the	 intensity	 of	 the	 Y	 band	 increased	significantly	(Figure	21F).	The	signal	of	the	X-band	was	consistently	weaker	in	the	cells	not	treated	with	etomoxir	(Figure	21E).	The	 treatment	with	etomoxir	had	no	significant	effect	on	 the	amount	of	TAG,	DAG,	PE	and	PC	in	3T3-L1	cells	fed	with	C19-FA	(Figure	22A	lanes	1-6,	B,	C,	D,	E).	The	etomoxir	treatment	 also	 virtually	 did	 not	 change	 the	 amount	 of	 C19-FA	 in	 the	medium	 (Figure	22A	lanes	7-12,	F).	In	both	conditions	the	C19-TAG	amount	constantly	increased	(Figure	22B).	After	a	4	hour	pulse	there	was	still	more	than	30%	of	C19-FA	left	in	the	medium	(Figure	22F).		
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Figure	21.	C11-FA	pulse	experiments	in	3T3-L1	cells.	3T3-L1	cells	were	grown	in	12-well	plates	until	confluence.	After	 two	more	days,	differentiation	medium	was	added	for	4	days.	After	4	days,	the	medium	with	50	μM	of	C11-FA	was	added	for	a	pulse	time	indicated	in	panel	A.	After	this	time	period	the	medium	was	collected	and	50	μl	of	it	was	used	for	lipid	extraction.	The	cells	were	washed	and	lipids	were	extracted.	Then	the	click	reaction	was	performed	both	with	lipids	from	the	medium	and	the	cells.	Finally,	 lipids	were	separated	on	a	TLC	plate	and	fluorescence	was	detected	by	fluorescence	imaging	(A).	In	the	indicated	samples	50	μM	of	etomoxir	was	added	to	the	medium	with	FA.	Lane	13	in	panel	A	represents	the	control,	where	the	medium	with	C11-FA	was	added	to	the	well	without	cells.	Graphs	B	and	C	 illustrate	quantifications	of	 the	bands	 indicated	at	 the	 left	side	of	 the	panel	A	(C11-TAG,	C11-PC).	Graphs	D,	E,	F	and	G	illustrate	quantifications	of	C11-FA	bands	and	the	unknown	bands	X,	Y	and	Z	indicated	at	the	right	side	of	the	panel	A.		The	data	represent	mean	±SD,	n=3.	*	stands	for	p≤0.05.			
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Figure	22.	C19-FA	pulse	experiments	in	3T3-L1	cells.	3T3-L1	cells	were	grown	in	12-well	plates	until	confluence.	After	two	more	days,	a	differentiation	medium	was	added	for	4	days.	After	4	days,	the	medium	with	50	μM	of	C19-FA	was	added	for	a	pulse	time	indicated	in	panel	A.	After	this	time	period	the	medium	was	collected	and	50	μl	of	it	was	used	for	lipid	extraction.	The	cells	were	washed	and	lipids	were	extracted.	Then	click	reaction	was	performed	both	with	lipids	from	the	medium	 and	 the	 cells.	 Finally,	 lipids	 were	 separated	 on	 a	 TLC	 plate	 and	 fluorescence	 was	 detected	 by	fluorescence	imaging	(A).	In	indicated	samples	50	μM	of	etomoxir	was	added	to	the	medium	with	FA.	Lane	13	 in	 panel	 A	 represents	 control,	 where	 the	medium	with	 C19-FA	was	 added	 to	 the	well	 without	 cells.	Graphs	B,	C,	D	and	E	illustrate	quantifications	of	bands	indicated	at	the	left	side	of	the	panel	A	(C19-TAG,	C19-DAG,	 C19-PE	 and	 C19-PC).	 Graph	 F	 illustrates	 quantification	 of	 C19-FA	 bands	 indicated	 at	 the	 right	side	of	the	panel	A.	The	data	represent	mean	±SD,	n=3.				
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4.5.2.5. C11	and	C19	pulse-chase	experiments	in	3T3-L1	cells		This	experiment	was	carried	out	to	determine	what	happens	with	C11	and	C19-TAG	after	one-hour	pulse	and	 then	a	 longer	 chase	 lasting	up	 to	24	hours.	When	3T3-L1	cells	were	pulsed	with	C11-FA	 for	1	hour	and	then	chased,	 the	 intensity	of	 the	C11-TAG	band	decreased	with	increasing	 chase	 times	 (Figure	 23A	 lanes	 1-3,	 C).	 C11-TAG	 and	 C11-PC	 bands	 were	 less	intense	 in	cells	 treated	with	etomoxir	(Figure	23A	 lanes	1-6,	C,	D).	When	3T3-L1	cells	were	pulsed	with	 C19-FA	 for	 1	 hour	 and	 then	 chased,	 the	 amount	 of	 C19-TAG	 stayed	 relatively	constant	over	time	(Figure	23A	lanes	7-12,	E).	The	intensity	of	C19-TAG	and	C19-PC	bands	in	cells	treated	with	etomoxir	was	higher.	However,	the	measured	difference	was	not	significant	(Figure	23E,	F).		An	 interesting	 result	 was	 the	 appearance	 of	 an	 additional	 TAG	 band	 in	 the	 pulse-chase	experiment	 with	 C11-FA	 (probably	 indicating	 C11-FA	 elongation),	 which	 was	 much	 more	intense	in	etomoxir	untreated	cells	and	increased	over	the	time	(Figure	23A	lanes	1-6	and	B).			
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Figure	23.	C11	and	C19-FA	pulse-chase	experiments	in	3T3-L1	cells.	3T3-L1	cells	were	grown	in	12-well	plates	until	confluence.	After	two	more	days,	a	differentiation	medium	was	added	for	4	days.	After	4	days,	the	medium	with	50	μM	of	C11-FA	or	C19-FA	in	the	presence	or	in	the	absence	of	50	μM	etomoxir	was	added	 for	1	hour.	After	 this	pulse	period,	 the	medium	was	removed	and	fresh	chase	medium	with	or	without	etomoxir	was	added	 for	chase	 times	 indicated	 in	panel	A.	After	 this	time	 period,	 the	 cells	 were	 washed	 and	 lipids	 were	 extracted.	 Then	 the	 click	 reaction	 was	 performed.	Finally,	 lipids	 were	 separated	 on	 a	 TLC	 plate	 and	 fluorescence	 was	 detected	 by	 fluorescence	 imaging.	Graphs	B,	C	and	D	illustrate	quantifications	of	bands	from	panel	A	lanes	1-6	(TAG	with	elongated	FA,	C11-TAG	and	C11-PC	bands).	Graphs	E	and	F	illustrate	quantifications	of	bands	from	panel	A	lanes	7-12	(C19-TAG	and	C19-PC	bands).	The	data	represent	mean	±SD,	n=3	for	C11	feeding	and	n=2	for	C19	feeding.			 		
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4.5.2.6. Extraction	 and	 alkaline	 hydrolysis	 experiment	 with	 lipids	 from	 the	
medium		In	 order	 to	 find	 out	 more	 about	 the	 nature	 of	 the	 unknown	 bands	 appearing	 in	 the	medium	of	dedifferentiated	hepatocytes	fed	with	C11-FA	(Figure	12A	lane	5),	different	lipid	extractions	were	performed	and	extracted	 lipids	were	hydrolyzed	under	alkaline	conditions.	When	the	 lipids	were	extracted	from	the	medium	using	water,	no	signal	of	unknown	 bands	 could	 be	 detected	 on	 the	 TLC	 plate	 (Figure	 24	 lane	 2).	 Substances	representing	unknown	bands	could	only	be	extracted	with	a	1%	acetic	acid	(Figure	24	lane	1).	This	 indicates	a	hydrophilic	nature	of	these	substances	and	the	most	probable	existence	 of	 least	 one	 carboxyl	 group.	With	 an	 alkaline	 hydrolysis	 experiment,	 it	 was	shown	that	at	least	X	and	Y	bands	were	not	hydrolyzed.	The	Z-band	was	either	partially	hydrolyzed	 or	 was	 lost	 during	 the	 extraction	 procedure.	 The	 most	 intensive	 of	 the	“unknown”	 bands	 was	 hydrolyzed	 (Figure	 24	 lane	 3).	 The	 only	 additional	 hydrolysis	product	could	be	detected	at	the	height	of	C19-FA	(Figure	24,	lane	3).	However,	the	click	reaction	mixture	background	band,	which	could	be	seen	in	Figure	24,	lanes	1	and	2	also	runs	at	this	height.	It	is	difficult	to	say	if	this	band	is	actually	a	product	of	hydrolysis	or	just	 a	 background	 band.	 It	 is	 also	 not	 clear	 where	 the	 clickable	 hydrolysis	 product	disappeared.		
 
Figure	24.	Extraction	and	alkaline	hydrolysis	experiment	with	the	medium	from	
dedifferentiated	hepatocytes	fed	with	C11-FA	overnight.		After	isolation	from	mouse	liver	hepatocytes	were	plated	on	collagen	coated	10	cm	dishes.	3.2	million	cells	were	plated	per	one	dish.	The	cells	were	grown	in	the	incubator	for	3	days.	Then	 50	 μM	 of	 C11-FA	 was	 added	 to	 the	 cells	 for	 overnight	 feeding.	 After	 feeding	 the	medium	was	collected.	150	μl	of	the	medium	was	used	for	lipid	extraction	with	water	(W)	or	with	 1	 %	 acetic	 acid	 (Ac).	 One	 probe	 of	 acetic	 acid	 extraction	 was	 used	 for	 alkaline	hydrolysis.	C19-TAG,	C19-DAG	and	C19-PC,	used	as	controls	for	hydrolysis	efficiency,	were	completely	 hydrolyzed	 to	 C19-FA	 (lanes	 4	 –	 5).	 X,	 Y	 and	 Z	 indicate	 unknown	 hydrophilic	substances.	
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4.5.3. TAG synthesis 	If	we	now	take	a	look	at	the	pathway	from	FA	outside	the	cell	to	TAG	synthesis	inside	the	cell,	introduced	in	chapter	4.5,	it	can	be	excluded	that	a	defect	of	C11-FA	entry	into	the	cell	was	the	reason	for	the	absence	of	C11-TAG	synthesis	in	hepatocytes	and	in	3T3-L1	cells	(4.5.1.1;	4.5.1.3).	Acyl-CoA	and	TAG	synthesis	are	the	most	interesting	parts	of	this	pathway	and	therefore	they	were	investigated	in	the	next	step.	At	the	initial	screening	of	sequencing	 data	 of	 differentiating	 3T3-L1	 cells,	 several	 acyl-CoA	 and	 TAG	 synthesis	related	hit	proteins	were	identified,	of	which	the	mRNA	expression	increased	in	the	time	period	between	24	and	48	hours.	Among	these	hits	were	ACSL1,	GPAT3	(AGPAT9)	and	DGAT2	 (Table	 15,	 rows	 13,	 18	 and	 30).	 This	was	 consistent	with	 results	 obtained	 by	Mikkelsen	et	al.,	2010.	They	have	shown	that	mRNA	levels	of	these	proteins	extremely	increase	on	day	2	of	3T3-L1	cell	differentiation.	In	order	to	see	a	possible	effect	of	these	proteins	 on	 C11-FA	metabolism	 they	were	 overexpressed	 either	 alone	 or	 in	 different	combinations	 in	 Hek293	 cells;	 a	 cell	 line	 that	 cannot	 incorporate	 C11-FA	 into	 TAG.	Original	 idea	 was	 to	 overexpress	 these	 proteins	 in	 undifferentiated	 3T3-L1	 cells	 and	Huh7	cells,	but	as	their	overexpression	was	not	efficient	(data	not	shown)	it	was	decided	to	 take	 another	 cell	 line,	 namely	 Hek293,	 which	 is	 good	 at	 transfection	 and	 cannot	synthesize	C11-TAG,	see	chapter	4.1.3	
4.5.3.1. Overexpression	of	DGAT2,	AGPAT9	and	ACSL1	in	Hek293	cells		DGAT2,	 AGPAT9,	 and	 ACSL1	 were	 overexpressed	 in	 Hek293	 cells	 either	 alone	 or	 in	different	 combinations.	 Overexpression	 of	 flag-tagged	 DGAT2	 worked	 very	 efficiently	(Figure	25B	lanes	6,	7,	8,	10;	FLAG	row).	Overexpression	of	the	other	plasmids	especially	in	 the	 triple	 combinations	 was	 weaker	 (Figure	 25B).	 Nevertheless,	 none	 of	 the	overexpressions	affected	the	metabolic	fate	of	C11-FA	as	no	C11-TAG	could	be	detected	at	 all	 (Figure	25A).	 The	 amount	 of	 C19-TAG	 increased	 in	 all	 conditions	where	DGAT2	flag	plasmid	was	present	compared	to	GFP	control	(Figure	25A	lanes	5,	7,	13,	15,	17	and	21;	 C).	 It	 could	 be	 that	 the	 overexpression	 of	 proteins	 was	 too	 weak	 to	 cause	 a	significant	metabolic	effect	on	C11-FA	metabolism.	For	this	reason	it	was	later	decided	to	 study	 the	 enzymatic	 activities	 of	 proteins	 participating	 in	 TAG	 synthesis	 more	thoroughly.			
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Figure	25.	Overexpression	of	ACSL1,	AGPAT9	and	DGAT2	in	Hek293	cells.	(A)	 Hek293	 cells	were	 grown	 up	 to	 60-70%	 confluence	 and	 transfected	with	 plasmids	 containing	sequences	for	ACSL1,	AGPAT9	and	DGAT2	either	alone	or	in	different	combinations.	24	hours	after	transfection	the	cells	were	fed	with	50	μM	of	C11	or	C19-FAs	for	1.5	hours.	The	cells	were	washed	and	lipids	were	extracted	from	the	cells.	Then	the	click	reaction	was	performed	both	with	lipids	from	the	medium	and	 from	 the	 cells.	 Finally,	 lipids	were	 separated	on	a	TLC	plate	 and	 the	 fluorescence	was	detected	by	 fluorescence	 imaging.	The	different	 lipid	classes,	 in	which	FAs	were	 incorporated,	are	indicated	on	the	right	side	of	the	image.		AC	stands	for	ACSL1	with	HA	tag,	Ag	–	AGPAT9	with	flag	tag,	Dg	–	DGAT2	with	flag	tag,	All	–	all	three	plasmids	together.	In	“All2”	different	DGAT2	plasmids,	which	had	HA	tag	instead	of	flag	tag	were	used.	In	“All4”	different	DGAT2	plasmids,	which	had	no	tag	at	 all	were	used.	 In	 “All3”	different	 transfection	 reagent	was	used.	 In	GFP	–	 cells	were	 transfected	with	GFP	plasmid.	 (B)	Western	blot	 showing	 the	overexpression.	The	 table	 shows	which	plasmids	were	overexpressed.	*	marks	that	DGAT2	had	an	HA	tag	instead	of	Flag	(lane	1).	**	marks	that	DGAT2	had	no	tag	at	all	(lane	2).	Lane	4	represents	untransfected	cells,	lane	5	represents	a	GFP	transfection.	The	row	with	ACSL1	antibody	shows	a	native	ACSL1	protein	(lower	band)	and	an	HA-tagged	protein	(higher	band).	The	row	with	the	HA	antibody	shows	the	HA-tagged	ACSL1	protein.	The	AGPAT9	row	shows	 native	 and	 transfected	 proteins.	 In	 the	 row	 for	 Flag	 antibody,	 flag-tagged	 AGPAT9	 (higher	band)	and	flag-tagged	DGAT2	(lower	band)	can	be	seen.	(C)	Quantification	of	data	in	panel	A.	Values	represent	the	fluorescence	intensity	of	C19-TAG	divided	by	the	sum	of	fluorescence	intensity	of	C19-TAG,	C19-TAG,	C19-PE	and	C19-PC.		
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4.5.3.2. Acyl-CoA	 synthesis	 assay	with	 lysates	 from	Huh7	 cells	 and	 primary	
mouse	hepatocytes		The	 acyl-CoA	 synthesis,	 GPAT,	 LPAAT	 and	DGAT	 activities	 are	 important	 steps	 in	 the	cellular	TAG	synthesis	pathway,	 see	chapter	1.4.	A	simplified	TAG	synthesis	scheme	 is	presented	 in	 Figure	 26C.	 An	 interesting	 question	 was	 if	 any	 of	 these	 activities	 are	disrupted	in	cells	that	cannot	synthesize	C11-TAG.	To	test	this,	lysates	from	Huh7	cells	and	primary	mouse	hepatocytes	were	prepared	for	activity	assays.	Both	cell	types	are	of	liver	origin,	but	Huh7	cells	 cannot	 convert	C11-FA	 into	TAG	while	hepatocytes	 can.	 In	order	to	determine	if	both	lysates	are	able	to	synthesize	C11-CoA,	an	acyl-CoA	synthesis	assay	was	performed	(Figure	26C	step	2):	alkyne-FA	+	CoA	+	ATP	è	alkyne-FA-CoA	+	AMP	+	PPi.		Unfortunately,	it	was	not	possible	to	perform	a	direct	acyl-CoA	synthesis	assay,	because	during	the	extraction	the	acyl-CoA	remained	in	the	water	phase	and	the	click	reaction,	which	 followed	 afterward,	was	 not	 compatible	with	 salts	 present	 in	 the	water	 phase.	Different	reaction	buffers	and	click	reaction	conditions	were	tested.	However,	the	click	reaction	did	not	work	(data	not	shown).	Therefore	coupled	acyl-CoA/LPCAT	and	acyl-CoA/LPAAT	reactions	were	performed,	where	the	additional	substrates	LPC	(for	LPCAT	assay)	or	LPA	(for	LPAAT	assay)	were	added.	These	substrates	could	react	with	forming	acyl-CoA:	alkyne-FA	+	CoA	+	ATP	è	alkyne-FA-CoA	+	AMP	+	PPi	(acyl-CoA	synthesis	assay	part);	alkyne-FA-CoA	+	LPA/LPC	è	alkyne-PA/PC	+	CoA	(LPAAT/LPCAT	assay	part).	The	 products	 from	 these	 coupled	 reactions	 (PA	 or	 PC)	 could	 be	 extracted	 in	 the	chloroform	phase	and	the	click	reaction	could	be	performed.	As	can	be	seen	from	Figure	26A	lanes	7	and	8	in	a	purple	boxed	area,	both	lysates	could	synthesize	C11-CoA,	as	C11-PC	was	detected	in	the	coupled	assay.	When	LPA	was	the	additional	substrate,	no	C11-PA	was	detected	in	the	samples	with	both	lysates	(Figure	26A	lanes	3	and	4	in	a	purple	boxed	area).	However,	C11-TAG	(a	final	product	of	the	glycerol	phosphate	pathway)	was	detected	upon	a	longer	exposure	of	the	TLC	plate	(Figure	26A,	lanes	3	and	4,	in	“longer	explosion”	part).	The	ability	of	both	lysates	to	synthesize	C11-TAG	was	later	confirmed	by	a	DGAT	assay	(Figure	27).	
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An	LPCAT	assay	was	performed	as	an	additional	control	to	determine	if	the	PC	synthesis	from	acyl-CoA	and	LPC	could	influence	the	result	of	the	acyl-CoA	synthesis	assay	(Figure	26B):	alkyne-FA-CoA	+	LPC	è	alkyne-PC	+	CoA.	This	 turned	 out	 not	 to	 be	 the	 case	 as	 both	 Huh7	 and	 hepatocyte	 lysates	 were	comparably	effective	in	the	LPCAT	assay,	i.e.	the	amount	of	C11-PC	was	similar	in	assays	with	both	lysates	(Figure	26B	lanes	1	and	2	in	the	orange	boxed	area).	It	is	evident	from	these	results	that	both	lysates	had	active	enzymes	for	acyl-CoA	synthesis	from	the	C11-FA.	Later	on	it	was	analyzed	if	the	ability	to	synthesize	LPA,	PA	and	TAG	from	C11-acyl-CoA	was	impaired	in	Huh7	lysates.		 		
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Figure	26.	 Coupled	acyl-CoA	 synthesis	 assays	with	 lysates	 from	Huh7	 cells	 and	primary	
mouse	hepatocytes.	(A)	C11	or	C19-FAs	and	LPA	or	LPC	were	added	to	a	reaction	tube	and	chloroform	and	ethanol	were	evaporated.	 Then	 13	 μl	 of	 delipidated	 BSA	 was	 added	 and	 the	 tube	 was	 vortexed.	 The	 reaction	mixture	containing	CoA	and	ATP	was	added.	Finally,	a	lysate	containing	200	μg	of	total	protein	was	added	and	the	mixture	was	incubated	at	30°C	for	30	min	while	shaking	at	800	rpm.	The	reaction	was	stopped	 by	 adding	 a	 mixture	 of	 chloroform	 and	 methanol.	 Lipids	 were	 extracted	 and	 the	 click	reaction	was	performed.	Finally,	lipids	were	separated	on	a	TLC	plate	and	fluorescence	was	detected	by	 fluorescence	 imaging.	 “7”	 indicates	 the	 lysate	 from	Huh7	cells	and	“H”	 indicates	 the	 lysate	 from	primary	mouse	hepatocytes.	“Add.	Substrate”	indicates	the	additional	substrate,	which	was	added	to	the	reaction	mixture.	The	upper	part	of	the	plate	is	additionally	showed	as	a	longer	exposition	image	to	make	TAG	visible.	(B)	LPCAT	assay.	First,	the	reaction	buffer	containing	CoAs	(C11	or	C19),	HSLi	and	LPC	was	added.	Then	the	 lysate	containing	200	μg	of	 total	protein	was	added	and	the	mixture	was	 incubated	at	30°C	 for	30	min	with	shaking	at	800	rpm.	Finally,	 the	same	extraction	procedure	followed	as	described	 in	panel	A.	 (C)	Graphical	 representation	of	 the	pathway	 from	FA	outside	 the	cell	to	TAG	synthesis	inside	the	cell.		
4.5.3.3. DGAT,	 LPAAT	 and	 GPAT	 assays	 with	 lysates	 from	 Huh7	 cells	 and	
primary	mouse	hepatocytes		In	the	DGAT	assay	alkyne-CoAs	react	with	DAG	to	form	TAG	(Figure	26C	step	6):	alkyne-FA-CoA	+	DAG	è	alkyne-TAG	+	CoA.	
-
        
7
C19
      LPA
H 7
C11
H 7
C19
      LPC
H 7
C11
H -
        
7 H
C19 C11
-
     
-
     
-
        
C19-PCC11-PC
C19-PA
C11-FA
C19-FA
Background
Background
C19-TAG
C11-TAG
Longer 
exposure
Cell line
FA
Add. substrate
7
   C11
           LPC
H - 7
   C19
H -Cell line
Acyl-CoA
Add. substrate
C19-FA
C19-PC
C11-FA
A
B
Lane no.   1    2    3    4     5    6    7    8     9   10  11  12  
Lane no.   1    2     3     4     5    6   
C
C11-PC
free FA
cytoplasmic
free FA
extracell.
FA-CoA
cytoplasmic
LPA
PA
DAG
TAG
PL
1 Uptake
2 FA-CoA Synthesis
3 GPAT
4 LPAAT
5 Lipin
6 DGAT
7 Kennedy
4 LPAAT
6 DGAT
Results	
		
	 77	
For	the	DGAT	assay	four	different	DAGs	were	used	to	find	out	the	best	conditions	for	the	reaction.	As	can	be	seen	from	Figure	27A	lanes	5-16	in	the	purple	boxed	area	and	Figure	27C	lanes	9-12	in	the	purple	boxed	area,	the	best	substrates	for	an	in	vitro	assays	were	DAGs	with	C10:0	and	C8:0	FAs.	With	these	DAGs	reasonable	amounts	of	both	C11	and	C19-TAGs	were	produced.	In	C12:0	and	C18:1	DAG	conditions	(Figure	27A	lanes	5-8	in	the	purple	boxed	area	and	Figure	27C	lanes	9-12	in	the	purple	boxed	area)	TAG	bands	were	slightly	more	intense	than	in	the	assay	with	only	alkyne-FA-CoA	(Figure	27A	lanes	1-4	in	the	purple	boxed	area).	Both	Huh7	and	hepatocyte	lysates	could	convert	C11-CoA	and	DAG	into	TAG.	The	ratio	C11-TAG/C19-TAG	was	similar	for	both	cell	lysates	(Figure	27B).	This	was	also	nicely	confirmed	by	the	LPAAT	assay	(Figure	26C	step	4):	alkyne-FA-CoA	+	LPA	è	alkyne-PA	+	CoA.		When	LPA	and	C11-CoA	were	present	in	the	assay	mixture,	C11-PA	(Figure	27C	lanes	7-8	in	the	green	boxed	area),	C11-DAG	(Figure	27C	lanes	7-8	in	the	blue	boxed	area)	and	even	 traces	 of	 C11-TAG	 (Figure	 27C	 lanes	 7-8	 in	 the	 purple	 boxed	 area)	 could	 be	identified	 in	 samples	with	each	 lysate.	Moreover,	 the	 ratio	of	C11-PA/C19-PA	was	 the	same	in	lysates	from	Huh7	cells	and	hepatocytes	(Figure	27D).	Unfortunately,	the	GPAT	assay	(Figure	26C	step	3)	did	not	work	for	C11-CoA	as	no	C11-LPA	or	C11-PA	could	be	identified	(Figure	27C,	lanes	3	and	4	in	the	orange	boxed	area).	GPAT	assay:	G3P	+	alkyne-FA-CoA	è	alkyne-LPA	+	CoA.	Generally	 speaking,	 as	 both	 lysates	 from	Huh7	 cells	 and	hepatocytes	 could	 synthesize	acyl-CoA,	PA	and	TAG	from	C11-FA	the	reason	for	the	absence	of	C11-TAG	synthesis	in	intact	Huh7	cells	most	probably	was	caused	by	other	mechanisms	than	the	absence	of	metabolizing	proteins.		Although	Huh7	and	hepatocytes	both	derive	from	the	liver,	they	are	different	cells.	Huh7	originates	from	human	carcinoma,	while	hepatocytes	are	primary	mouse	cells.	In	order	to	 compare	 the	ability	 to	 synthesize	C11-CoA,	C11-LPA,	C11-PA	and	C11-TAG	 in	more	related	cells,	assays	were	performed	with	lysates	from:	freshly	isolated	hepatocytes	and	dedifferentiated	hepatocytes	kept	in	the	medium	for	four	days;	undifferentiated	3T3-L1	cells	and	3T3-L1	cells	differentiated	for	10	days.		
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Figure	27.	DGAT,	GPAT	and	LPAAT	assays	with	lysates	from	Huh7	cells	and	primary	mouse	
hepatocytes.	For	 the	 DGAT	 assays	 (A,	 C)	 DAG	 (C12:0,	 C10:0,	 C8:0	 or	 C18:1)	 was	 added	 to	 the	 reaction	 tube	 and	chloroform	was	evaporated.	Then	PC	and	reaction	buffer	with	CoAs	(C11	or	C19)	and	HSLi	were	added.	For	the	GPAT	and	LPAAT	assays	(C)	the	reaction	buffer	containing	CoAs	(C11	or	C19),	HSLi	and	either	G3P	or	LPA	respectively	was	added	to	the	reaction	tube.	Finally,	 lysate	containing	30	μg	of	total	protein	was	added	to	all	types	of	assays	and	the	mixture	was	incubated	at	30°C	for	30	min	with	shaking	at	800	rpm.	The	reactions	were	stopped	by	adding	a	mixture	of	chloroform	and	methanol.	Lipids	were	extracted	and	the	 click	 reaction	 was	 performed.	 Finally,	 lipids	 were	 separated	 on	 a	 TLC	 plate	 and	 fluorescence	 was	detected	by	 fluorescence	 imaging.	 “7”	 indicates	 a	 lysate	 from	Huh7	 cells	 and	 “H”	 a	 lysate	 from	primary	mouse	hepatocytes.	“Add.	Substrate”	indicates	the	additional	substrate,	which	was	added	to	the	reaction	mixture.	 C11-CoA	has	 three	 unspecific	 background	 (BG)	 bands	 shown	 in	 grey	 color	while	 C19-CoA	has	four	 unspecific	 BG	 bands.	 Graph	 B	 illustrates	 quantification	 of	 data	 in	 panel	 A.	 Values	 represent	fluorescence	 intensity	 of	 C11-TAG	 divided	 by	 fluorescence	 intensity	 of	 C19-TAG	 (purple	 boxed	 areas).	Graph	D	illustrates	quantifications	of	the	data	 in	panel	C	 lanes	5-8	(green	boxed	area).	Values	represent	fluorescence	 intensity	of	C11-PA	divided	by	 fluorescence	 intensity	of	C19-PA.	The	data	 represent	mean	+SD,	n=3.	
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4.5.3.4. Acyl-CoA	synthesis	assay	with	 lysates	from	3T3-L1	cells	and	primary	
mouse	hepatocytes		It	was	shown	that	undifferentiated	3T3-L1	cells	and	dedifferentiated	hepatocytes	cannot	synthesize	 C11-TAG	 from	C11-FAs	 (see	 Figure	 9	 and	 Figure	 11).	 The	 gain	 of	 function	feature	 of	 differentiating	 3T3-L1	 cells	 and	 the	 loss	 of	 function	 feature	 of	dedifferentiating	 hepatocytes	 was	 used	 for	 activity	 assays.	 First,	 lysates	 from	 freshly	isolated	hepatocytes	and	from	hepatocytes	kept	in	the	medium	for	four	days	as	well	as	from	 undifferentiated	 3T3-L1	 cells	 and	 from	 3T3-L1	 cells	 differentiated	 for	 10	 days	were	 prepared.	 As	 in	 the	 previous	 experiment	 (4.5.3.2)	 an	 acyl-CoA	 synthesis	 assay	coupled	with	LPCAT	assay	was	performed.	From	the	coupled	acyl-CoA	synthesis	assay	it	could	be	seen	that	both	hepatocyte	lysates	had	similar	acyl-CoA	activities	towards	C11-CoA	 synthesis	 (Figure	 28A,	 lanes	 1-4	 in	 the	 purple	 boxed	 area,	 Figure	 28B).	 The	activities	 in	 the	 control	 LPCAT	 assay	 were	 also	 similar	 (Figure	 28C,	 lanes	 1-4	 in	 the	orange	boxed	area,	Figure	28D).	On	the	other	hand,	the	lysate	from	differentiated	3T3L1	cells	was	much	more	effective	 in	C11-CoA	 synthesis	 compared	 to	 the	undifferentiated	cells	(Figure	28A,	lanes	5-8	in	the	purple	boxed	area,	Figure	28B).	This	difference	is	even	more	pronounced	as	undifferentiated	cells	had	more	activity	in	the	control	LPCAT	assay	(Figure	 28C,	 lanes	 5-8	 in	 the	 orange	 boxed	 area,	 Figure	 28D).	 Next,	 hydrolysis	experiment	 with	 pancreatic	 lipase	 was	 done.	 This	 experiment	 should	 help	 to	 see	 at	which	position	of	TAG	molecule	C11-FA	is	 incorporated	 in	order	to	better	understand,	which	enzymatic	activity	contributes	to	C11-TAG	synthesis	in	3T3-L1	cells	and	primary	mouse	hepatocytes.			
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Figure	 28.	 Coupled	 acyl-CoA	 synthesis	 assays	 with	 lysates	 from	 primary	 mouse	
hepatocytes	and	3T3-L1	cells.	In	A	and	C	lysates	from	freshly	isolated	hepatocytes	(day	0)	or	hepatocytes	kept	in	culture	for	4	days	(day	4)	after	isolation	were	used	as	well	as	lysates	from	undifferentiated	3T3-L1	cells	(day	0)	or	3T3-L1	cells	that	were	differentiated	for	10	days	(day	10).	(A)	First,	C11	or	C19-FAs	and	LPC	were	added	to	the	reaction	tubes	and	chloroform	and	ethanol	were	evaporated.	Then	13	μl	of	DL-BSA	was	added	and	the	tube	was	vortexed	and	the	reaction	mixture	containing	CoA	and	ATP	was	added.	Finally,	the	lysate	containing	200	μg	of	 total	protein	was	added	and	 the	mixture	was	 incubated	at	30°C	 for	30	min	while	 shaking	 at	 800	 rpm.	 The	 reaction	was	 stopped	 by	 adding	 a	mixture	 of	 chloroform	 and	methanol.	Lipids	were	extracted	and	the	click	reaction	was	performed.	Finally,	lipids	were	separated	on	 a	 TLC	 plate	 and	 fluorescence	 was	 detected	 by	 fluorescence	 imaging.	 (C)	 LPCAT	 assay.	 Same	conditions	as	in	Figure	26,	panel	B.	Graph	B	illustrates	quantifications	of	data	in	panel	A.		The	values	represent	fluorescence	intensity	of	C11-PC	(detected	in	lanes	1,	2,	5,	6	in	purple	boxed	area)	divided	by	 fluorescence	 intensity	 of	 C19-PC	 (detected	 in	 lanes	 3,	 4,	 7,	 8	 in	 purple	 boxed	 area).	 Graph	 D	illustrates	 quantifications	 of	 data	 in	 panel	 C.	 Values	 represent	 fluorescence	 intensity	 of	 C11-PC	(detected	 in	 lanes	 1,	 2,	 5,	 6	 in	 orange	 boxed	 area)	 divided	 by	 fluorescence	 intensity	 of	 C19-PC	(detected	 in	 lanes	3,	4,	7,	8	 in	orange	boxed	area).	The	data	represent	mean	+SD,	n=3.	*	stands	 for	p≤0.05.	
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4.5.3.5. Lipase	treatment		The	 experiment	 described	 in	 this	 chapter	 was	 performed	 to	 determine	 at	 which	stereospecific	 position	 of	 the	 TAG	 molecule	 C11-FA	 was	 incorporated.	 A	 pancreatic	lipase	 treatment	was	 performed	with	TAGs	 from	both	 differentiated	 3T3-L1	 cells	 and	freshly	 isolated	 hepatocytes	 fed	 with	 C11-FA.	 During	 the	 lipolysis	 process,	 the	pancreatic	 lipase	 hydrolyzes	 TAG	 at	 sn1	 and	 sn3	 positions.	 Using	 this	 method	 it	 is	possible	to	show	if	the	FA	of	interest	is	at	the	sn1/sn3	or	at	the	sn2	position,	see	Figure	29B.	As	evident	from	Figure	29A	lanes	1-4,	when	standard	TAG	with	C11-FA	at	the	sn2	position	was	hydrolyzed,	 the	main	clickable	product	of	hydrolysis	was	C11-MAG	(lane	2).	On	the	other	hand,	during	the	hydrolysis	of	sn3	labeled	C11-TAG,	the	main	clickable	product	was	C11-FA	(lane	4).	Later	the	cellular	lipids	from	differentiated	3T3-L1	cells	and	hepatocytes	both	fed	with	C11-FA	were	analyzed.	First	of	all,	neutral	lipids	were	separated	from	all	other	lipids	by	applying	 chromatography.	 Then	 a	 lipase	 treatment	 was	 performed	 and	 the	 main	product,	which	was	identified	on	a	TLC	plate	for	both	3T3-L1	cells	and	hepatocytes,	was	C11-FA	 (Figure	 29A,	 lanes	 6	 and	 8).	 This	 indicates	 that	 in	 both	 cases	 C11-FA	 was	incorporated	mainly	at	sn1	or	sn3	position.	In	the	glycerol-3-phosphate	pathway,	GPATs	are	responsible	 for	 the	 incorporation	of	FA	at	 the	sn1	position	and	DGATs	 incorporate	FAs	at	the	sn3	position,	see	chapters	1.4.2	and	1.4.5.	As	the	GPAT	activity	in	the	glycerol-3-phosphate	pathway	is	rate	limiting	(Wendel	et	al.,	2009)	it	is	most	likely,	that	C11-FAs	get	directly	 incorporated	 into	 already	existing	DAGs	 to	 form	TAG	molecules	 via	DGAT	activity.	 In	 the	 next	 section	 LPAAT,	DGAT	 and	GPAT	 assays	with	 lysates	 from	3T3-L1	cells	and	primary	hepatocytes	are	analyzed.		
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Figure	29.	TAG	treatment	with	a	pancreatic	lipase.	(A)	 TAG	 standards	 having	 C11-FA	 at	 either	 Sn2	 or	 Sn3	 positions	 and	 TAGs	 isolated	 from	 cellular	lipids	 from	differentiated	3T3-L1	cells	and	primary	mouse	hepatocytes	 fed	with	50	μM	C11-FA	 for	1.5	hours	were	treated	with	a	pancreatic	lipase.	After	treatment	lipids	were	extracted	and	the	click	reaction	was	performed.	Finally,	lipids	were	separated	on	a	TLC	plate	and	fluorescence	was	detected	by	 fluorescence	 imaging.	 (B)	 Principal	 scheme	 illustrating	 hydrolysis	 of	Sn1	 or	Sn2	 or	Sn3	 alkyne-labeled	TAG.	Pancreatic	 lipase	hydrolyzes	TAG	molecule	both	at	Sn1	and	Sn3	positions.	Products	of	hydrolysis	are	used	 for	 the	click	reaction.	 If	alkyne-FA	 is	detected	on	TLC	plate,	 then	 it	means	that	alkyne-FA	was	at	either	Sn1	or	Sn3	position.	If	alkyne-MAG	is	detected	on	TLC	plate,	then	alkyne-FA	was	at	Sn2	position.			
4.5.3.6. LPAAT	 synthesis	 assay	 with	 lysates	 from	 3T3-L1	 cells	 and	 primary	
mouse	hepatocytes		The	LPAAT	assay	was	performed	in	a	similar	way	as	in	4.5.3.3.	The	lysates	from	freshly	isolated	 hepatocytes	 and	 from	 hepatocytes,	 which	 were	 kept	 in	 the	medium	 for	 four	days,	as	well	as	from	undifferentiated	3T3-L1	cells	and	from	3T3-L1	cells	differentiated	for	10	days	were	used.	Moreover,	two	types	of	LPA	and	acyl-CoA	were	used.	In	the	first	LPAAT	assay,	alkyne-acyl-CoAs	and	normal	LPA	were	used.	In	the	second	assay,	normal	acyl-CoAs	and	alkyne-LPA	were	used.	In	both	LPAAT	assays	 the	 ratio	C11-PA/C19-PA	 (Figure	30A	 lanes	1-8	 in	 green	boxed	area,	Figure	30C)	and	the	ratio	C10-PA/C18-PA	(Figure	30B	in	green	boxed	area,	Figure	30D)	 was	 lower	 in	 lysates	 from	 day	 4	 hepatocytes	 and	 undifferentiated	 3T3-L1	compared	 to	day	0	hepatocytes	and	day	10	3T3-L1	cells,	 respectively.	This	 indicates	a	lower	LPAAT	activity	 towards	medium-chain	acyl	CoAs	 in	 these	 lysates.	However,	 this	decrease	 in	 the	 ratio	 was	 not	 extremely	 high	 just	 in	 the	 range	 of	 30-40%.	 The	
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sequencing	data	show	that	the	expression	of	two	AGPAT	proteins	(AGPAT2	and	AGPAT3	also	 known	 as	 LPAAT2	 and	 LPAAT3,	 see	 chapter	 1.4.3)	 decrease	 during	 hepatocyte	dedifferentiation	(Table	15,	gene	no.	22	and	23).	Similarly,	the	expression	of	AGPAT2	in	3T3-L1	 cells	 increases	 upon	 differentiation	 (Table	 15,	 gene	 no.	 22).	 A	 feasible	explanation	would	be	that	these	AGPAT	proteins	are	more	specific	for	C11-PA	synthesis	than	other	members	 of	 the	AGPAT	 family	 and	 therefore	 the	 LPAAT	activity	 decreases	when	 there	 is	 less	 of	 these	 proteins	 (in	 dedifferentiated	 hepatocytes	 and	undifferentiated	3T3-L1	cells).	Similarly	as	in	LPAAT	assay,	described	in	chapter	4.5.3.3,	DAG	 and	 TAG	 bands	 (Figure	 30A	 lanes	 1-8	 in	 the	 purple	 boxed	 area	 and	 Figure	 30B	lanes	1-8	 in	 the	purple	boxed	area)	 and	DAG	bands	 (Figure	30A	 lanes	1-8	 in	 the	blue	boxed	area	and	Figure	30B	lanes	1-8	in	the	blue	boxed	area)	were	detected.		
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Figure	30.	LPAAT	assays	with	lysates	from	primary	mouse	hepatocytes	and	3T3-L1	cells.	In	A	and	B	lysates	from	freshly	isolated	hepatocytes	(day	0)	or	hepatocytes	kept	in	culture	for	4	days	(day	4)	after	isolation	were	used	as	well	as	lysates	from	undifferentiated	3T3-L1	cells	(day	0)	or	3T3-L1	 cells	 that	were	 differentiated	 for	 10	 days	 (day	 10).	 First,	 the	 reaction	 buffer	was	 added,	which	contained	HSLi,	C11	or	C19-CoAs	(A),	C10	or	C18	CoAs	(B)	and	LPA	(A)	or	alkyne-LPA	(B).	Finally,	the	 lysate	 containing	 30	 μg	 of	 total	 protein	was	 added	 to	 all	 types	 of	 assays	 and	 the	mixture	was	incubated	at	30°C	for	30	min	with	shaking	at	800	rpm.	Reactions	were	stopped	by	adding	a	mixture	of	 chloroform	 and	methanol.	 Lipids	were	 extracted	 and	 the	 click	 reaction	was	 performed.	 Finally,	lipids	 were	 separated	 on	 a	 TLC	 plate	 and	 fluorescence	 was	 detected	 by	 fluorescence	 imaging.	 In	panel	A	both	C11-CoA	and	C19-CoA	have	three	unspecific	background	bands	(BG)	each	shown	in	grey	color.	 Graph	 C	 illustrates	 quantifications	 of	 data	 in	 panel	 A.	 	 Values	 represent	 the	 fluorescence	intensity	 of	 C11-PA	 (detected	 in	 lanes	 1,	 2,	 5	 6	 in	 green	 boxed	 area)	 divided	 by	 the	 fluorescence	intensity	 of	 C19-PA	 (detected	 in	 lanes	 3,	 4,	 7	 8	 in	 green	 boxed	 area).	 Graph	 D	 illustrates	 the	quantifications	of	the	data	in	panel	B.	Values	represent	fluorescence	intensity	of	C10-PA	(detected	in	lanes	1,	2,	5,	6	in	green	boxed	area)	divided	by	fluorescence	intensity	of	C18-PA	(detected	in	lanes	3,	4,	7,	8	in	green	boxed	area).	The	data	represent	mean	+SD,	n=4	(A),	n=3	(B).	*	stands	for	p≤0.05.	
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4.5.3.7. DGAT	and	GPAT	synthesis	assays	with	 lysates	from	3T3-L1	cells	and	
primary	mouse	hepatocytes		DGAT	and	GPAT	assays	were	performed	in	a	similar	way	as	 in	chapter	4.5.3.3.	Lysates	from	 freshly	 isolated	 hepatocytes	 and	 from	 hepatocytes	 kept	 in	 the	medium	 for	 four	days	as	well	as	 from	undifferentiated	3T3-L1	cells	and	 from	cells	differentiated	 for	10	days	 were	 used.	 C10-DAG	 was	 used	 as	 a	 DAG	 source.	 It	 was	 shown	 that	 the	 ratio	between	C11	and	C19-TAG	stayed	the	same	in	assays	with	lysates	from	both	fresh	and	dedifferentiated	 hepatocytes	 (Figure	 31A	 lanes	 9-12	 in	 the	 purple	 boxed	 area,	 Figure	31B).	This	indicates	that	although	dedifferentiated	hepatocytes	cannot	synthesize	C11-TAG	 when	 fed	 with	 C11-FA,	 lysates	 from	 these	 cells	 have	 enzymes	 for	 C11-TAG	synthesis	from	C11-acyl-CoA.		Figure	31B	shows	that	the	ratio	between	C11	and	C19-TAG	was	lower	in	the	lysate	from	undifferentiated	 3T3-L1	 cells	 compared	 to	 the	 lysate	 from	 differentiated	 cells	 (Figure	31A	 lanes	 13-16	 in	 the	 purple	 boxed	 area,	 Figure	 31B).	 This	 suggests	 that	 the	 lysate	from	 undifferentiated	 cells	 is	 not	 as	 effective	 in	 C11-TAG	 synthesis	 as	 a	 lysate	 from	differentiated	cells.		Unfortunately,	the	GPAT	assay	did	not	work	for	C11-CoA	as	no	C11-LPA	or	C11-PA	could	be	 identified	 (Figure	 31A	 lanes	 1,	 2,	 5	 and	 6	 in	 the	 orange	 boxed	 area).	 On	 the	 other	hand,	C19-PA	was	identified	(Figure	31A	lanes	3,	4,	7	and	8	in	the	orange	boxed	area).	
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Figure	31.	DGAT	and	GPAT	assay	with	lysates	from	primary	mouse	hepatocytes	and	3T3-
L1	cells.	(A)	Lysates	from	freshly	isolated	hepatocytes	(day	0)	or	hepatocytes	kept	in	culture	for	4	days	(day	4)	after	isolation	were	used	as	well	as	lysates	from	undifferentiated	3T3-L1	cells	(day	0)	or	3T3-L1	cells	that	were	differentiated	for	10	days	(day	10).	For	DGAT	assays	first	C10:0	DAG	was	added	to	the	reaction	tube	and	chloroform	was	evaporated.	Then	PC	and	reaction	buffer	with	CoAs	(C11	or	C19)	and	HSLi	were	added.	For	the	GPAT	assay	the	reaction	buffer	containing	CoAs	(C11	or	C19),	HSLi	and	G3P	was	added	to	the	reaction	tube.	Finally,	the	lysate	containing	30	μg	of	total	protein	was	added	to	both	assays	and	the	mixture	was	 incubated	at	30°C	for	30	min	with	shaking	at	800	rpm.	Reactions	were	stopped	by	adding	a	mixture	of	chloroform	and	methanol.	Lipids	were	extracted	and	the	click	reaction	was	performed.	Finally,	lipids	were	separated	on	a	TLC	plate	and	fluorescence	was	detected	by	fluorescence	imaging.	Both	C11-CoA	and	C19-CoA	have	three	unspecific	background	bands	(BG)	each	 shown	 in	 grey	 color.	 Graph	 B	 illustrates	 quantification	 of	 data	 in	 panel	 A.	 Values	 represent	fluorescence	 intensity	 of	 C11-TAG	 (detected	 in	 lanes	 1,	 2,	 5,	 6	 in	 purple	 boxed	 area)	 divided	 by	fluorescence	 intensity	 of	 C19-TAG	 (detected	 in	 lanes	 3,	 4,	 7,	 8	 in	 purple	 boxed	 area).	 The	 data	represent	mean	+SD,	n=5.					
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4.5.3.8. Competition	assay	in	hepatocytes		In	 the	 experiments	 described	 in	 this	 chapter	 cells	 were	 incubated	 in	 the	 presence	 of	multiple	 FAs.	 The	 purpose	 was	 to	 determine	 if	 C11-FA	 and	 C19-FA	 influence	 the	metabolism	of	each	other.	It	was	also	important	to	verify	if	and	at	which	concentrations	C11-FA	competes	with	C10:0	FA	or	C18:1	FA	and	weather	C19-FA	competes	with	C18:1	FA	 or	 C10:0	 FA.	 For	 this	 a	 competition	 assay	 with	 different	 combinations	 of	 C11-FA,	C19-FA,	C10:0	and	C18:1	FAs	was	performed.		Figure	32A,	B	shows	that	at	concentrations	up	to	50	µM	neither	C10-FA	nor	C18-FA	nor	C19-FA	 competed	 with	 C11-FA	 as	 no	 decrease	 in	 C11-TAG	 synthesis	 was	 detected.	Moreover,	the	amount	of	C11-TAG	increased	significantly	after	adding	C10:0	FA	(Figure	32A	 lane	2	 compared	 to	 lane	4;	B),	while	 the	addition	of	C18:1	did	not	 cause	 such	an	effect	(Figure	32B	lane	1	compared	to	lane	4,	B).	This	could	be	explained	by	sparing	C11-FA	from	β-oxidation.	As	at	smaller	concentrations	C10:0	and	C18:1	FAs	didn’t	compete	with	C11-FA,	the	amount	of	these	FAs	was	raised	up	to	500	µM.	The	amount	of	C11-TAG	increased	slightly	after	raising	C10-FA	concentration	up	to	100	µM	(Figure	32C	lanes	9-11,	E	dark	bars).	By	raising	the	concentration	of	C10-FA	to	500	µM	the	amount	of	C11-TAG	decreased	 and	 additional	 two	 lower	TAG	bands	 appeared	 (Figure	32C	 lane	12,	 E	dark	bars).	These	additional	bands	 indicated	 the	presence	of	TAGs	with	 two	and	with	three	 MCFAs.	 Similarly,	 three	 TAG	 bands	 appeared	 in	 C19-FA	 fed	 cells,	 when	 the	competitor	was	 C10-FA	 at	 concentration	 of	 500	 µM	 (Figure	 32C	 lane	 4).	 These	 three	bands	 indicated	 the	presence	of	TAGs	with	none,	 one	or	 two	MCFAs.	 	Native	 lipids	 in	hepatocytes	 mostly	 have	 LCFAs.	 The	 resulting	 TAG,	 which	 is	 observed	 in	 C11-FA	experiments	with	up	to	100	µM	of	competitor	FAs	had	two	LCFAs	and	one	MCFA	(C11-FA).	When	500	µM	of	C10-FA	was	added	two	additional	types	of	TAG	were	synthesized,	namely	TAG	having	two	MCFAs	and	one	LCFA	as	well	as	TAG	having	three	MCFAs.	TAG	that	includes	one	C11-FA,	one	C10-FA	and	one	LCFA	runs	lower	on	the	TLC	plate	as	TAG	that	includes	only	one	C11-FA	and	two	LCFAs.	Furthermore,	TAG	with	one	C11-FAs	and	two	C10-FAs	would	run	even	lower	than	the	one	containing	one	C11-FA,	one	C10-FA	and	one	 LCFA.	When	 500	 µM	 of	 C10-FA	was	 added	 together	with	 C19-FA,	 two	 additional	types	of	TAG	were	synthesized,	namely	TAG	having	two	LCFAs	and	one	C10-FA	as	well	as	TAG	having	one	LCFA	and	two	C10-FAs.	TAG	that	includes	two	LCFAs	and	one	C10-FA	runs	lower	on	the	TLC	plate	as	TAG	that	includes	three	LCFAs.	Furthermore,	TAG	with	
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one	C19-FAs	and	two	C10-FAs	would	run	even	lower	than	the	one	containing	two	LCFAs	and	one	C10-FA.	After	500	µM	of	C18:1	FA	was	added	 to	 the	cells	 the	amount	of	C11-TAG	increased	significantly	(Figure	32C	lane	16,	E	light	bars).	In	this	experiment	neither	the	addition	of	C11-FA	 (Figure	32A	 lanes	9-12,	B)	nor	C10:0	 (Figure	32C	 lanes	1-4,	D	dark	bars)	nor	C18:1	(Figure	32C	lanes	5-8,	D	light	bars)	significantly	changed	the	C19-TAG	amount.	
	
Figure	 32.	 Medium	 and	 long-chain	 FA	 competition	 experiment	 in	 primary	 mouse	
hepatocytes.	After	 isolation	 from	 the	 liver,	 primary	mouse	 hepatocytes	were	 plated	 on	 collagen	 coated	 12-well	dishes.	 150.000	 cells	were	 plated	 per	well.	 (A)	 Different	 combinations	 of	 C11-FA,	 C19-FA,	 C10-FA	(C10:0,	decanoate)	and	C18-FA	(C18:1,	oleate)	were	added	to	cells	for	1.5	hours.	20	µM	of	C11-FA,	20	µM	of	C19-FA,	50	µM	of	C10-FA	and	50	µM	of	C18-FA	were	used.	 (C)	cells	were	 fed	with	50	µM	of	C11-FA	or	C19-FAs	for	1.5	hours.	Additionally,	50,	100	or	500	µM	of	C10-FA	or	C18-FA	was	added	for	competition.	After	incubation	with	FAs	cells	were	washed	and	lipids	were	extracted	from	cells.	Then	the	 click	 reaction	 was	 performed,	 lipids	 were	 separated	 on	 a	 TLC	 plate	 and	 fluorescence	 was	detected	by	 fluorescence	 imaging.	Graph	B	 represents	quantifications	of	data	 from	panel	A.	Values	represent	the	fluorescence	intensity	of	C11	and	C19-TAG	bands.	D	and	E	represent	quantifications	of	data	 from	 C.	 Values	 represent	 fluorescence	 intensity	 of	 C19-TAG	 bands	 and	 C11-TAG	 bands	respectively.	The	data	represent	mean	+SD,	n=4.	*	stands	for	p≤0.05;	**	p≤0.01;	***	p≤0.001.			
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5. Discussion 
Although	MCFAs	are	not	 the	main	constituents	of	 lipids	consumed	with	 food,	 they	are	still	an	important	part	of	our	modern	human	diet.	However,	data	concerning	MCFAs	are	still	relatively	sparse	and	controversial.	In	this	work	several	important	aspects	of	MCFA	metabolism	such	as	the	uptake	and	the	TAG	synthesis	are	analyzed.	This	study	is	based	on	 two	 very	 important	 cell	 types	 participating	 in	 cellular	 metabolism,	 namely	hepatocytes	 and	 adipocytes.	 In	 this	 chapter	 the	most	 important	 findings	 described	 in	this	 thesis	 will	 be	 discussed	 in	 relation	 to	 the	 data	 obtained	 by	 other	 scientists.	 The	discussion	is	concluded	by	presenting	a	new	hypothetical	model	for	MCFA	metabolism.			
5.1. Metabolism of C11-FA in different cell lines and 
mouse organs 	C11-FA	 metabolism	 in	 different	 cell	 lines,	 primary	 cells	 and	 mouse	 organs	 was	investigated.	It	was	found	that	different	cancer	cell	 lines	(e.g.	Huh7,	HepG2,	A431),	the	fibroblast	line	3T3-L1	and	some	other	lines	cannot	incorporate	C11-FA	into	TAG	(Figure	9).	On	the	other	hand,	the	organs	(e.g.	liver),	from	which	these	cells	(e.	g.	Huh7,	HepG2)	originate,	possess	this	particular	ability	(Figure	8).	This	allows	us	to	draw	two	important	conclusions.		First,	 cell	 lines	 used	 in	 experiments	 as	 representatives	 of	 certain	 organs	 do	 not	necessarily	 have	 the	 same	 features	 or	 metabolic	 capabilities	 as	 these	 organs.	 Good	examples	illustrating	this	are	hepatoma	cell	lines	such	as	Huh7	and	HepG2.	Compared	to	primary	 hepatocytes	 these	 cells	 have	 very	 low	 levels	 of	 cytochrome	 P450	 enzymes	participating	in	the	drug	biotransformation	process	and	therefore	are	of	 limited	use	in	drug	metabolism	studies	 (Castell	et	al.,	2006;	Rodríguez-Antona	et	al.,	2002).	 It	 seems	that	 in	 these	 cells	 not	 only	 the	 drug	 metabolism	 but	 also	 the	 lipid	 (at	 least	 MCFA)	metabolism	is	affected.	In	agreement	with	this	data	was	the	finding	that	HepG2	cells	did	not	esterify	MCFA	octanoate	into	TAG	(Wen	et	al.,	2000).	All	in	all,	Huh7	and	HepG2	cells	cannot	be	used	in	MCFA	research	as	liver	representatives.	
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Second,	 the	metabolism	of	MCFAs	and	LCFAs	 in	cultured	cells	 is	different.	Though	not	being	able	to	synthesize	TAG	from	MCFAs,	hepatoma	cell	lines	produce	TAG	from	LCFAs.	This	was	a	very	interesting	finding,	which	encouraged	us	to	investigate	the	metabolism	of	MCFAs	in	more	detail.	The	high	efficiency	of	C11-TAG	production	in	the	gut	and	in	the	liver	(Figure	8)	is	related	to	the	function	of	these	organs:	the	intestine	resynthesizes	digested	TAGs	coming	from	the	 diet	 and	 the	 liver	 synthesizes	 TAGs,	 which	 are	 either	 stored	 in	 lipid	 droplets	 or	secreted	 in	a	 form	of	 lipoproteins.	The	ability	 to	synthesize	TAGs	 from	MCFAs	 in	 liver	cells	was	already	shown	earlier	with	radioactivity	experiments	(Mayorek	and	Bar-Tana,	1983).	 In	 these	 experiments	 octanoate	 and	 decanoate	 were	 almost	 exclusively	incorporated	into	TAG	and	not	in	other	lipid	classes.	In	experiments	with	the	intestine,	MCFAs	 showed	a	higher	potential	 to	be	 incorporated	 into	TAG	 than	LCFAs	 (Figure	8).	This	 result	was	unexpected.	According	 to	 the	 literature,	most	of	 the	generated	MCFAs	leave	the	 intestine	 in	the	form	of	FAs	after	 lipid	digestion	and	not	 in	the	form	of	TAGs	(Bach	 and	 Babayan,	 1982).	 However,	 there	 is	 literature	 showing	 that	MCFAs	 are	 also	found	in	the	lymph	(Bloom	et	al.,	1951;	Nancy	You	et	al.,	2008).	Data	presented	in	this	thesis	 suggest	 that	 the	 intestine	 is	 capable	 of	 synthesizing	 a	 decent	 amount	 of	MCTs,	which	then	could	be	incorporated	into	chylomicrons.			
5.2. Differentiation of adipocytes and dedifferentiation 
of hepatocytes: gain and loss of function in MCT 
synthesis 	Our	experiment	with	cell	lines	(Figure	9)	showed	that	undifferentiated	3T3-L1	cells	did	not	 incorporate	 C11-FA	 into	 TAG,	 however,	 from	 Figure	 7	 it	 could	 be	 seen	 that	differentiated	 cells	 can	 synthesize	 C11-TAG.	 Differentiation	 of	 3T3-L1	 cells	 from	fibroblast-like	 cells	 into	 adipocyte-like	 cells	 is	 a	 complex	 process	 determined	 by	changing	 expression	 of	 multiple	 transcription	 factors,	 cell	 cycle	 regulators,	 structural	proteins	or	proteins	participating	in	cellular	metabolism	(Farmer,	2006;	Mikkelsen	et	al.,	2010).	 During	 differentiation	 3T3-L1	 cells	 gain	 the	 function	 of	 TAG	 synthesis	 from	MCFAs.	The	C11-TAG	 synthesis	 can	be	observed	after	42	hours	 from	 the	beginning	of	differentiation	(Figure	10).	The	inability	to	synthesize	TAG	from	MCFA	[1-13C]	octanoate	in	undifferentiated	3T3-L1	cells	was	also	demonstrated	in	the	study	of	Wen	et	al.	(Wen	
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et	al.,	2000).	The	potential	of	adipocytes	to	incorporate	MCFAs	into	TAGs	was	confirmed	by	many	other	studies	(Brandes	et	al.,	1985;	Bugaut,	1989;	Sarda	et	al.,	1987;	Wen	et	al.,	2000).		The	dedifferentiation	of	primary	hepatocytes,	which	starts	directly	after	plating	cells	on	the	 collagen	 layer	 (Baker	 et	 al.,	 2001),	 makes	 the	 work	 with	 primary	 cells	 more	complicated	and	also	can	distort	the	results.	This	encouraged	the	development	of	three-dimensional	 culture	 techniques,	 which	 protect	 primary	 hepatocytes	 from	dedifferentiation	(Bell	et	al.,	2016;	Brophy	et	al.,	2009;	Godoy	et	al.,	2013;	van	Zijl	and	Mikulits,	 2010).	 In	 this	 thesis	 it	was	 examined	how	dedifferentiation	 affects	 the	 LCFA	and	MCFA	metabolism	(Figure	11).	A	striking	finding	was	that	the	dedifferentiating	cells	lost	 the	 ability	 to	 synthesize	TAG	 from	C11-FA,	 but	 continued	 to	 synthesize	 C19-TAG.	Hepatocytes	 that	 spent	 one	 day	 in	 culture	 almost	 completely	 lost	 the	 ability	 to	synthesize	C11-TAG	(Figure	11A).	In	addition	to	adipocytes	this	gives	us	one	more	cell	type,	this	time	with	a	loss	of	function,	for	the	investigation	of	the	MCFA	metabolism.	To	the	 best	 of	 the	 author’s	 knowledge,	 this	 work	 is	 the	 first	 to	 show	 that	 the	dedifferentiation	 of	 hepatocytes	 changes	 the	 metabolism	 of	 lipids,	 particularly	 the	metabolism	of	MCFAs.	RNA	 sequencing	 of	 differentiating	 adipocytes	 and	 dedifferentiating	 hepatocytes	delivered	 a	 broad	 spectrum	 of	 data	 from	 which	 changes	 in	 the	 expression	 of	 genes	belonging	 to	 different	 classes	 and	 having	 a	 broad	 variety	 of	 functions	 could	 be	determined.	Genes	participating	in	lipid	metabolism	are	of	particular	relevance	for	this	work.	 The	 expression	 level	 of	 the	 majority	 of	 the	 genes	 related	 to	 lipid	 metabolism	increased	 in	 differentiating	 adipocytes	 and	 decreased	 in	 dedifferentiating	 hepatocytes	(Table	 15).	 Similar	 trends	were	 observed	 in	 proteomic	 or	mRNA	 analyses	 from	other	studies	(Mikkelsen	et	al.,	2010;	Rowe	et	al.,	2010).	Nevertheless,	because	of	the	immense	complexity	 of	 biological	 processes	 of	 differentiation	 and	 dedifferentiation	 and	 the	numerous	 changes	 in	 the	expression	of	different	genes,	 it	was	not	possible	 to	 identify	genes	 directly	 responsible	 for	 changes	 in	 C11-TAG	 synthesis.	 Still,	 these	 data	 can	support	 the	 hypothesis	 related	 to	 C11-TAG	 synthesis	 in	 hepatocytes	 and	 3T3-L1	adipocytes	and	suggest	candidates	for	further	studies.		In	general,	 two	cell	models	 for	work	with	MCFAs:	a	 loss	of	 function	hepatocyte	model	and	a	gain	of	function	adipocyte	model	were	established.		
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5.3. MCFA uptake 	It	is	possible	to	follow	the	FA	uptake	by	detecting	alkyne-FAs	in	the	medium	using	a	click	labeling	method.	The	FA	amount	 from	the	samples	with	cells	 is	compared	to	a	control	medium	samples	without	cells.	Using	pulse	experiments	it	was	shown	that	the	uptake	of	C11-FA	is	faster	than	the	uptake	of	C19-FA	in	both	hepatocytes	and	3T3-L1	cells	(4.5.2).	The	FA	uptake	was	evaluated	by	measuring	the	reduction	of	alkyne-FAs	in	the	medium.	FAs	 that	 cells	 take	 up	 from	 the	 medium	 could	 be	 used	 for	 lipid	 synthesis	 or/and	degraded	in	catabolic	processes.	In	experiments	with	undifferentiated	3T3-L1	cells	and	dedifferentiated	hepatocytes	C11-FA	was	used	up	from	the	medium	(Figure	13,	Figure	12A),	which	was	an	interesting	finding.	As	previously	mentioned	these	cells	do	not	use	C11-FA	 for	 lipid	 synthesis.	 Apart	 from	 being	 incorporated	 in	 cellular	 lipid	 structure,	there	are	other	known	ways	for	FA	to	be	used	up	by	the	cells,	such	as	mitochondrial	β-oxidation,	 peroxisomal	 β-oxidation,	 microsomal	 ω-oxidation	 and	 peroxisomal	 α-oxidation.	 ω-oxidation	 is	 not	 possible	 with	 alkyne-FAs	 as	 the	 ω	 carbon	 atom	 is	incorporated	in	an	alkyne	structure	and	is	not	susceptible	to	ω-oxidation.	Peroxisomal	α-oxidation	 is	 a	 minor	 pathway	 used	 for	 the	 degradation	 of	 FAs	 that	 have	 a	 methyl	group	at	the	β-carbon	atom	and	therefore	it	is	not	relevant	for	the	C11-FA.	It	is	believed	that	 the	 main	 oxidation	 type	 for	 MCFAs	 is	 the	 mitochondrial	 β-oxidation	 (Bach	 and	Babayan,	1982).	Yet	some	scientists	suggest	that	MCFAs	could	be	β-oxidized	to	a	 large	extent	 in	 peroxisomes	 (Bian	 et	 al.,	 2005;	 Christensen	 et	 al.,	 1989).	 Compared	 to	palmitate	treatment,	increased	amounts	of	hydrogen	peroxide,	which	is	an	indicator	for	peroxisomal	β-oxidation,	were	found	in	the	liver	perfused	with	octanoate	and	decanoate	(Foerster	et	al.,	1981)	and	also	in	hepatocytes	fed	with	different	MCFAs	(Leighton	et	al.,	1982).	Data	from	the	experiments	with	dedifferentiated	hepatocytes	and	undifferentiated	3T3-L1	cells	(Figure	11A,	Figure	12A,	Figure	9	and	Figure	13)	imply	that	although	C11-FAs	can	 be	 transferred	 into	 the	 cells,	 they	 are	 not	 incorporated	 into	 TAG.	 Huh7	 cells,	 in	contrary,	do	not	metabolize	C11-FA	at	all	as	C11-FA	remains	in	the	medium.	This	implies	that	MCFAs	either	cannot	get	inside	the	Huh7	cells	or	they	do	get	inside,	but	cannot	be	metabolized	 and	 are	 secreted	 back	 into	 the	medium.	 The	 assumption	 that	 Huh7	 cells	may	 lack	 enzymes	 for	MCFA	metabolism	 is	 supported	by	 earlier	 studies	 showing	 that	the	expression	level	of	mitochondrial	ACSMs	in	Huh7	cells	was	much	lower	compared	to	liver	samples	(Boomgaarden	et	al.,	2009).	However,	from	enzymatic	assays	with	lysates	
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it	can	be	seen	that	Huh7	cells	have	enzymatic	activities	for	the	synthesis	of	MCFA-CoAs	and	 MCTs	 (Figure	 26,	 Figure	 27).	 This	 question	 remains	 unclear	 and	 needs	 further	investigation.		
5.4. The etomoxir effect 	Etomoxir	 is	 known	 as	 an	 inhibitor	 of	 the	mitochondrial	 LCFA	 β-oxidation	 (Jew	 et	 al.,	1997).	 LCFA-CoAs	 can	 get	 inside	 mitochondria	 only	 in	 a	 form	 of	 acylcarnitine.	 To	participate	 in	 mitochondrial	 β-oxidation	 LCFA-CoAs	 have	 first	 to	 be	 converted	 to	acylcarnitines	by	the	enzyme	CPT1.	Etomoxir	can	be	used	to	prevent	LCFA	conversion	to	acylcarnitine.	 Once	 inside	 the	 cell	 etomoxir	 is	 converted	 into	 etomoxir-CoA,	 which	irreversibly	 binds	 to	 the	 active	 site	 of	 CPT1	 and	 in	 such	 a	way	 inhibits	 its	 enzymatic	activity	 (Kiorpes	 et	 al.,	 1984).	 Malonyl-CoA	 is	 a	 physiological	 reversible	 inhibitor	 of	CPT1	(McGarry	et	al.,	1977,	1978).	It	 is	known	 from	the	 literature	 that	etomoxir	can	protect	 the	heart	 from	a	FA-induced	ischemic	 injury	 (Lopaschuk	 et	 al.,	 1988).	Moreover,	with	 the	 growing	 evidence	 of	 the	role	of	FA	metabolism	in	tumor	growth	(Carracedo	et	al.,	2013),	CPT1	and	its	inhibitors	attracted	attention	in	cancer	research	(Qu	et	al.,	2016).	It	was	shown	that	etomoxir	can	induce	 cancer	 cell	 death	 by	 inhibiting	 FA	 oxidation	 (Pike	 et	 al.,	 2011;	 Samudio	 et	 al.,	2010;	 Schlaepfer	 et	 al.,	 2014).	 However,	 the	 treatment	with	 etomoxir	 proved	 to	 have	some	serious	adverse	effects	related	to	 the	 induction	of	oxidative	stress	(Merrill	et	al.,	2002)	and	activation	of	transcription	factors	such	as	peroxisome	proliferator-activated	receptor	 alpha	 (PPARα)	 and	 nuclear	 factor-kappaB	 (NF-κB)	 (Cabrero	 et	 al.,	 2003;	Forman	et	al.,	1997).	As	a	consequence,	its	usage	as	a	drug	was	not	approved	(Carracedo	et	al.,	2013).	The	mitochondrial	β-oxidation	of	MCFAs	was	studied	 in	various	studies.	 In	contrast	 to	LCFAs,	 CPT1	 is	 not	 required	 for	 the	 oxidation	 of	 MCFAs	 (Bach	 and	 Babayan,	 1982;	Papamandjaris	 et	 al.,	 1998).	 It	 is	 generally	 accepted	 that	 MCFAs	 can	 cross	 the	 inner	mitochondrial	 membrane	 without	 having	 to	 be	 converted	 into	 acylcarnitine.	 This	concept	is	supported	by	studies	showing	that	the	inhibition	of	CPT1	does	not	decrease	the	oxidation	rate	of	octanoate	(Abdel-aleem	et	al.,	1994;	Guo	et	al.,	2006).	 It	 is	worth	mentioning	 that	 the	 plasma	 concentrations	 of	 free	 carnitine	 were	 lower	 and	 the	concentrations	 of	 carnitine	 derivatives	were	 higher	 in	 healthy	 humans	 infused	with	 a	
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mixture	 of	 LCT	 and	MCT	 compared	 to	 a	mere	 LCT	 infusion	 (Rössle	 et	 al.,	 1990).	 This	suggests	the	role	of	carnitine	in	the	metabolism	of	MCT.	In	this	work	the	term	“etomoxir	effect”	is	used	to	describe	a	distinctive	cell	response	to	etomoxir	treatment.	This	response	has	the	following	two	characteristics.	The	first	one	is	the	appearance	of	unknown	substances	in	the	medium	after	etomoxir	treatment	of	C11-FA	 fed	 hepatocytes.	 The	 second	 is	 a	 decrease	 of	 the	 C11-TAG	 amount	 in	 cells	 treated	with	etomoxir.	The	etomoxir	effect	was	evident	in	hepatocytes,	whereas	in	3T3-L1	cells	this	 effect	 was	 expressed	 to	 a	 lesser	 extent.	 Therefore,	 the	 further	 etomoxir	 related	discussion	will	focus	mainly	on	hepatocytes.		Treatment	 with	 etomoxir	 enhanced	 the	 appearance	 of	 unknown	 substances	 in	 the	medium	 of	 C11-FA	 fed	 hepatocytes.	 With	 an	 increasing	 pulse	 time,	 some	 of	 these	substances	disappeared	from	the	medium,	showing	that	they	were	taken	up	again	by	the	cells	 and	 were	 metabolized	 (Figure	 19E,	 G,	 F).	 Furthermore,	 these	 substances	 also	appeared	in	control	cells	without	etomoxir	treatment,	but	the	amount	was	significantly	lower	 and	 they	 disappeared	 faster	 (Figure	 19E,	 G,	 F).	 No	 such	 substances	 could	 be	detected	 in	 the	 C19	 feeding	 condition	 (Figure	 20E,	 F).	 These	 substances	 are	 quite	hydrophilic	as	they	could	only	be	extracted	from	the	medium	by	addition	of	acetic	acid,	but	not	with	water	(Figure	24).	Studies	of	FA	oxidation	also	mention	the	development	of	acid-soluble	products	(ASPs)	in	the	 medium	 of	 cells	 incubated	 with	 [1-14C]	 labeled	 FAs.	 Indeed	 14CO2,	 which	 is	 most	often	 measured	 to	 determine	 the	 β-oxidation	 rate,	 represents	 only	 5-40%	 of	 the	 FA	degradation	 products	 whereas	 the	 rest	 (60-95%)	 is	 found	 in	 the	 medium	 as	 ASPs	(1988).	 The	 appropriate	 way	 to	 evaluate	 the	 β-oxidation	 rate	 would	 be	 to	 sum	 the	fractions	of	both	14CO2	and	radioactive	ASPs	as	it	was	shown	that	measuring	only	14CO2	is	inaccurate	(van	Hinsbergh	et	al.,	1978;	Veerkamp	et	al.,	1986).	A	 greater	 amount	 of	 ASPs	 was	 found	 in	 the	medium	while	 feeding	 cells	 with	MCFAs	compared	 to	 LCFAs.	 (Christensen	 et	 al.,	 1989,	 1991).	 The	 composition	 of	 ASPs	 was	partially	identified.	They	primarily	include	acetate,	ketone	bodies,	succinate	and	citrate	(Kawamura	and	Kishimoto,	1981;	Lin	et	al.,	1996).		When	an	alkyne-FA	with	an	odd	number	of	carbon	atoms	undergoes	a	full	process	of	β-oxidation,	propiolyl-CoA	is	generated	as	the	end	product.	This	substance	is	unstable	and	in	several	reactions	it	is	converted	to	an	enoyl-CoA	derivative	(Patel	and	Walt,	1988).	As	a	result	the	alkyne	label	is	lost	and	the	click	reaction	cannot	take	place.	Therefore	with	alkyne	 labeling	 it	 is	not	possible	 to	detect	ketone	bodies	or	 intermediates	of	 the	citric	
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acid	 cycle.	 Unknown	 substances	 that	 were	 found	 in	 the	 medium	 during	 experiments	with	 C11-FA	 fed	 cells	most	 probably	 are	 forms	 of	 shortened	 or	modified	 FAs	 such	 as	acylcarnitines,	3-hydroxy	acyl-CoAs,	3-oxoacyl-CoAs	or	their	carnitine	intermediates.	A	preliminary	lipid	mass	spectrometry	analysis	performed	in	collaboration	with	Gerhard	Liebisch	 from	Regensburg	allowed	 to	 identify	hydroxy	FA	with	7	 carbon	atoms	 in	 the	medium	of	day	3	hepatocytes	incubated	overnight	with	C11-FA,	data	not	shown.	A	more	detailed	analysis	would	be	required	to	identify	other	unknown	substances	present	in	the	medium.	In	order	to	follow	the	β-oxidation	of	FAs	using	the	click	labeling	method	oxa-alkyne-FA	based	methodology	was	developed	by	Christoph	Thiele.	In	oxa-FAs	one	carbon	atom	is	replaced	with	 an	 oxygen	 atom,	 so	 a	 full	 β-oxidation	 cannot	 take	 place.	 It	 stops	 at	 the	point	where	oxygen	is	at	the	β	position	of	the	FA	chain	(Figure	33).	As	a	consequence,	an	alkyne	 group	 of	 shortened	 oxa-FA	 is	 not	 degraded	 and	 can	 be	 labeled	 with	 the	 click	reaction.	 Therefore	 the	 amount	 of	 oxa-FA	 used	 for	 the	 β-oxidation	 can	 be	 quantified.	Medium	and	 long-chain	oxa-FAs	were	synthesized	by	Maria	Fiedler	and	 Jennifer	Saam	and	were	fed	to	hepatocytes	and	adipocytes.	Preliminary	data	indicate	that	the	C11	oxa-FA	 was	 more	 efficiently	 β-oxidized	 than	 the	 C17	 oxa-FA	 (data	 not	 shown)	 and	 that	etomoxir	did	not	influence	the	β-oxidation	rate	of	C11	oxa-FA,	because	the	amount	of	C9	oxa-FA	in	the	medium	was	the	same	in	etomoxir	treated	and	untreated	cells	(Figure	34,	lanes	 7-9	 and	 11-13).	 Similarly	 as	 in	 the	 C11-FA	 experiments	 etomoxir	 significantly	reduced	the	C11	oxa-TAG	amount	(Figure	34,	lanes	1-6).			
	
Figure	33.	Structures	of	oxa-FAs.	Red	lines	mark	in	how	many	cycles	of	β-oxidation	C17	oxa-FA	and	C11	oxa-FA	can	participate.	The	final	β-oxidation	product	of	both	FAs	is	C9	oxa-FA,	which	cannot	be	further	β-oxidized.	Oxa-FAs	were	synthesized	by	Maria	Fiedler	and	Jennifer	Saam.					
Discussion	
	 96	
	
Figure	34.	C11	oxa-FA	metabolism	in	hepatocytes.	Hepatocytes	isolated	from	a	mouse	liver	were	plated	on	collagen	coated	12-well	plates.	150.000	cells	were	 plated	 per	 well.	 First,	 cells	 were	 incubated	 with	 50	 μM	 etomoxir	 for	 2	 hours.	 Then	 1	 hour	incubation	with	50	μM	of	C11	oxa-FA	followed.	The	medium	was	collected	and	50	μl	of	it	was	used	for	lipid	extraction.	Cells	were	washed	and	lipids	were	extracted	from	cells.	Then	click	reaction	was	performed	both	with	lipids	from	the	medium	and	cells.	Finally,	lipids	were	separated	on	a	TLC	plate	and	 the	 fluorescence	 was	 detected	 by	 fluorescence	 imaging.	 In	 the	 indicated	 samples	 50	 μM	 of	etomoxir	was	added	to	the	medium	with	FA.	Lanes	10	and	14	represent	controls,	where	the	medium	with	 FA	 was	 added	 to	 the	 well	 without	 cells.	 Data	 taken	 from	 Bachelor	 thesis	 of	 Maria	 Fiedler,	submitted	2016.		As	already	mentioned,	 there	were	two	characteristics	of	 the	etomoxir	effect	 in	C11-FA	fed	 hepatocytes.	 The	 first	 one,	 i.e.	 the	 appearance	 of	 unknown	 substances	 in	 the	medium,	was	already	discussed.	The	second	one,	the	decrease	of	the	C11-TAG	amount,	will	be	analyzed	 in	this	paragraph.	To	the	best	of	 the	author’s	knowledge,	this	work	 is	the	first	to	describe	that	a	CPT1	inhibitor	hinders	the	C11-FA	incorporation	into	TAG	in	hepatocytes	 and	 to	 some	 extent	 in	 adipocytes.	 The	 decrease	 in	 TAG	 synthesis	 is	observed	 in	minutes	 after	 adding	 etomoxir	 (Figure	 19A	 and	 C).	 This	 hints	 to	 a	 direct	inhibition	of	a	protein	participating	in	the	processes	of	the	C11-TAG	synthesis	and	not	to	an	effect	related	to	changes	in	the	gene	transcription.	Some	studies	indeed	hint	to	a	role	of	etomoxir	in	the	activation	of	the	transcription	regulators	PPARα	and	NF-κB	(Cabrero	et	al.,	2003;	Forman	et	al.,	1997).	The	fact	that	etomoxir	affects	the	C11-TAG	synthesis	points	to	the	role	of	CPT1	in	the	MCT	synthesis.	Theoretically,	MCFAs	could	be	converted	to	acyl-CoAs	in	the	cytosol	by	ACSLs	as	these	enzymes	possess	the	activity	both	towards	
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LCFAs	and	MCFAs	(Normann	et	al.,	1981).	 If	 this	were	the	case,	 the	 inhibition	of	CPT1	would	not	have	an	effect	on	the	MCT	amount.	This	leads	to	an	assumption	that	C11-FA	is	converted	to	C11-CoA	in	mitochondria	and	then	transported	from	the	mitochondria	to	the	cytosol	in	a	C11-carnitine	form.	CPT1	is	needed	for	the	conversion	of	C11-carnitine	back	 into	 C11-CoA,	 which	 is	 then	 used	 for	 the	 C11-TAG	 synthesis.	 This	 hypothesis	suggests	 the	 role	 of	 mitochondrial	 MCFA-CoA	 formation	 in	 the	 C11-TAG	 synthesis	pathway.	The	mRNA	data	in	Table	15	indicate	that	in	dedifferentiating	hepatocytes	the	amount	 of	 CPT1	 diminishes.	 In	 3T3-L1	 adipocytes,	 however,	 CPT1	 declines	 with	 the	differentiation,	 and	 most	 probably	 C11-TAG	 synthesis	 is	 enabled	 by	 a	 different	mechanism	than	in	hepatocytes.		In	 pulse	 experiments	 with	 C11-FA	 fed	 hepatocytes	 the	 TAG	 band	 of	 higher	 mobility,	probably	 containing	 elongated	 FA	 could	 be	 identified	 on	 a	 TLC	 plate.	 This	 band	 was	significantly	weaker	in	etomoxir-treated	cells	(Figure	19A,	B).	Presumably,	in	etomoxir-treated	 cells	 the	 FA	 elongation	 process	 was	 disturbed.	 Inside	 the	 cells	 FAs	 can	 be	elongated	in	mitochondria,	in	microsomes	or	in	the	cytosol,	as	a	part	of	the	de	novo	FA	synthesis	(Jump,	2009).	The	microsomal	FA	elongation	is	considered	to	be	the	dominant	pathway	 for	 the	 FA	 elongation	 (Jakobsson	 et	 al.,	 2006).	 The	 lack	 of	 C11-CoAs	 in	microsomes	 is	 a	 possible	 reason	 for	 the	 failed	 C11-FA	 elongation.	 According	 to	 the	recently	 introduced	 assumption,	 C11-CoAs	 are	 synthesized	 in	mitochondria	 and	 their	accumulation	in	the	cytosol	and	subsequently	in	microsomes	is	inhibited	by	etomoxir.		The	etomoxir	 treatment	does	not	 cause	 the	development	of	 the	previously	mentioned	unknown	substances	in	C19-FA	fed	hepatocytes	and	also	does	not	change	the	amount	of	C19-TAG,	however,	it	causes	a	slight	increase	in	the	amount	of	PC	and	PE	(Figure	20A,	C,	D).	 LCFAs	 need	 CPT1	 to	 get	 inside	 the	 mitochondria	 to	 be	 able	 to	 participate	 in	 β-oxidation.	By	inhibiting	CPT1	with	etomoxir,	this	pathway	of	LCFAs	is	blocked.	FAs	that	are	spared	from	β-oxidation	are	channeled	to	other	metabolic	pathways.	It	was	shown	that	etomoxir	 increased	oleate	 incorporation	 into	TAG	(Boren	and	Brindle,	2012).	The	data	 from	 experiments	 presented	 in	 this	 thesis	 suggest	 that	 a	 C19-FA	 is	 rather	channeled	to	the	phospholipid	synthesis.	In	general,	the	minimum	effect	of	etomoxir	on	the	 LCFA	 metabolism	 was	 likely	 predetermined	 by	 the	 circumstance	 that	 in	 all	experiments	 described	 in	 this	 work	 a	 high	 glucose	 medium	 was	 used.	 However,	 the	LCFA	 oxidation,	 which	 is	 the	 target	 of	 etomoxir,	 is	 normally	 activated	 under	 fasting	conditions	when	the	level	of	glucose	is	low	(Guo	et	al.,	2006).		
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5.5. TAG synthesis from MCFAs 	Experiment,	where	C11-TAG	was	hydrolyzed	with	a	pancreatic	lipase,	showed	that	C11-FA	 was	 incorporated	 at	 the	 sn1	 or	 sn3	 position	 of	 a	 TAG	 molecule	 (Figure	 29).	 This	accounts	 for	 either	 GPAT	 (sn1)	 or	 DGAT	 (sn3)	 enzymatic	 activities	 in	 the	 glycerol	phosphate	pathway,	see	chapters	1.4.2	and	1.4.5.	Experimental	studies	have	shown	that	MCFAs	 are	 poor	 substrates	 for	 the	 esterification	 of	 G3P	 both	 in	 hepatocytes	 and	adipocytes	and	that	they	are	good	substrates	for	the	DAG	esterification	(Brandes	et	al.,	1985;	Mayorek	and	Bar-Tana,	1983).	This	implies	that	C11-TAG	was	produced	by	DGAT	enzymes	 in	 experiments	 with	 C11-FA	 fed	 cells.	 The	 expression	 of	 DGAT2	 extremely	increases	during	the	differentiation	of	3T3-L1	cells	(Table	15,	gene	no.	30),	however,	the	increase	in	DGAT1	expression	is	much	smaller	(Table	15	gene	no.	29).	This	indicated	a	possible	role	of	DGAT2	in	C11-TAG	synthesis.	Experiments	with	an	in	vitro	DGAT	assays	showed	 that	both	day	0	and	day	4	hepatocyte	 lysates	can	synthesize	C11-TAG	(Figure	31).	 For	 the	 DGAT	 reaction	 acyl-CoA	 and	 DAG	 are	 needed	 and	 they	 both	 need	 to	 be	accessible	 for	 the	 DGAT	 enzymes.	 The	 data	 from	 an	 in	 vitro	 acyl-CoA	 synthesis	 assay	show	 that	 both	 hepatocyte	 lysates	 (day	 0	 and	 day	 4)	 are	 able	 to	 synthesize	 similar	amounts	 of	 C11-CoA	 (Figure	 28).	 This	 acyl-CoA	 synthesis	 assay	 was	 not	 direct	 (i.e.	coupled),	 therefore	the	comparison	of	 the	activities	 in	 lysates	 is	questionable.	Still	 this	assay	 can	 show	 if	 there	was	 any	 acyl-CoA	 synthesis	 activity	 at	 all.	 Experimental	 data	from	acyl-CoA	synthesis	leads	to	the	conclusion	that	dedifferentiated	hepatocytes	have	a	potential	to	synthesize	C11-CoA.	The	DAG	amount	in	cells	is	also	not	a	limiting	factor	for	the	DGAT	reaction.	This	was	confirmed	using	a	control	assay	with	only	C11-CoA	added	to	 the	 lysates	 (Figure	 30A	 lanes	 9-12	 in	 purple	 boxed	 area).	 This	 control	 assays	with	both	hepatocyte	lysates	contained	small	amounts	of	C11-TAG	and	C19-TAG,	which	had	been	 produced	 from	 added	 C11-CoA	 and	 C19-CoA	 and	 endogenous	 DAG	 residing	 in	cellular	 lysates.	 If	 dedifferentiated	 cells	 can	 synthesize	 C11-CoA	 and	 have	 sufficient	reserves	of	DAG,	then	it	could	be	that	the	C11-CoA	does	not	reach	the	TAG	synthesis	site,	see	the	upcoming	chapter.	A	 different	 trend	 was	 observed	 in	 assays	 with	 lysates	 from	 undifferentiated	 and	differentiated	 3T3-L1	 cells.	 The	 difference	 in	 C11-CoA	 production	 efficiency	was	 very	high	between	these	two	cell	types	(Figure	28A).	This	raises	the	question	if	enough	C11-
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CoA	 is	 produced	 in	 undifferentiated	 cells	 for	 effective	 C11-TAG	 synthesis.	 Moreover,	data	from	the	DGAT	assay	implies	that	undifferentiated	3T3-L1	cells	synthesized	much	less	 C11-TAG	 than	 differentiated	 cells	 (Figure	 31).	 These	 results	 suggest	 that	dedifferentiated	hepatocytes	and	undifferentiated	3T3-L1	cells	do	not	 synthesize	C11-TAG	 due	 to	 different	 mechanisms	 involved.	 This	 will	 be	 discussed	 in	 the	 upcoming	chapter.	The	 data	 from	 the	 competition	 experiments	 suggest	 that	 C11-FA	 is	 spared	 from	 β-oxidation	 by	 adding	 50	 or	 100	 μM	 of	 C10-FA.	 As	 a	 result,	 more	 C11-TAG	 can	 be	synthesized	(Figure	32).	 In	general	β-oxidation	of	MCFAs	was	shown	to	be	very	active	(Christensen	et	al.,	1989;	Metges	and	Wolfram,	1991;	Pégorier	et	al.,	1988).	When	 the	concentration	of	C10-FA	reaches	a	physiologically	very	high	level	of	500	μM,	the	C10-FA	starts	 to	 compete	 with	 C11-FA	 and	 the	 amount	 of	 the	 C11-TAG	 decreases.	 In	 the	previous	 paragraph,	 it	was	mentioned	 that	 cells	 have	 relatively	 high	 reserves	 of	DAG,	which	can	be	used	for	TAG	synthesis	after	supplementing	cells	with	FAs.	However,	when	the	amount	of	C10-FA	increased	to	very	high	levels,	presumably	C10-FA	was	channeled	to	other	enzymatic	steps	of	the	glycerol	phosphate	pathway,	such	as	the	esterification	of	G3P	 to	 produce	 LPA	 and	 the	 esterification	 of	 LPA	 to	 produce	 PA	 followed	 by	 DAG	synthesis	 (Figure	26C).	No	PA	and	DAG	 intermediates	were	detected	on	 the	TLC	plate	because	C11-FA	was	not	used	in	reactions	generating	these	lipids.	C11-FA	was	used	only	for	 the	 final	 DGAT	 reaction,	 involving	 either	 endogenous	 DAGs	 or	 DAGs	 synthesized	from	supplemented	C10-FAs.	Three	C11-TAG	bands	were	identified	on	the	TLC	plate	as	TAGs	having	one,	 two	or	 three	MCFAs	 run	differently	 (Figure	32C	 lane	12).	 It	 is	most	likely	that	at	very	high	concentration	C10-FA	competes	with	C11-FA	for	DGAT	enzymes.		When	500	μM	of	oleate	(C18:1)	was	added,	the	C11-TAG	amount	increased.	This	could	be	explained	by	the	fact	that	oleate	 is	a	relatively	good	substrate	for	GPAT	and	LPAAT	enzymes	 and	 that	 at	 high	 concentrations	 oleate	 was	 very	 efficiently	 used	 for	 the	synthesis	of	LPA	followed	by	the	synthesis	of	PA	and	DAG.	This	newly	synthesized	DAG	could	 then	 be	 used	 by	 DGAT	 enzymes	 for	 C11-TAG	 synthesis.	 Brandes	 et	 al.,	 1985	showed	that	when	adipocytes	were	fed	with	600	μM	of	octanoate	(C8:0),	the	addition	of	up	to	200	μM	of	palmitate	(C16:0)	slightly	increased	the	C8-TAG	amount.	However,	with	higher	 concentrations	 of	 palmitate,	 the	 C8-TAG	 amount	 started	 to	 decrease.	 In	 future	experiments	 the	 concentrations	 of	 FAs	 would	 have	 to	 be	 increased	 deliberately	 for	oleate	to	compete	with	C11-FA	for	DGAT	activity.	
Discussion	
	 100	
	
5.6. The concluding hypothesis 
 Based	on	experimental	data	analysis	and	literature	research	a	concluding	hypothesis	for	the	 MCFA	metabolism	 in	 hepatocytes	 and	 3T3-L1	 adipocytes	 is	 presented.	 Figure	 35	shows	a	generally	accepted	metabolism	scheme	of	LCFAs	and	MCFAs.	According	to	this	model	under	normal	physiological	conditions	LCFAs	(red	arrows)	are	used	for	cellular	lipid	synthesis	and	MCFAs	(blue	arrows)	are	used	for	mitochondrial	β-oxidation.	For	 hepatocytes	 a	 slightly	 different	 model	 is	 proposed	 where	 MCFAs	 can	 also	 be	incorporated	into	TAG,	Figure	36A	(blue	arrows).	In	hepatocytes	MCFAs	first	get	inside	mitochondria	 and	 are	 activated	 there	 by	 ACSMs.	 A	 part	 of	 these	 FAs	 is	 used	 for	 β-oxidation.	Remaining	FAs	 are	 transported	 as	FA-carnitines	 via	 the	 carnitine	 shuttle	 to	the	cytosol,	where	they	are	converted	to	acyl-CoAs	by	CPT1.	These	acyl-CoAs	can	then	be	used	by	DGAT	enzymes	for	the	TAG	synthesis.		In	dedifferentiated	hepatocytes	(Figure	36A	red	arrows)	CPT1	level	is	decreased	(Table	15,	 gene	 no.	 45).	 It	 is	 likely	 that	 the	 conversion	 of	 acylcarnitines	 into	 acyl-CoAs	 is	affected	 by	 the	 low	 amount	 of	 CPT1.	 Consequently,	 the	 amount	 of	MCFA-CoAs	 in	 the	cytosol	 is	 not	 sufficient	 for	 TAG	 synthesis.	 As	 MCFAs	 cannot	 be	 utilized	 for	 the	 TAG	synthesis,	 they	 are	 oxidized	 to	 a	 larger	 extent.	 As	 a	 result,	 various	 shortened	 and	modified	forms	of	C11-FA	are	secreted	into	the	medium.	The	oxidation	process	of	C11-FA	most	likely	takes	place	in	mitochondria,	but	peroxisomes	and	the	cytosol	could	also	contribute.	In	differentiated	3T3-L1	cells	(Figure	36A	blue	arrows)	the	expression	level	of	ACSL1	is	very	 high	 (Table	 15,	 gene	 no.	 13).	 Therefore	 it	 is	 possible	 that	 MCFA-CoAs	 are	synthesized	not	only	in	mitochondria	but	also	in	the	cytosol,	which	is	the	main	source	of	the	 MCFA-CoA	 synthesis.	 A	 part	 of	 mitochondrial	 MCFA-CoAs	 is	 channeled	 to	 β-oxidation	and	a	part	to	the	TAG	synthesis.	In	 undifferentiated	 cells	 (Figure	 36A	 red	 arrows),	 the	 expression	 levels	 of	 ACSMs	 are	extremely	low	(Table	15,	gene	no.	51-53),	hence	mitochondria	hardly	play	a	big	role	in	the	MCFAs	metabolism.	 The	 amount	 of	 ACSL1	 is	 also	much	 lower	 in	 undifferentiated	cells	 than	 in	 differentiated	 cells	 (Table	 15,	 gene	 no.	 13)	 and	 is	 hardly	 sufficient	 for	efficient	 MCFA-CoA	 and	 subsequent	 TAG	 synthesis.	 C11-FAs	 disappeared	 from	 the	
Discussion		
	 101	
medium	of	undifferentiated	3T3-L1	cells	fed	with	C11-FAs	overnight	(Figure	14),	what	happened	with	these	FAs	is	unclear.		
	
Figure	35.		LCFA	and	MCFA	metabolism,	conventional	model.	According	 to	 the	 conventional	 model,	 LCFAs	 (red	 arrows)	 are	 mainly	 used	 for	 TAG,	 DAG	 and	phospholipid	synthesis.	MCFAs	 (blue	arrows)	are	metabolized	 in	mitochondria	via	β-oxidation	and	the	final	metabolite	is	CO2.	Ox	–	oxidized.				
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Figure	 36.	 Hypothetical	 model	 of	 MCFA	 metabolism	 in	 hepatocytes	 and	 3T3-L1	
adipocytes.	A)	 In	 hepatocytes	 (blue	 arrows)	 MCFAs	 are	 used	 for	 both	 mitochondrial	 β-oxidation	 and	 TAG	synthesis	and	to	some	extent	for	PL	synthesis.	MCFA-CoAs	are	synthesized	in	the	mitochondria	and	transported	via	carnitine	transport	system	to	the	cytosol,	where	they	are	used	for	TAG	synthesis.	In	dedifferentiated	 hepatocytes	 (red	 arrows)	 the	 acyl-carnitine	 conversion	 to	 acyl-CoA	 is	 disturbed.	Shortened	and	oxidized	FA	derivatives,	formed	in	the	mitochondria,	are	released	into	the	medium.	B)	In	differentiated	3T3-L1	cells	(blue	arrows)	MCFA-CoAs	synthesized	both	in	mitochondria	and	in	the	cytosol	are	used	for	TAG	and	to	some	extent	for	PL	synthesis.	Some	of	FAs	are	oxidized	and	secreted	as	a	modified	substance	into	the	cytosol.	In	undifferentiated	3T3-L1	cells	(red	arrows)	the	expression	of	 ACSMs	 is	 extremely	 low.	 Therefore	 the	 role	 of	 the	 mitochondria	 in	 the	 MCFA	 metabolism	 is	unclear.	Not	enough	of	cytoplasmic	MCFA-CoA	is	synthesized	for	the	MCT	synthesis.	Ox	–	oxidized.			
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6. Outlook 
In	order	to	support	or	deny	the	hypothesis,	which	was	raised	in	the	discussion	chapter,	there	are	several	 important	experiments,	which	should	be	addressed	in	future	studies.	For	hepatocytes	it	was	hypothesized	that	MCFA-CoA	is	synthesized	in	mitochondria	and	that	 CPT1	 is	 involved	 in	 the	 conversion	 of	MCFA-carnitine	 to	MCFA-CoA.	However,	 in	etomoxir-treated	cells	and	in	dedifferentiated	hepatocytes	this	conversion	is	disturbed.	In	 future	 experiments	 it	 is	 important	 to	 determine	 MCFA-CoA	 and	 MCFA-carnitine	amounts	in	different	cellular	compartments,	e.g.	mitochondria,	cytosol	and	microsomes.	Moreover,	the	role	of	carnitine	in	MCFA	metabolism	is	an	interesting	aspect	and	should	be	investigated.		In	 general,	 it	 is	 important	 to	 make	 some	 control	 experiments	 by	 feeding	 cells	 with	natural	MCFAs	such	as	decanoate	and	measure	MCTs	 in	cells	as	well	as	metabolites	 in	the	 medium	 applying	 MS.	 In	 such	 way	 a	 possible	 effect	 of	 alkyne	 group	 on	 MCFA	metabolism	could	be	excluded.		The	other	question	to	clarify	is	what	happens	with	MCFAs	when	they	cannot	efficiently	be	incorporated	into	TAG	but	still	disappear	from	the	medium.	This	was	observed	with	dedifferentiated	 hepatocytes,	 hepatocytes	 treated	 with	 etomoxir	 and	 undifferentiated	3T3-L1	cells.	To	answer	this	question,	oxidative	processes	could	be	investigated.	To	get	a	 better	 understanding,	 which	 oxidative	 processes	 are	 involved	 in	 the	 MCFA	metabolism,	 it	 is	 important	 to	 analyze	metabolites	 that	 are	 secreted	 into	 the	medium.	For	 this	 lipid	MS	 should	 be	 applied.	Moreover,	 oxa-FAs	 could	 be	 used	 to	 quantify	 the	potential	of	β-oxidation	both	in	hepatocytes	and	3T3-L1	cells.	Furthermore,	the	role	of	peroxisomal	β-oxidation	could	also	be	evaluated.	The	 finding	 that	 the	 gut	 can	 very	 effectively	 synthesize	 C11-TAG	 is	 promising	 and	therefore	should	be	further	investigated	by	performing	similar	experiments	as	were	did	with	hepatocytes	and	adipocytes.	Future	work	could	also	include	animal	experiments	such	as	feeding	mice	with	C11-FA	or	decanoate	and	examining	lipids	from	the	blood	and	from	different	organs	by	using	click	method	and	MS.	
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